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Summary  I 
SUMMARY 
Parkinson’s disease (PD) is the second major neurodegenerative disease and the most 
common movement disorder. Due to age being a critical risk factor, the rapid ageing of the 
world population further increases the prevalence of PD. So far no treatment is available 
and therapies mainly focus on motor symptoms by pharmacologically substituting striatal 
dopamine, caused by the loss of dopaminergic neurons in the substantia nigra. This 
neuronal loss and intracellular protein aggregates, termed Lewy bodies (LBs), are 
pathological characteristics of PD. With disease progression, a spread of LBs through the 
brain can be observed which mainly follows axonal projections. Understanding the 
mechanisms of this progressive spread could be central to discovering the underlying 
molecular pathogenesis of the disease. As LBs mainly consist of alpha-synuclein (a-syn), a 
prion-like spreading of a-syn was suggested and is now widely accepted as a component in 
the PD pathogenesis. New dopaminergic model systems to study the exact mechanisms 
underlying a-syn spread are urgently needed. As PD is a human disease, in vitro models 
should be derived from humans. Lund human mesencephalic (LUHMES) cells are a 
suitable alternative to other, mostly non-human, dopaminergic cell lines. However, 
difficulties cultivating them in microfluidics devices has made them thus far inaccessible 
for co-cultivation studies in the field of PD spreading. 
In the first part of this thesis, a human dopaminergic cell model system for studying the 
spreading of a-syn fibrils is presented. First, the well-characterized LUHMES cell line was 
tested for suitability of PD research on prion-like spreading, as no data is currently 
available on this matter. For the analysis, immunofluorescence light microscopy was 
employed. An extended period of differentiation aimed for a high degree of neuronal 
maturity and long neurites to facilitate the connectivity of spatially-separated cell 
populations. Seeding experiments with a-syn fibrils revealed a weak toxicity against these 
assemblies, even at prolonged differentiation. Second, to study the transmission of a-syn 
fibrils via neuronal projections, we developed a light microscopy-compatible microfluidic 
co-culturing device, to maintain two LUHMES cell populations in separate cell 
compartments for up to two weeks of differentiation. During this time, a neurite network is 
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formed which connects the fluidically isolated cell growth compartments. The ability to 
cultivate cells with neurites and soma in an isolated environment enabled seeding and 
transmission experiments in anterograde and retrograde directions.  
In the second part of this thesis, implementation strategies of the microfluidic co-culturing 
chip for alternative analysis methods are discussed. Firstly, the accessibility of the cells in 
the co-culturing device using a single-cell lysis instrument is evaluated. The tool allows for 
targeted lysis of individual adherent cells. Preliminary tests point in a promising direction, 
while LUHMES single cell lysate was successfully transferred to different analysis 
techniques. However, direct access to the channels of the microfluidic co-culturing chip 
was problematic and needs further modifications. Secondly, an implementation of the 
microfluidic device aiming for co-cultivation of LUHMES cells on electron microscopy 
grids to study neurite architecture was pursued. Thereby, microfluidic devices harbor only 
cell soma, but neurites can grow onto an electron microscopy grid, as only they are thin 
enough to be visualized by cryo-electron microscopy. Proof-of-concept experiments 
demonstrate the direct visualization of LUHMES cell neurites in a near-native, frozen-
hydrated state. 
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Chapter 1  1 
CHAPTER 1 
Introduction 
This introduction provides a general overview of neurodegenerative diseases with a focus 
on Parkinson’s disease. The relevant biological background for this thesis is discussed. 
Special attention was paid to a more detailed discussion about current knowledge of the 
Parkinson’s-related protein alpha-synuclein in terms of disease outbreak and progression. 
Thereafter, an overview of microfluidics is given with regard to its upcoming role in cell 
culture and its advantages and disadvantages therein. Parts of this introduction are being 
prepared for publication elsewhere. 
1.1 Neurodegenerative Diseases: A Global Public Health Problem 
The umbrella term “neurodegenerative disorders” combines brain-affecting processes with 
progressive loss of normal neuronal function, neuronal degeneration, and death of neurons. 
As a result of progressing neurodegeneration, diseases like Alzheimer’s disease (AD), 
Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis 
(ALS) occur, and are therefore termed neurodegenerative diseases (NDs). Most 
mechanisms behind these incurable neuronal degenerations are not yet understood.  
Often, the disease’s typical neurological alteration in the cerebral and peripheral nervous 
system starts long before its diagnosis. Although the nervous systems usually cannot repair 
itself, it is often very robust to changes, which leads to a detection of NDs in advanced 
years. Partly because of ageing populations and worldwide demographic changes disease 
prevalence is likely to increase. Especially in less developed countries – often with higher 
exposure to environmental risks, increasing life expectancy, and large populations – NDs 
will become a problem too. The World Health Organization (WHO) predicts that by mid-
century NDs will overtake cancer as cause of death [1]. The current mortality of NDs does 
not reflect the overall burden of the disease since disabling effects are mostly present over 
many years. Taking the WHO estimates for “Disability-Adjusted Life Years” to compare 
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the impact among diseases, brain diseases are developing to be one of the leading global 
disease burdens (Figure 1) [2]. 
However, NDs are far from being fully understood and therapies often bring only 
symptomatic relief but do not stop the progress of neurodegeneration. The growing 
knowledge about the various NDs gathered in the last four decades reveales many 
similarities between these diseases on a molecular basis. This brings in another level of 
complexity but also the hope that research findings and subsequent therapies might be 
applicable to several diseases simultaneously.  
Figure 1. Percentage of total disability-adjusted life-years (DALYs) for neurological disorders and a selection 
of other diseases. One DALY is the equivalent of a healthy life year a disabled individual has lost. Modified 
from WHO report on Neurological Disorders 2006 [2]. 
1.2 Parkinson’s Disease 
Parkinson’s disease (PD) was named in honor of James Parkinson who thoroughly 
documented the disease in “An Essay on the Shaking Palsy” in 1817 [3]. 200 years later, 
the disease is widely known by the public as it becomes increasingly prevalent, affecting 
approximately 0.1-0.2% of the population at any time [4]. Generally, the incidence 
increases with age, independent of gender [5]. The occurrence increases to over 1% of the 
population older than 65 years and to 5% when over the age of 80 [6]. The disease is not 
restricted to the elderly as 5% of diagnoses affects people under the age of 40. Young-
onset PD is generally defined by an onset before the age of 45, with about 10% of patients 
showing a genetic predisposition. Genetically defined cases rise to over 40% of individuals 
with onset before 30 years of age [7, 8]. 
Gender differences were reported in several studies. In some, men are twice as likely to be 
affected than women [9-11]. Other studies only observed significant gender differences in 
prevalence among specific age groups or none when stratified by geographic location [5, 
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12]. PD is the second most common ND after AD, and represents the most common 
movement disorder.  
Figure 2. Prevalence (a) and Incidence (b) of PD in men and women. Reprinted with permission from ref 
[9]. Copyright (2017) Springer Nature. 
1.2.1 Symptoms and Diagnosis 
The characteristic motor features observed by James Parkinson are still considered the 
hallmark signs for idiopathic PD and are the prerequisite for clinical diagnosis. The motor 
aspects of the disease are bradykinesia, rigidity, and resting tremor, whereas in clinical 
diagnosis the obligated symptom of bradykinesia must be observed in combination with 
one or both of the other motor features [13]. Postural instability also used to be a 
diagnostic criterion, but this fourth cardinal sign was recently revised by the International 
Parkinson and Movement Disorder Society [4, 14]. However, only the main three motor 
symptoms are defined to be cardinal parkinsonism manifestations. If parkinsonism, the 
essential criterion of PD, is given, a range of supportive criteria, red flags, and absolute 
exclusion criteria are described to diagnose a clinically-defined PD patient [15]. Although 
older diagnostic criteria already increased the accuracy of clinical diagnosis up to 90% by 
including non-motor symptoms, the discrepancy between clinical diagnosis and 
pathological confirmation as gold standard persists [16, 17]. The newly defined supportive 
criteria also include non-motor symptoms which will probably improve the diagnostic 
accuracy. 
However, the correct diagnosis of PD is important in order to evaluate possible and 
immediate therapeutic actions – the earlier the better. The difficulty is that parkinsonism 
can also occur in conditions other than PD. Still, with the help of defined criteria, the 
diagnosis remains primarily clinical. As no reliable test exists yet, clinicians are mainly 
forced to rule out other conditions leading to parkinsonism. This is usually the case for the 
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later stages of the disease and thus not useful for an early diagnosis. Besides misdiagnosed 
patients, there is an unknown number of unreported cases, mainly because only few 
develop cardinal signs under the age of 50. On the other hand, parkinsonian features in 
older populations are often mistaken for normal ageing signs [18].  
Although clinical diagnostic techniques and laboratory analyses were developed, they do 
not make a defined diagnosis and can solely support the physicians in their final decision. 
By the 1980s 18F-DOPA positron-emission tomography (PET) scanning techniques to 
visualize striatal dopamine (DA) depletion were demonstrated [19]. Since then, several 
other techniques in the field of neuroimaging were developed and approved for clinical 
diagnosis of PD. For example, the DaTscan (GE Healthcare) – a single-photon emission 
computer tomography (SPECT) technique – can be used to image dopaminergic 
degeneration by visualizing the amount of DA transporters [20]. This helps to distinguish 
PD from other diseases with similar symptoms. Several advanced magnetic resonance 
imaging (MRI) techniques are being developed for early disease detection and to monitor 
disease progression [21].  
Besides imaging techniques, patients with early onset PD or a suggestive familial history 
can be tested for known genetic mutations. As PD is genetically heterogeneous and 
monogenetic forms only account for 3%-10% of the sporadic cases [22, 23], genetic testing 
is not yet a diagnostic routine, nor is it used for practical treatment decisions. However, 
many mutations leading to monogenetic PD are identified and the list of genes which 
contribute to a higher risk for sporadic PD continues to grow. With the application of 
genome-wide association studies, many low-risk loci were identified, which might account 
for an interacting effect in genetically heterogeneous PD [23]. Thus, advances in the field 
of genetics could make PD diagnosis based on genetic findings a tool in clinical routine. 
Currently, there is no reliable test available that can achieve this task. Therefore, there is an 
urgent need for biomarkers to diagnose PD at a prodromal disease stage, that is, before 
cardinal signs show up, and to differentiate from other diseases but also to assess disease 
severity and prognosticate the course of the disease. To date, only a few biomarkers have 
been tested and there are currently none in standard clinical use, besides biomarkers for 
neuroimaging [24]. The general approach is to test for biochemical markers in 
cerebrospinal fluid or in the blood of patients. The most studied biomarker present in 
several biofluids is a-syn. The most prominent studies compared the total a-syn levels in 
the cerebrospinal fluid of PD patients with those of healthy control subjects. However, 
conflicting results with an overlap of a-syn levels in patients and healthy controls 
precluded clinical development as a diagnostic or prognostic biomarker [24]. A recent 
longitudinal study, which measured a-syn concentration changes in the cerebrospinal fluid 
of PD patients, did not show any substantial changes during a period of 4 years [25]. 
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Similarly, biochemical markers quantitated in blood led to limited success. Despite the 
extensive search for biomarkers as a clinical tool, definitive diagnosis can only be made 
based on clinical symptoms in combination with neuropathological examination [26].  
 
1.2.2 Neuropathology 
The defining neuropathological characteristics of PD are loss of dopaminergic neurons in 
the substantia nigra (SN), which leads to DA depletion in the striatum, and abnormal 
intracellular protein aggregate formation [14, 27]. Currently, both of these 
neuropathological features are required to ultimately diagnose idiopathic PD. However, as 
with clinical diagnosis of PD, there are only provisional operating procedures and criteria 
used for the neuropathological assessment of PD [27]. 
The first hallmark of PD, neuronal loss, is not restricted to the SN but in early-stage 
disease predominantly affects the ventrolateral SN (Figure 3A). It is assessed by 
comparing pigmented melanine-containing neurons in the SN on histological sections with 
a control template. Other midbrain dopaminergic neurons might be affected at a later stage, 
whereas conclusions on disease duration can only be drawn from depletion in SN, not from 
other DA-containing cell groups [28]. Still, neuronal depletion is relatively localized in SN 
and a general atrophy of the brain is not typical for PD. Striatal DA deficiency and 
consequently onset of motor symptoms can be directly linked to the nigral neuronal loss 
via the nigrostriatal DA pathway and therefore to PD [29-32]. However, the loss of 
pigmented neurons in the SN is also observed in normal elders and in several other NDs 
[18].  
The other neuropathological hallmark of PD is the cytoplasmic deposition of protein 
aggregates in different brain regions (Figure 3B-D). When located in neuron somas, they 
are termed Lewy bodies (LBs), and when the aggregates form in axons they are called 
Lewy neurites (LNs). The precise building block and the mechanism of formation of LBs 
remain unclear. The main constituents are neurofilament subunits, a-syn, and ubiquitin 
[33-35]. Furthermore, other proteins such as synaptophysin, synphilin-1, Tau, and heat 
shock proteins were found, as well as whole cell organelles, mostly mitochondria [36]. It 
was suggested that LBs might be related to aggrosomes, and thus are only a symptom, not 
the cause of PD [37].  
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Figure 3. Demonstration of the pathological hallmarks of PD, Lewy bodies and depigmentation of the SN. 
(A) Horizontal sections through the midbrain of a PD patient (left) and a healthy control (right). Loss of 
pigmentation can be seen in the SN. (B) Concentric LB on a conventional haematoxylin and eosin stained 
histological section. (C) LB stained against a-syn. (D) Electron micrograph of a LB reveals a dense core and 
radiating filaments. Scale bars 10 µm. Reprinted and modified with permission from refs [38-40]. Copyright 
(2013) Springer Nature, (1996) Oxford University Press. 
Initially, LBs are formed in monoaminergic and cholinergic brainstem neurons and in 
neurons of the olfactory system. With the progression of the diseases, they can also be 
found in limbic and neocortical brain regions [41]. In PD, Lewy pathology is often found 
at sites of neuronal loss. This has led to the conclusion that LBs might be the reason for 
neuronal degeneration [42]. Although more LBs can be found in patients with less severe 
neuronal depletion, it does not mean that all the lost neurons were affected by LBs and 
died. Indeed, it was shown that most SN neurons do not contain LBs when undergoing 
apoptotic cell death. Therefore, it was also not possible to correlate LB density with 
clinical disease symptoms or disease duration [43]. As for nigral neuronal degeneration, 
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LBs can also occur as a feature of normal ageing and in several other NDs, including 
dementia with Lewy bodies, AD, subacute sclerosing panencephalitis, Down’s syndrome, 
infantile neuroxanal dystrophy, and Hallervorden-Spatz syndrome [18, 44]. Therefore, LBs 
are most likely not a sign of presymptomatic PD [27]. Overall, this pathophysiological 
feature of PD does not explain the neurodegeneration and is probably not even associated 
to the cell loss [43, 45]. 
For a definitive diagnosis of PD, LBs must be found in the SN or in the locus ceruleus in 
combination with nigral neuronal loss and cardinal clinical signs as obligated symptoms 
[14]. The postmortem findings can be quite challenging and conflicting to interpret, as 
individual pathological features can be heterogeneous. There may be patients with typical 
clinical symptoms but no LB pathology or nigral neuronal degeneration [46]. Still, based 
on the general neuropathological findings, a staging system was proposed to evaluate the 
progression of PD post-mortem [47]. This system, developed by Braak and colleagues, 
categorizes six stages with distinct topographical localization of the brain lesions, which is 
linked to a spatiotemporal route of Lewy pathology spreading (Figure 4). Therefore, an 
initial site of PD-related brain alteration had to be determined and defined in stage 1 and 2 
as specific regions in the lower brainstem [48]. More precisely, in the dorsal vagal nucleus 
of the medulla oblongata and the olfactory bulb in stage 1, with spreading to medullar 
structures like the locus coeruleus and lower raphe nuclei in stage 2. In stages 3 and 4, the 
severity of these previously located lesions increases and spreads to the upper brainstem 
without cortical lesions, and it is not till stage 4 that a depigmentation in the SN is 
detectable. This devastation of the melano-neurons is likely to be the clinical manifestation 
of PD onset. Eventually, initial lesions in the mesocortex can be found in stage 4. In the 
final stages, 5 and 6, the destructive process of previously staged regions proceeds and the 
involvement of the neocortex becomes extensive [49].  
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Figure 4. Representation of the Braak staging system for PD. Lewy pathology spreads from the possible 
initiation site in the olfactory bulb or via vagal inputs to the cortical regions. Reprinted from ref [41] with 
permission obtained from John Wiley and Sons. Copyright (2011) Movement Disorder Society. 
However, due to significant heterogeneity in neuropathological examinations, several 
critical reappraisals suggested modifying the criteria of the Braak staging [50-52]. 
Especially with regard to the Lewy pathology, it was reported that half of the subjects 
could not be classified with the current staging system. The Braak hypothesis then also 
fails to explain why parkinsonism cannot be found in all patients with the characteristic 
Lewy pathology [53], or why not every PD pathology follows the predicted spreading 
pattern [54]. This shows the complexity of the disease and that several factors might 
influence initial disease outbreak, eventually leading to alternative spatiotemporal 
progression routes [55].  
1.2.3 Pathophysiology  
Based on neuropathological findings, the cardinal signs of PD can be explained by the loss 
of neuronigral substance [4]. But neither is there a clear clinical manifestation of the other 
neuropathological hallmarks LBs and LNs, nor can the significance of the pathological 
brain depletion explain clinical symptoms like dementia, depression, and several other 
non-motor symptoms. 
With the discovery that PD patients’ brains show a severe loss of DA in the caudate 
nucleus and the putamen, combined with the knowledge about the loss of SN neurons, 
which also show greatly reduced DA levels, a link between striatum and SN was 
concluded [31]. This so called “nigrostriatal DA pathway” starts in the SN where the cell 
bodies of the dopaminergic neurons are located and follows neuronal projections that lead 
to the dorsal striatum. Since these regions are critical for the motor system, neuronigral 
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depletion and subsequent reduction of DA leads to the symptomatic motor symptoms of 
PD, but not until 50% of the dopaminergic neurons in the SN are lost [50, 56]. 
Non-motor symptoms, including sleep disorder, cognitive impairment, autonomic 
dysfunction, and sensory symptoms are not easily explained by DA depletion. Several of 
these symptoms can precede the onset of the classical motor symptoms by more than a 
decade. Interestingly, some are partially treatable with dopaminergic drug strategies [57]. 
However, some of the physiological processes may be explained by Braak’s hypothesis. 
For example, olfactory dysfunction can be a result of a degeneration in the olfactory bulb 
and the olfactory nucleus in Braak stage 1. Progression to the lower brain stem in Braak 
stage 2 might explain the involvement with sleep homeostasis and the links to other 
autonomic dysfunctions [58]. The role of LBs can only be indirectly assumed via their 
possible relation to brain lesions. It is only partially possible to assign the clinical signs to 
multiple sites of the pathology. How LBs and nigral pathology produce the clinical signs is 
not yet understood is the subject of intense debate [18, 50]. 
1.2.4 Epidemiology, Etiology, and Risk Factors 
The etiology of PD remains unclear in most cases, with some being associated to genetic 
or environmental risk factors. It is agreed that increasing age remains the greatest risk 
factor for PD [59]. The lifetime risk of developing PD is as high as 6.7% at an age of 45 
and the annual incidence increases nearly exponentially between the age groups of 60-64 
and 85-89, from 0.07% to 0.6% [60]. The prevalence of several other diseases like AD and 
heart disease increase with ageing too, but none of them show such a marked increase as 
PD [61]. Ageing itself is a complex phenomenon. It is characterized by a progressive 
deterioration of physiological process, but the involved cellular mechanisms are only 
poorly understood. Besides PD, susceptibility to other diseases increases, but varies among 
individuals of a population and even in the different tissues of an individual [62]. Thus, 
age-related alteration of the brain is a risk factor for PD, but must not be regarded solely, 
since other PD risk factors might have simultaneous impacts on the mechanisms of ageing 
itself. That is to say, genetic and environmental factors influence ageing and ageing itself 
can lead to different responses to these factors. Some studies consider that PD is caused by 
a specific risk factor, which affects a certain population of dopaminergic neurons [61]. 
These neurons are usually also affected by normal ageing. Thus, there might not only be a 
single etiopathogenesis for neurons to degenerate in PD, but the condition arises because 
affected neurons might be particularly vulnerable to ageing in combination with other risk 
factors [63]. These competing theories are discussed in more detail in section 1.4.3. 
In epidemiological studies, gender differences were reported with men carrying up to a 
twofold increased risk of developing PD compared to women [11]. In contrast, other 
studies did not observe any differences or even a higher risk for the female population 
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[64]. However, the general consensus tends to see gender differences, with PD in men 
being more common (Figure 2). A possible role of oestrogen as neuroprotective agent has 
been discussed [65], but gender-specific differences in exposure to environmental factors 
and healthcare discrepancies like underdiagnoses could also contribute. 
Furthermore, different PD rates were found among a geographically defined population 
with different race and ethnicity, but evidence for biological causes could not be found, 
which leaves social causes as a possible explanation for these findings [10]. Generally, 
epidemiologic studies have to be carefully assessed since race and, therefore, genetic 
differences can have a dominant role over environmental contribution or vice versa. For 
example, increased prevalence was detected in Ashkenazi Jews [66], Native Americans, 
Alaska Natives [67], and Inuit [68], but could not be explained solely by either genetic or 
environmental factors.  
Accumulation of PD cases in certain family trees led to the assumption of a genetic cause 
for the disease. It was not until 1997 when the first PD mutation, Ala53Thr in SNCA on 
chromosome 4q22.1, was discovered [69]. However, it was already clear by then that a 
single gene or even a single mutation cannot account for most of the sporadic and familial 
cases. Since then, more of these potent monogenetic causes of PD were discovered. Most 
significantly, the autosomal-dominant SNCA and LRRK2, but also autosomal-recessive 
PINK1, PARKIN, and DJ1, which – based on family history or early onset PD – were 
particularly amendable to discovery. It is believed that all monogenetic causes of PD are 
known and well described [70]. However, they are comparatively rare in familial PD and 
likely make only a small contribution to the etiology of PD. Together, they account for 5-
10% of all PD cases [23], whereas it is estimated that heritability accounts for 27% overall 
[71]. To date, 23 gene loci were assigned to the “PD associated genes” (PARK) 
designation. Besides the known monogenetic forms, larger population-based studies found 
genetic low-risk factors within these genes, and new loci in which mutations are more 
frequent than in monogenetic PD but with a lower penetrance [72]. Genome-wide 
association studies have proven to be a powerful tool to identify and confirm more of the 
highly frequent low-risk variants which account for a small contribution to the risk of PD 
[73]. The interaction of these genes and their contribution to sporadic PD pathogenesis has 
become apparent during recent years but are yet to be understood [74].  
In addition to this polygenetic etiology, it is presumed that multiple other factors like 
epigenetics and somatic mutations participate in the pathology of PD. There is growing 
evidence that epigenetic modifications introduce environmental risk factors into the 
disease development with multifactorial origin [75]. How and to what extent epigenetics 
act as a mediator for the gene-environment interaction remains to be elucidated [76]. 
However, environmental factors are considered to have an important role in PD 
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pathogenesis. Some studies have related the increase of PD during the industrial revolution 
to environmental toxins, some to the ageing of the population [77]. Epidemiological 
studies indicated an increased prevalence of PD in rural areas, likely due to elevated levels 
of environmental toxins from pesticides, herbicides, and insecticides [78]. Other factors 
like air pollution and metal emissions tend to have a higher influence in urban areas [79, 
80]. It was hypothesized that biological and clinical factors such as influenza viruses, 
endotoxins from bacteria, and traumatic brain injury could act as indirect causes of PD [81-
83]. Additionally, lifestyle factors including dietary factors could positively or negatively 
correlate with the incidence of PD, for example, it is lower in caffeine consumers and 
smokers but increases with a diet low in antioxidants [84]. 
Despite the evidence that environmental risk factors correlate with increased prevalence of 
PD, it would be an oversimplification to consider exposure to certain toxins a sole trigger 
for PD. For example, a meta-analysis of studies related to PD and pesticides revealed 
significant heterogeneity in the results, which may be biased by PD pathogenesis-related 
genes, different pathological mechanisms, and variations in patients [78]. Thus, it has 
become clear that PD has a multifactorial and polygenetic etiology defined by several 
factors including age, gender, race, genetic predisposition, and environment.  
1.2.5 Therapy 
1.2.5.1 Pharmacological Treatment Strategies 
Unlike for other NDs, the list of treatment options for PD is quite unique with several 
effective medications used for symptomatic relief. Still, there is no cure or therapy that 
slows the progression of the disease currently available.  
With the discovery that DA plays a role in the pathophysiology of PD, a key target for 
pharmacological treatment was found. Consequently, DA replacement treatments were 
started, first with intravenous and later with oral administration of the DA precursor L-
DOPA [85-87]. More than 50 years after this revolutionary breakthrough, L-DOPA is still 
the most powerful drug against PD and almost all patients will eventually receive L-DOPA 
treatment at some point [88]. Co-administration with inhibitors of the aromatic amino acid 
decarboxylase is necessary to prevent early DA formation from L-DOPA, because DA is 
not able to cross the blood-brain barrier (BBB) and is further converted to norepinephrine. 
Since the use of such inhibitors shifts the metabolism of L-DOPA to another pathway, 
catechol-O-methyltransferase inhibitors are additionally administered to prevent further 
degradation. Advances in therapy often focus on more efficient administration or 
alternative delivery of L-DOPA to the brain and on preventing the side effects of long term 
therapies. The main complication upon chronic L-DOPA treatment is the development of 
dyskenesias among other motor and non-motor fluctuations [89]. The reason for the L-
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DOPA-induced complications are still poorly understood, but irregular dosage due to rapid 
peripheral clearance, and variability in uptake and transport may affect such clinical 
responses [90]. The pharmaceutical industry, therefore, concentrates on novel release 
formulations and a more continuous delivery to improve the clinical response. 
With L-DOPA still being the gold standard in PD treatment, deeper understanding of the 
nigrostriatal pathway revealed other possible targets in the dopaminergic system. Besides 
the peripherally active inhibitors to prevent the metabolism of L-DOPA, targeting the 
synaptic clearance of dopamine itself is an established treatment. For example, monoamine 
oxidase type A and B (MAOA/B) inhibitors, like selegiline and rasagiline, increase the 
synaptic concentration of dopamine [91]. Interestingly, selective inhibition of MAOA or 
MAOB does not alter the striatal dopamine levels [92].  
Figure 5. Schematic overview describing dopamine biosynthesis and metabolism. Natural L-DOPA is 
produced from the catalysis of the amino acid Tyrosine with the enzyme Tyrosine Hydroxylase (TH). 
Subsequently, Dopamine is the result of L-DOPA by decarboxylation with dopa decarboxylase (DDC). Since 
Dopamine itself cannot cross the BBB but L-DOPA can, the synthesis has to be blocked by DDC inhibitors 
that cannot cross the BBB. Dopamine metabolization happens by monoamine oxidase A and B. To 
efficiently increase striatal dopamine levels, both MAOA/B have to be inhibited. Reprinted with permission 
from ref [93]. Copyright (2006) Springer Nature. 
Furthermore, there are also postsynaptic active treatment strategies available. Dopamine 
agonists act directly on dopamine receptors and are often used in combination with L-
DOPA to prevent motor fluctuations. The main advantage of these agonists is their longer 
half-life and the possibility for continuous administration via transdermal patches. 
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Unfortunately, the effects are much smaller compared to L-DOPA and possible side 
effects, such as drowsiness and loss of impulse control, are serious drawbacks [94]. 
Besides the mentioned symptomatic dopaminergic therapy, there is a need for therapies 
that focus on the L-DOPA-induced complications and on the non-motor symptoms. Since 
non-motor symptoms originate from various regions in the nervous system, PD seems to 
have impacts on other parts of the nervous system apart from the dopaminergic pathways. 
Amantadine is the only drug for L-DOPA induced dyskensia currently in clinical use, 
although its efficacy is still a controversy [9, 95]. Often, the non-motor symptoms such as 
cognitive dysfunction, autonomic failure, and depression cannot be reduced by 
dopaminergic therapy strategies and can even be aggravated [57]. Clozapine is currently 
the most efficient drug to treat PD-related psychosis that does not worsen parkinsonism. 
Depressions – which are widely spread among PD patients – can be treated with common 
tricyclic antidepressants and serotonin reuptake inhibitors. Additionally, there are several 
drugs available to treat the autonomic failure in late-stage PD. In particular, droxidopa is 
used as special PD drug for postural hypotension, and common drugs to treat incontinence 
and constipation are available.  
1.2.5.2 Non-Pharmacological Treatment Strategies 
Besides pharmacological management to treat PD, there are surgical treatments and 
various non-invasive and experimental treatment options available. In cases of surgical 
treatments, deep-brain stimulation (DBS) has mainly replaced all other ablative procedures 
[96]. It needs the correct surgical implantation of small electrodes in either the globus 
pallidus internus or the subthalamic nucleus. These can be programmed to fire high-
frequency pulses usually of 130-185 kHz to reduce the inhibitory state of the thalamus. 
The mortality of DBS’s surgical implantation lies below 0.5%, but there is no guarantee of 
success with the therapy [97]. The candidate’s response to L-DOPA is an important 
criterion for a benefit-risk profile. Generally, DBS is favourable if the patient has an 
excellent response to L-DOPA but develops long-term motor complications. On the other 
hand, patients with no improvement of motor symptoms upon dopaminergic treatment also 
do not respond to DBS. Although there is only poor evidence for a neuroprotective effect 
of DBS, motor symptoms and the severity of L-DOPA-induced dyskinesia can be 
improved significantly in certain patients [98].  
Additional non-medical and non-surgical therapies include physical exercise, occupational 
therapy, language therapy, and cognition therapy. Various studies have documented the 
positive effects on motor and non-motor disabilities in PD [99]. Especially physiotherapy 
with exercises seems to help in disabilities like mobility, balance, and speech functions 
when the patients respond poorly to drugs and DBS [100].  
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1.2.5.3 Alternative Therapeutic Strategies and Clinical Trials 
Since a-syn is now widely regarded as a key contributor to the sporadic form of PD it has 
become a high value target for drug development. The main purpose is to identify and 
inhibit pathological species from transmission to other cells. Since a-syn accumulates in 
LBs, the hallmark of PD, prevention of such aggregate formation and its clearance may 
bring a disease-modifying effect. If a-syn really is involved in the disease progressing 
mechanisms, these strategies might even have a disease-halting effect. Currently, several 
anti-a-syn strategies are being pursued in clinical trials. The two most advanced strategies 
are both based on immunotherapy to remove toxic forms of a-syn and to stop the passing 
of the condition from one cell to another. AFFITOPE®, also called PD03A, from the 
company AFFiRiS, is a vaccine based on a a-syn-mimic plus an adjuvant for which a 
Phase II efficacy trial is currently planned. Besides this active immunization strategy, the 
company Prothena has developed a drug with a passive immunization approach [101]. 
PRX002, also called RG7935, is an anti-a-syn monoclonal antibody drug currently in 
Phase II clinical trial [102]. Other anti-a-syn drugs in early-stage trials are BIIB054 from 
Biogen, ACI-870 from AC Immune, NPT088 from Proclara Biosciences, and NPT200-11 
from NeuroPore Therapies Inc. 
Gene therapy is another strategy to overcome nigral neuronal loss and reduced dopamine 
levels by increasing the expression of disease-relevant proteins on site. Mainly two 
strategies are being tested to either increase expression of growth factors or enzymes in 
neurotransmitter synthesis pathways. All the gene therapies in human trials used either 
adeno-associated viral vector serotype 2 or lentivirus vector platforms [103]. Two PD gene 
therapies aimed for a neurotrophic factor approach by increasing the expression of 
neurturin or glia cell-derived neurotrophic factor. This could be an important step to form a 
neuroprotective environment for the remaining brain tissue in case a drug for slowing 
down PD progression is found. Another three approaches have tried to improve motor 
symptoms by indirectly increasing levels of GABA or DA via expression of glutamic acid 
decarboxylase or DDC and tyrosine hydroxylase (TH). So far, all five clinical gene therapy 
approaches in PD showed low efficacy, with some still being tested in clinical trials [104]. 
Nevertheless, the trials showed that viral vectors can be safely delivered to the brain and 
the foreign genes can be expressed without serious long term adverse effects. These 
progressions in the field provide an important basis for future trials. 
Besides stopping PD from progressing, bringing symptomatic relief for the patient, and 
stabilizing the condition in a neuroprotective environment, there is a need for replacing the 
affected cells. Unless there are early disease markers, parkinsonism is only diagnosed after 
half of the dopaminergic neurons in the SN have already been lost. Consequently, stopping 
disease progression will not provide normal motor function without further dopamine 
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replacement. The two strategies for a cell replacement-based therapy are either based on 
fetal cells or stem cells. The relatively old-fashioned approach of transplanting 
dopaminergic cells from aborted embryos or fetuses showed promising motor 
improvements in early reports. It even created some long-term improvements in a few 
patients, but limited beneficial effects overall, as well as adverse effects like graft-induced 
dyskinesias, were reported in several other clinical programs and contradicted these initial 
trials [105-107]. On the basis of a re-evaluation of these early studies, a new trial with fetal 
ventral mesencephalic dopaminergic cells was designed and is currently ongoing. This 
European clinical trial, known as TRANSEURO, aims to find a solution for graft-induced 
dyskinesias, which is important for future trials, especially when stem cell grafting in 
humans is being initiated [9, 106]. 
The second ongoing clinical study for cell replacement – the very first using stem cells – is 
being conducted by International Stem Cell Corporation (www.internationalstemcell.com). 
The company will be using human parthenogenetic neural stem cells (hpNSC), which are 
produced by chemically triggering cell division of unfertilized female egg cells. Using this 
process called parthenogenesis to produce cells for transplantation has the advantage of not 
destroying viable organisms as it is the case with embryonic cells, fetal cells, and 
embryonic stem cells. However, the GForce-PD consortium criticized these trials for being 
premature [108]. This international initiative of leading scientists working on stem-cell 
therapy for PD are discussing key issues to translate stem cell treatment in PD to a safe 
clinical model [106]. Besides hpNSC and human embryonic stem cells (hESCs), human 
induced pluripotent stem cells (iPSCs) can also be used to generate dopaminergic neurons, 
though hESCs seem to have the most potential [106]. However, using iPSCs would avoid 
most ethical problems associated with hESCs transplantation. The development of new 
differentiation protocols has brought hESCs to a similar level of efficacy as fetal 
dopaminergic neurons when tested in animal models [109]. Thus, the launch of stem cell 
grafting in human trials seems to be feasible within the next years. 
Another important issue that has to be considered regarding the long-term effects of such 
neuroregenerative strategies is that the pathology itself might affect the newly grafted 
tissue. In 2008, two studies showed that grafted embryonic dopaminergic neurons 
developed LB pathology in patients a decade after transplantation [110, 111]. It is likely 
that this will also be the case for stem cell grafting. This additionally exemplifies the 
urgent need for disease-modifying therapies in PD in order to avoid a compromise of 
neuroregenerative therapies. Nevertheless, the effects on grafted tissue might impair its 
function only after a decade, since the pathology progresses slowly and does only affects a 
minority of transplanted cells. Thus, the transplanted neurons could potentially be of 
therapeutic value for an extended period [112]. 
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1.3 Alpha-Synuclein 
1.3.1 a-Synuclein in Parkinson’s Disease 
The first time a-syn drew the attention of scientists was when its involvement in AD was 
discovered. In 1993, it was isolated from amyloid plaques in AD brains and was first called 
NACP, for non-amyloid component of plaques [113]. Later it was renamed to alpha-
synuclein due to the homology with synuclein from Torpedo electroplaques, where the 
name originated from the high abundance of synuclein in both synapses and nuclei of 
neurons [114]. The first link to PD was drawn in 1997 when a missense mutation A53T of 
a-syn was discovered in the “Contursi kindred” – relatives of a family branch originating 
in the town of Contursi Terme –  with apparent autosomal-dominant PD [69, 115]. This 
was also the first discovery of a genetic cause leading to PD. Additional mutations in the 
SNCA gene were discovered in the following years, which supported the evidence of an 
involvement of a-syn in PD. The most important autosomal-dominant mutations are A30P 
and E46K [116, 117], along with the more recently discovered H50Q and G51D [118, 
119]. Autosomal-dominant forms of PD were also reported for duplication and triplication 
in the SNCA gene, providing evidence that increased a-syn expression may result in a 
causal increased risk of developing PD [120, 121]. 
The most supporting discovery was made in 1997, soon after the first PD gene was found, 
showing that LBs were strongly immunoreactive to a-syn [33]. Sensitive antibody labeling 
soon replaced ubiquitin staining for detecting LBs and most importantly was applicable to 
sporadic PD and DLB [122]. This demonstrated that a-syn is most likely involved in more 
than only some specific types of monogenetic PD [123]. However, it is still unclear how a-
syn is involved in PD and other a-syn-related pathologies. 
1.3.2 Structure 
The SNCA gene consist of 6 exons with a size of 42 to 1110 base pairs. Exon 2 encodes 
the start codon ATG and the translation stops at a TAA stop codon which is encoded by 
exon 6. The full-length a-syn is the predominant form, but shorter isoforms have been 
reported as well [124]. a-Syn is an acidic protein (pKa of 4.7) of 140 amino acids with a 
molecular weight of 14.46 kDa.  
The alpha helical lysine-rich amino terminal domain (residues 1-87) has a crucial role in 
membrane interaction. It is a positively charged region, including seven series of 11 amino 
acid repeats which contains a highly conserved KTKEGV motif (Figure 6). The ability of 
a-syn to interact with lipid membranes is attributed to this repeat sequence which is similar 
to the a-helical domain of apolioproteins [125]. The core region (residues 65-90) contains 
a highly hydrophobic motif and is known as non-amyloid-β component (NAC), as this was 
the region of a-syn that was first purified from AD amyloid plaques [113]. The NAC 
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region is involved in a-syn amyloid formation because it can form cross β-sheets [126, 
127]. The acidic carboxyl-terminal domain (residues 91-140) is disordered and might be an 
important reaction site for small molecules, metals, and proteins. It contains 10 glutamic 
and 5 aspartic acid residues, which gives the tail a low hydrophobicity with a high net 
charge and thus, a random coil structure [128].  
Figure 6. Domain organization of a-syn. Common mutations in hereditary PD are labeled with red font. The 
blue parts show the N-terminal region with a positive charge, the red region shows the negatively charged 
C-terminus. The full length human micelle-bound a-syn structure was determined by NMR (PDB ID: 1XQ8) 
[129]. 
When expressed in Escherichia coli, a-syn predominantly exists as a stable intrinsically 
disordered monomer with few secondary structures [130]. In physiological conditions an 
unfolded monomer is expected to be susceptible to degradation, which is not in agreement 
with the high abundance of a-syn in various brain regions [131]. Therefore, 
oligomerization or association with other proteins and subsequent structural and functional 
changes were proposed. Indeed, a predominant oligomeric a-syn form could be isolated 
from mammalian cells, red blood cells, and even from Escherichia coli [132, 133]. These 
studies used NMR, SEC, chemical crosslinking, and native PAGE to show that a-syn folds 
to a tetrameric a-helical form, which seems to be resistant to aggregation. Conflicting 
results from other studies could not verify these findings, and showed in native gels that a-
syn derived from mammalian cell lines and red blood cells, or isolated from mice, rats, and 
human brains behaved similarly to stable unfolded a-syn produced in E. coli [134]. 
Additional NMR data ruled out a substantial population of stable oligomers but still 
recommended dynamic oligomer species that exist in an equilibrium with unfolded 
monomers [135].  
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The conformational flexibility of a-syn seems to allow the protein to adapt specific 
conformations depending on the interaction partner, such as membranes or other proteins. 
For example, an a-helical a-syn structure is stabilized upon binding with synthetic 
phospholipid membranes [125]. Several factors, including oxidative stress, post-
translational modifications, and the concentration of membrane constituents, were shown 
to shift the equilibrium from monomeric to different conformational or oligomeric states 
[131]. So far, little is known about the regulation of interaction and equilibrium 
mechanisms with different conformational or oligomeric changes of a-syn. Knowing how 
the conformational variability is involved in a-syn toxicity would be a crucial factor in 
targeting a-syn for therapeutic reasons. Currently, there are no studies resolving the a-syn 
oligomeric structure at a high resolution, likely due to a high heterogeneity of the formed 
oligomers. However, cryo-TEM single particle reconstruction of in vitro-produced a-syn 
oligomers showed that a hollow cylindrical architecture was a characteristic to all the 
heterogenous species, despite variations in size, β-sheet content, and exposed 
hydrophobicity [136]. This cylindrical architecture is similar to the amyloid fibrillary 
structure, suggesting that these oligomers which accumulate during the process of fibril 
formation are kinetically trapped in this state. In other studies, several more species have 
been observed including annular and chain-like oligomers and more might exist [137]. 
Besides the oligomeric species of a-syn, protofibrils and fibrils have been associated with 
the pathology of PD. Radially-oriented filaments were observed in early electron 
microscopic studies of LBs [32, 35]. Later, filaments were extracted from PD patients’ 
brains, which stained strongly with anti-a-syn-antibodies [122, 138]. Initial thoughts were 
that these aggregates of fibrils have the purpose of clearing toxic oligomeric species to 
form more stable fibrils with reduced toxicity. However, it was shown that the PD-linked 
mutations A53T and E46K enhance the fibril formation in vitro and in animal models 
[139]. 
During in vitro reconstitution, several different polymorphisms of a-syn fibrils were 
observed, including ribbon-like and helical filaments [140]. A number of studies 
determined the NAC region as crucial for such aggregations. For example, deletion of 
residues 71-82 within this region prevents the fibril formation, but the 12-residues segment 
itself can undergo self-aggregation [141]. Other regions outside of NAC are less crucial 
but can influence the filament structure. Electron paramagnetic resonance spectroscopy 
studies indicated a highly-ordered NAC region and a less ordered N-terminal region with 
heterogeneous secondary structures. The C-terminus is completely unfolded [142]. To 
date, no full-length structure of any a-syn fibril species has been determined. However, a 
central segment of the NAC domain with the crucial role for fibrillization (residues 68-78) 
was synthetically produced and the atomic resolution structure has been determined by 
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micro-electron diffraction [126]. The observed pairs of face-to-face β-sheets form the 
spine of the fibril.  
Recently, a cryo-EM structure of a-syn fibrils (residues 1-121) has been reported [143] 
where two protofilaments form the fibril. Interestingly, the NAC region in this structure 
was located at the center of a single protofilament, and therefore, cannot be responsible for 
the interaction between two protofilaments but rather contributes to the filament formation. 
Additionally, several familial SNCA mutations have been located at the core of the fibril, 
where they would compromise fibril formation and stability. 
1.3.3 Interaction Partners 
The physiological function of a-syn and its role in PD is not entirely understood. However, 
its role can be associated with its ability to interact with membrane lipids and with many 
proteins [128]. After the discovery that a-syn interacts with membranes in cell cultures and 
brain tissue in vitro, experiments with membrane mimics and physiologically relevant 
membranes were started to describe the a-syn-lipid interaction and to elucidate the 
membrane properties that affect the binding [144]. Binding experiments with liposomes 
comprised of different types of lipids suggested an electrostatic interaction with the lysine 
rich a-syn N-terminus. It was observed that a-syn only binds to anionic not zwitterionic 
lipids [125]. The preferred binding to negatively charged headgroups is in agreement with 
the physiological interaction of a-syn with phospholipids in biological membranes [145, 
146]. Upon membrane binding, the natively unfolded a-syn adopts a a-helical structure 
exclusively on the N-terminus, which is in contrast to the β-sheet formation in a-syn fibrils 
[147]. Furthermore, studies demonstrated the ability of a-syn to bind to small and large 
unilamellar vesicles with diameters of 10-100 nm and 100-1000 nm respectively [148]. 
The binding was stronger to the small vesicles and binding to giant unilamellar vesicles 
with a diameter larger than 1 µm was drastically reduced. This suggests that the membrane 
curvature has a strong effect on the membrane binding affinity of a-syn [149]. 
Furthermore, the binding affinity is affected by small packaging defects in the lipid 
ordering [150]. Taken together, binding of a-syn monomers to lipids is accompanied by a-
helix formation of the N-terminus and happens preferentially on negatively charged lipids 
in membranes with high curvature and defect structures. 
Besides the ability of a-syn to bind to membranous structures, it is possible that certain 
physiological or disease-related functions are caused by its ability to interact with many 
proteins. For example, an interaction with tubulin was suggested, since the formation of a-
syn fibrils is accelerated by inoculating the reaction solution with tubulin [151]. On the 
other hand, oligomeric species a-syn can inhibit the polymerization of tubulin into 
microtubules [152]. Co-immunoprecipitation studies also indicated a relation between a-
syn and LRRK2 although a direct biochemical interaction was not shown. It is assumed 
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that both proteins are involved in many common intracellular and potential pathogenic 
pathways, including microtubule assembly, function of mitochondria, and autophagy 
[153]. Furthermore, it was shown that A53T and A30P mutants of a-syn interact with 
syniphilin-1 in a different way than wild type a-syn. Instead of protecting a-syn from 
degradation by the proteasome [154], the mutant forms only bind and increase the number 
of a-syn-syniphilin-1 complexes [155].  
A list of interaction partners at the presynaptic terminal is compatible with a possible 
neurotransmitter regulation function of a-syn. Like mutations in LRRK2 and SNCA, 
mutations in parkin are a cause of familial PD. All three proteins are involved in synaptic 
vesicle dynamics, where they might interact with each other. Additionally, direct binding 
of a-syn NAC domain to the DA transporter (DAT) was reported. It was suggested that 
this interaction leads to membrane clustering of DAT, and thereby to enhances DAT 
activity with subsequent increased levels of intracellular DA, which can be damaging to 
neurons [156]. Further presynaptice protein interactions of a-syn include SNARE 
complex, synaptobrevin-2, vesicle-associated membrane protein 2 (VAMP2), rab3, and 
synaptic vesicle proteins synapsin III and synaptophysin [157].  
1.3.4 Function 
Human a-syn is mainly expressed in the SN, neocortex, hippocampus, thalamus, and 
cerebellum, where it is located predominantly at presynaptic terminals in a soluble state 
[158]. The nuclear localization of endogenous a-syn was never confirmed in humans and 
is the subject of controversial debates [128]. Several studies reported the existence of 
recombinant a-syn in nuclei of mouse brains and cell cultures [159]. In mice, a co-
localization with histones was observed as a consequence of exposure to the herbicide 
paraquat and subsequent increased concentration of a-syn in nuclei [160] or upon 
overexpression of a-syn in transgenic mice [161]. The physiological and pathological 
importance of these findings are not clear at the present time. 
Several immunohistochemical studies have reported a predominant synaptic co-
localization of a-syn and subcellular fractionation revealed an extensive synaptosomal 
localization [162]. Because a-syn has later been detected in vesicular fractions of the 
human brain [163] and a-syn binding to liposomes was demonstrated [125], the 
physiological function of a-syn was assumed to be associated with synaptic vesicles. 
Primary cell cultures with suppressed expression of a-syn showed a decrease of the 
vesicular pool [164]. A modest overexpression of a-syn led to a reduced neurotransmitter 
release and a smaller synaptic vesicle recycling-pool due to a reduced synaptic vesicle 
reclustering after endocytosis [165], with the consequence of impaired neurotransmission 
[166]. At this position, a-syn might act as a modulator of intersynaptic vesicle mobility to 
maintain recycling-pool homeostasis [167]. Overall, these studies suggest a physiological 
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role of a-syn to attenuate neurotransmitter release. However, late a-syn agglomeration 
during neurodevelopment and its sole expression in vertebrates does not concede an 
essential function for basic neurotransmitter release [168]. 
The exact mechanisms of the a-syn action on synaptic vesicle regulation are yet to be 
determined. As of now, many interaction partners with a neurotransmitter release function 
were found, though some of them might be responsible for the synaptic physiology of a-
syn. One associated protein family of utmost importance in the neurotransmitter release 
cycle are the SNARE complexes. These proteins mediate the membrane fusion of synaptic 
vesicles and are, therefore, crucial for vesicle release and recycling. During SNARE 
complex assembly/disassembly in each neurotransmitter release cycle, the SNARE 
proteins are particularly vulnerable to degeneration. At this stage, a-syn acts as a 
molecular chaperone, assisting in SNARE complex assembly [169, 170]. Specifically, a-
syn directly binds to the SNARE proteins synaptobrevin-2 and VAMP2, and assists the 
assembly through a nonenzymatic mechanism [171]. In vitro assembly was only possible 
with proteins reconstituted in plasma membrane mimics, thus cytosolic monomeric a-syn 
is not able to enhance the assembly, it requires the formation of a multimeric membrane-
bound state [172, 173].  
The chaperone function of a-syn has been reported in other cellular processes and is 
consistent with important chaperone qualities: i) a-syn is capable to interact with other 
intracellular proteins via the N-terminus; ii) it is structurally and functionally homologous 
to the 14-3-3 family of chaperone proteins [174]; and iii) the C-terminus of a-syn acts as a 
solubilizing domain based on the observation that it suppresses aggregation under chemical 
and thermal denaturing conditions [175]. 
a-Syn has been reported to bind to polyunsaturated fatty acids, suggesting a role in 
controlling the polyunsaturated fatty acid level in the brain. However, this is controversial 
because it is unlikely that a-syn acts as a carrier for fatty acids [176]. 
a-Syn may also be involved in suppression of apoptosis and may act as an antioxidant. By 
modulating nuclear factor-!B it indirectly acts on the protein kinase C " levels, which is 
involved in apoptosis mechanisms [177]. Protein kinase C " is oxidative stress sensitive, 
therefore, the antioxidant effect of a-syn has an impact on apoptosis too. Furthermore, 
dopaminergic neurons are particularly prone to oxidation of unsaturated phospholipids 
because they generate highly reactive dopamine. Only the monomeric form of a-syn can 
bind to lipid membranes in such a manner that it prevents lipid oxidation [178]. 
Another hypothesis suggests the involvement of a-syn in apoptosis not via antioxidant 
effects or protein kinase C, but via interaction with cytochrome c oxidase in mitochondrial 
membranes [179].  
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Generally, it is believed that the main physiological function is attributed to the 
localization of a-syn to presynaptic terminals. Subcellular localization also revealed 
substantial concentrations in nuclei, mitochondria, endoplasmatic reticulum, golgi, and red 
blood cells. At this locations, the functional significance remains unclear [168]. Whilst 
understanding the physiological role of a-syn does not directly lead to pathological effects 
in PD, it might be important therein. 
1.3.5 Neurotoxicity 
Since a-syn was found to be a main constituent of LBs it has become the most promising 
candidate to be involved in PD pathogenesis. The underlying molecular mechanisms 
related to toxic a-syn species and PD are poorly understood and highly controversial 
(Figure 7). In cases where one or more misfolded a-syn strains are the cause of PD, during 
the folding process of natively disordered monomers to multimers, and oligomers towards 
protofibrils, fibrils, and eventually LBs, there must be an a-syn species which has acquired 
neurotoxic properties. Therefore, it is crucial to investigate the mechanisms that lead to the 
initial misfolding, detect the toxic species, and understand their biomolecular action on 
neurons. In order to develop a neurotoxic effect, disease-responsible forms of a-syn need 
to spread over several brain regions to finally affect the brain in a neuropathological 
pattern. The theories behind the spreading of PD neuropathology are discussed in 
chapter 1.4.2 and 1.4.3. Independent of the species that might play the main role in the 
disease pathogenesis, all of them are in an equilibrium whereby higher order species are 
constantly built and disintegrated from a pool of endogenous a-syn. How these equilibria 
behave would be an interesting study but challenging due to problems in categorizing 
different species in a constantly moving ensemble. 
Starting from monomers, overexpression of a-syn in mice led to increased neurotoxic 
effects [161, 180, 181] and outweighed the neuropathological alterations resulting from a-
syn depletion [182, 183]. This correlates with the higher risk of developing PD in patients 
with SNCA gene multiplication [121, 184]. It does not necessarily indicate a possible 
pathogenic role of monomeric a-syn. It rather suggests that higher concentrations increase 
the likelihood of forming higher order a-syn complexes, in which toxic a-syn species 
might also be produced. 
When assessing the toxicity of the monomeric, oligomeric, or fibrillary form of a-syn, 
either the in vitro-produced or in vivo-recovered a-syn species is often seeded into model 
systems to induce PD pathology. Under these physiological conditions, fibrillary a-syn 
forms have proven to be the only species capable of recruiting endogenous a-syn, and the 
cytotoxic potential was demonstrated [185]. The relevance of seeding capacity is subject of 
the ‘a-syn spreading theories’ (Chapter 1.4.2). Regarding the cytotoxic effects, there is 
some controversial evidence of toxic effects of fibrils, depending on the model system. In 
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animal experiments, inoculation of synthetic human a-syn fibrils into transgenic mice 
initiated LB pathology and reduced lifetime [186]. Importantly, this was observed for 
experiments with wild-type mice as well [187]. Even the brain homogenate of older 
transgenic mice with a-syn pathology had a pathology-accelerating effect upon inoculation 
in younger mice [186]. Fibrils were also isolated directly from PD patients brain 
homogenate, but there is no literature repeating those studies with control subjects [122].  
However, as fibrils are an inert entity, they might have a sort of storage or clearance effect 
compared to the several types of metastable oligomers that exist during the assembly 
process [188]. Furthermore, some data suggest that fibrils cannot be efficiently formed 
without an air-water interface [189]. Thus, fully developed amyloid assemblies might play 
an important role in PD, but scientific opinion has been shifted to transient oligomeric 
species as being the important cytotoxic species [139, 190]. Still, recent findings have 
revealed fundamental differences of fibril polymorphisms with different levels of toxicity, 
which brings a-syn fibrils as disease-responsible candidate back to the discussion [140]. 
Figure 7. Possible toxic effects of a-syn. Reprinted with permission from ref [191]. Copyright (2016) 
Ingelsson Creative Commons License 4.0. 
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In vivo experiments with a rat lentiviral system demonstrated a significantly higher toxic 
effect of the oligomer-forming E35K and E57K a-syn mutants versus the human wild type 
form [137]. The loss of nigral tyroxine hydroxalse positive neurons was most striking for 
the oligomer-forming mutants but was not significantly higher compared to the fibril-
forming E46K mutant. In cell-based systems, the E57K oligomer-forming mutation had the 
highest toxic effect. Besides the acute lentiviral expression of oligomer forming a-syn 
mutations, transgenic mouse models were developed where these mutations are chronically 
expressed throughout the brain. A chronic a-syn mutation E57K expression showed 
extensive synaptic and dendritic loss, and a reduction of synapsin 1 and synaptic vesicles 
[192].  
In addition to a large number of studies on cellular and animal models, direct clinic-
pathological observations in brains with LB pathology were made regarding the oligomeric 
a-syn species. Compared to healthy controls, increased levels of soluble a-syn oligomers 
with various sizes were detected [193, 194].  
There are far more studies focusing on the toxicity of oligomeric species. Therefore, most 
proposed a-syn cytotoxic mechanisms are based on oligomer-mediated effects. Since 
several physiological functions of a-syn have been proposed, direct cytotoxic effects may 
arise by perturbing these natural functions. Specifically, it was speculated that altering the 
regulating role of a-syn in SNARE complex mediated processes leads to synaptic toxicity 
and impaired neuronal signaling. In vitro studies revealed that large a-syn oligomers 
efficiently inhibited SNARE complex mediated vesicle docking [195]. Extracellularly 
added a-syn oligomers, but not monomers and fibrils, displayed an impairment of long 
term potentiation in hippocampal brain slices of rats [196]. An increased synaptic 
transmission based on N-metyl-D-aspartate receptor activation was suggested to abolish 
the long term potentiation, since the effect could be avoided by blocking this glutamate 
receptor subtype.  
Another toxic property of a-syn is thought to be a consequence of its ability to impair 
membrane integrity and permeability. On synthetic vesicles, protofibrils rather than fibrils 
or monomers were binding very tightly and permeabilized the membrane [197]. Further, 
the oligomer-prone mutants A30P and A53T have revealed greater permeabilizing ability 
than wild type a-syn [198]. Consequently, rupture of the lipid membrane can induce 
calcium influx into the cell and disrupt cellular ion homeostasis. In cell cultures, various 
oligomers were reported to induce cell death, presumably by forming a pore in the cell 
membrane [199]. This would be consistent with earlier studies where perturbed calcium 
homeostasis was suggested to be important in the pathogenesis of AD [200]. 
Intracellular degradation of a-syn is assigned to the autophagy-lysosome pathway and the 
ubiquitin-proteasome system. The first seems to be more important in the clearance of 
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oligomeric a-syn species, mainly by macroautophagy and chaperone-mediated autophagy 
[201]. Impairment of these systems could contribute to accumulation of misfolded a-syn 
due to weak clearance. Since the activity of both systems decline with normal ageing, the 
increasing level of a-syn in the SN is consistent with the reduced proteostasis activity 
[202]. In return, it was reported that the ubiquitin-proteasome system could be impaired by 
a-syn oligomers [203] and a-syn overexpression, or that different forms of a-syn inhibit 
both main mechanisms of the lysosomal autophagy system [204, 205]. Another study 
showed that accumulation of a a-syn reduced the lysosomal activity in dopaminergic cell 
models likely due to decreased hydrolase trafficking [206]. Thus, this vicious cycle where 
the degradation systems are inhibited by their target needs fewer initial toxic species to 
trigger a pathologic chain reaction. With respect to ageing – the widely accepted main risk 
factor – a progressive impairment of proteolytic mechanisms, which leads to an increasing 
aggregate accumulation in the ageing brain, might explain the higher risk of PD in older 
age and LB formation in otherwise neurologically healthy individuals. 
Mitochondrial dysfunction by direct and indirect action of different forms of a-syn has 
been implicated as an important cytotoxic effect in the pathogenesis of PD. Furthermore, 
dopaminergic neurons are particularly sensitive to mitochondrial defects as they have a 
high-energy consumption and increased oxidative stress [207]. There is evidence from 
several in vitro studies to suggest that a-syn localize to mitochondria where it 
predominantly associates to the inner mitochondrial membrane [208, 209]. Consequently, 
increased mitochondrial dysfunction due to impaired complex I function was detected 
[210]. Overexpressed oligomer-forming a-syn A53T and A30P or overexpressed wild type 
a-syn in SH-SY neuroblastoma cells were aggregated and localized inside mitochondria 
[211]. The binding to mitochondria is concentration dependent. Simultaneously, decreased 
mitochondrial transmembrane potential, increased mitochondrial reactive oxygen species, 
and impaired cellular respiration was shown. In mice, overexpression of A53T a-syn in 
dopaminergic neurons led to a localization of monomeric and oligomeric a-syn to 
mitochondria, and increased mitophagy was detected along with impaired complex I 
function [212]. Morphological changes of mitochondria were observed in a-syn 
overexpressing SH-SY5Y cells. The increased expression caused the formation of a-syn 
oligomers which were suggested to be involved in the mitochondrial fragmentation [213]. 
Interestingly, the fission preceded any defective mitochondrial function [214]. Overall, it 
was shown in animal and cell models that a-syn oligomers, rather than monomers and 
fibrils, are able to elicit several mitochondrial phenotypes, including reduced complex I 
activity, reduced mitochondrial transmembrane potential, altered Ca2+ homeostasis, and 
enhanced cytochrome c release [215]. Overall, mitochondrial deficits, with or without a-
syn toxicity, is recognized as a crucial pathogenic event in PD [216]. Besides natural age-
related progressive mitochondrial dysfunction, the role of mitochondria in PD is 
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underlined by neurotoxins like methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) and 
rotenone, which can induce nearly identical symptoms to parkinsonism [217]. 
Additionally, several mitochondria-related gene mutations, including PINK1 and DJ-1 are 
associated with familial PD [70].  
Endoplasmatic reticulum is another cell organelle that is involved in the cellular toxicity of 
a-syn. Accumulation of a-syn with toxic oligomer formation within the endoplasmatic 
reticulum has been demonstrated in mice overexpressing A53T a-syn mutants and in 
human brain with LB pathology [218]. The subsequent chronic stress and impaired protein 
quality control of the endoplasmatic reticulum may contribute to PD pathology. 
Medication with an endoplasmatic reticulum stress inhibitor reduced levels of oligomers in 
mouse endoplasmatic reticulum and [218] reduced microsomal accumulation of both 
monomeric and oligomeric a-syn [219]. Furthermore, only oligomeric a-syn but not 
monomeric or fibrillar a-syn was efficiently able to induce the endoplasmatic reticulum 
response factor x-box binding protein 1 [220]. 
Inducing a neuroinflammatory response of glia cells might be a further mechanism in a-
syn neurotoxicity. While physiologically working astrocytes and microglia participate in 
clearance of pathologically active protein aggregates, upon contact with a-syn aggregates 
they have a pro-inflammatory effect and cause inflammation and enhanced 
neurodegeneration [221, 222]. Although there are reports that fibrillar a-syn species lead 
to a stronger inflammatory response [223], several in vivo and in vitro studies showed 
enhanced oligomer-induced inflammatory signals in microglia [224-226]. It was proposed 
that the phagocytosis of oligomers leads to the activation of NADPH oxidase and 
production of reactive oxygen species [224]. Another report showed that MAP kinase 
inhibitors could prevent the oligomer-induced microglia activation and attenuated the 
neuronal loss in rats [225]. Altogether, several studies suggest that mostly a-syn oligomers 
could develop toxic effects and enhance inflammatory responses by microglia activation.  
Overall, several mechanisms for fibrillar and oligomeric a-syn-induced neurodegeneration 
were suggested, and oligomers are the most convincing candidates for being responsible 
for several damaging effects, and thus a possible target for a therapeutic interventions 
[191].  
1.4 Synucleinopathies 
Synucleinopathies is an umbrella term for all neurodegenerative conditions with a 
pathological LB characteristic. As it is not known to what extent a-syn pathology is 
involved in the mechanisms of the individual diseases and a-syn pathology also occurs in 
neurologically healthy individuals, this term might have little practical value in 
diagnostics. Still, pathological similarities raise hopes of transferring scientific findings 
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among the conditions and eventually making use of one potential pharmaceutical treatment 
in several a-syn related diseases. The three main synucleinopathies are sporadic PD, DLB, 
and multi system atrophy (MSA). However, AD was the first identified and likely the most 
frequent neurodegenerative disorder with a-syn-containing deposits in patients [113]. 
Additionally, pathologic a-syn accumulations have been found in several other rare ND, 
including neurodegeneration with brain iron accumulation 1 (formerly Hallervorden-Spatz 
syndrome) [227, 228], amyotrophic lateral sclerosis (ALS) [229], Parkinsonism-dementia 
complex of Guam [230], frontotemporal dementia [231], Pick disease [232], diffuse LB 
disease [233], pure autonomic failure [234], progressive supranuclear palsy [235], Krabbe 
disease [236] and corticobasal degeneration [237]. It is unclear whether synucleinopathies 
share a common pathogenic mechanism or if there is a mutual relationship with a common 
final pathology [238]. 
1.4.1 Lewy Pathology 
The function of LBs is not understood. Most studies view LBs as neurotoxic, whereas 
some theories attribute a certain neuroprotective function by clearing cytotoxic a-syn 
species from neurons [37, 188]. Since Lewy pathology occurs in many diseases, mostly not 
in consistent patterns, and 10% of neurologically normal individuals over 60 years are 
affected [239], the relevance of these abnormal deposits are often questioned. Furthermore, 
the severity of the Lewy pathology often does not correlate with the disease progression 
[240] and patients with parkin gene mutations or the LRRK2 G2109S mutation often do 
not show any LB formation [46]. 
To understand the pathological function of LBs, the formation process and exact structure 
is crucial. Although the molecular composition was determined, LBs could not be 
generated artificially and there is only speculation about the formation mechanism. The 
ultrastructure of LBs was determined in 1965 and remains the primary described structure 
to date [35]. This study revealed that LBs are not confined circular bodies with a densely 
packed core surrounded by radiating filaments. This was confirmed later and two different 
types of LBs were proposed, a common classical type and a second cortical type without a 
dense core but mainly composed of circular fibrils [32]. Later, dense core vesicles were 
described as being located in the vicinity of LBs [241]. 
However, recent findings suggest a different structure, in which the LB contains a crowded 
mass of membranes from vesicles, deformed mitochondria, and disrupted cytoskeletal 
elements [242]. In contrast to all the other studies, no filamentous structures were 
observed, mitochondria were most frequently found in the periphery and the vesicular 
structures were detected in the center of the LBs. Based on these findings, a five-step 
model of LB formation was proposed with the conclusion that impaired trafficking of 
organelles is a key driver of PD pathogenesis [242]. These results are currently still under 
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review and have not yet been replicated. Thus, further research is needed to understand the 
nature and the role of LBs in synucleinopathies. Support for these findings could be 
provided by a recently developed transgenic mouse model [243]. By inactivation of 
constitutive autophagy in dopaminergic neurons, LB formation was induced, which 
contained many mitochondria. 
1.4.2 Prion-like Spreading 
The Braak staging proposed a characteristic spatiotemporal spreading pattern of Lewy 
pathology between interconnected regions in the PNS and CNS in PD patients [244]. 
Additionally, spreading of the host pathology onto grafted neurons in PD-affected brains 
was discovered [110, 111]. These neuropathological findings suggested a spread of Lewy 
pathology in a prion-like manner [245]. This prion hypothesis has been supported by a 
growing number of studies, which show the necessary steps for a-syn to spread along 
neuronal projections, being internalized and released by neurons, and recruiting 
endogenous a-syn to misfold [246].  
The prion-like spreading theory presumes an initial misfolding of a-syn to trigger the 
disease. The subsequent toxic function of oligomer and fibril species has been discussed in 
chapter 1.3.5. Although oligomer and fibril formation is reproducible in vitro, the initial 
formation in the nervous system remains elusive, especially since an air-water interface is 
required for the aggregation [189]. It is assumed that normal stochastic misfolding and 
failing quality control mechanisms can result in a meta stable species that starts the 
spreading. Thus, high local a-syn concentrations due to relative overproduction may favor 
such an equilibrium shift from monomeric to oligomeric species [247], or certain 
mutations could increase the stability of a-syn in an oligomeric state [139]. Impaired 
proteolytic defense mechanisms, which normally degrade protein accumulations, and 
certain vulnerable neuronal populations may also play an important role in the initial 
triggering of a-syn accumulation and aggregation [248]. To assess the other elements of 
protein spreading, specifically axonal transport, uptake and release by neurons, and 
accumulation of endogenous a-syn, a list of experiments have been done in cell cultures 
and in vivo.  
1.4.2.1 Transport 
The relatively long distances between the typical LB-affected brain regions makes axonal 
transport likely to be involved in the spreading of PD pathology. Experiments with 
neuronal cell culture systems showed both retrograde and anterograde transport of 
preformed oligomeric [249] and fibrillar a-syn [250], with transport in retrograde direction 
being more efficient [251]. Although transport velocity in the anterograde direction is 
similar to fast axonal transport, it was suggested that a-syn aggregates are transported by 
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the axonal slow component b transport due to observed characteristic pauses. Additionally, 
a-syn fibrils might share features with the slow component b cargo [250]. Axonal transport 
of preformed aggregates from an initial neuron to second and third order neurons was 
observed and aggregation of endogenous a-syn was induced in the new cellular hosts [252, 
253]. Thus, initial misfolded a-syn has the potential to progressively spread and induce 
Lewy pathology in distant regions, which is consistent with the Braak staging. 
Cell-to-cell transmission of a-syn aggregates was shown in several in vivo experiments. 
Wild type and a-syn transgenic mice injected with preformed fibrils or fibrils isolated 
from PD brain homogenate of transgenic mice showed endogenous a-syn aggregate 
formation at the injection site and in axonal retrograde and anterograde connected brain 
regions [186, 187]. Similarly, the intracerebral inoculation of isolated a-syn derived from 
DLB and PD patient brains induced a-syn pathology in monkeys and wild-type mice [254, 
255].  
Overall, axonal transport was shown in cell culture systems and animal experiments with 
intrastriatal pathogenic a-syn injection, which suggests a disease progression that is 
consistent with the Braak spreading. Still, the involved cellular mechanisms are largely 
unknown. 
Besides axonal transport, a direct cell-to-cell transfer of a-syn assemblies over short 
distances was hypothesized, since transmission via tunneling nanotubes was already 
demonstrated for the scrapie prion protein [256]. Recent findings confirmed the spreading 
of fibrillar a-syn in co-cultured neurons through tunneling nanotubes [257]. Importantly, 
this transport was also demonstrated between non-neuronal cell types, which would ease 
the transfer throughout the brain [258]. The transfer of the aggregates from the initial cell 
happened inside lysosomal vesicles. The recipient cell showed clear signs of seed 
fibrillization of endogenous a-syn. These findings suggest a new role for lysosomes in the 
spreading of a-syn assemblies. 
1.4.2.2 Release 
In cell culture based experiments axonal transport of preformed fibrils from an initial cell 
population up to a third order population was observed [252]. Consequently, an uptake and 
release must have happened in order to spread the aggregation. Importantly, a-syn 
monoclonal antibodies reduced spreading in vivo and in vitro by inhibiting aggregate 
uptake and, therefore, cell-to-cell transmission [252]. Since antibodies have access to the 
preformed fibrils, they are not being secreted in vesicles.  
In vitro, soluble forms of a-syn may be secreted by non-classical endoplasmatic reticulum 
independent vesicle-mediated exocytosis [259, 260]. Whether the same pathway mediates 
the release of aggregated a-syn is not clear. Recently, involvement of ubiquitin-specific 
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peptidase 19 and DnaJ/Hsc70 pathways in the release of a-syn was demonstrated [261, 
262]. Both chaperone-mediated pathways secrete their cargo in a non-encapsulated form. 
Furthermore, release of fibrils after retrograde and anterograde transport is likely to be 
independent of cell lysis, as observed in primary cell cultures [251]. Overall, a non-
conventional secretion of a-syn assemblies seems likely.  
Exosomes might also participate in bridging the extracellular space during cell-to-cell 
transfer. However, exosomal release of fibrillar a-syn has not been demonstrated yet [246]. 
In general, the amount of endogenous a-syn secreted in exosomes is significantly lower 
than a-syn secreted by exocytosis [263, 264]. Other a-syn assemblies, like smaller 
oligomeric species, may still participate in the release via exosomes. 
Additionally, the transfer from cell-to-cell through tunneling nanotubes was shown, which 
makes the release of toxic a-syn into the extracellular space obsolete [257]. Although this 
type of transfer is believed to be highly efficient, it remains unclear to what extent it 
participates in the spreading of a-syn. 
1.4.2.3 Uptake 
The uptake of preformed aggregates from the cell media is a rapid process in cell culture 
systems. It was reported that after 16 hours incubation of cells with a fibril concentration 
of 0.5 and 1 µM the uptake efficiency of the cells was 75 and 100 %, respectively [257]. In 
general, incubation for 1 hour in vitro for seed uptake was sufficient [265]. When a-syn 
fibrils were injected in mouse brains, they were found in neurons and glia cells close to the 
site of injection within a few hours [266]. Aggregates were taken up in cell soma, 
dendrites, and axons, explaining the transport in axonally retrograde and anterograde 
connected brain regions [250, 252, 253]. There are various reasons for the conflicting 
uptake concentrations and kinetics reported. Different cell culture types and conditions 
could influence the ability of the cell model to internalize the protein aggregates. 
Furthermore, a-syn oligomer and fibril formation could have been conducted under 
different conditions, and prolonged sonication time and power to fragment the fibrils could 
have produced different seeds. Especially, in vitro-prepared fibrils can be influenced by 
many conditions, including type of buffer, temperature, and concentrations, leading to 
different fibrillary strains, which might have different spreading properties [140, 267, 268]. 
It is likely that uptake of a-syn aggregates follows endocytic pathways, based on the 
observation that reduced uptake was found when endocytosis was inhibited by low 
temperatures or blocking of dynamin 1 [259]. Marking endosomal trafficking against early 
endosome proteins EEA1 and Rab5, and late endosomal markers Rab5 and LAMP1, 
revealed that internalized proteins merged in early and late endosomes and in lysosomes 
[269-272]. For most internalized aggregates, lysosomal degradation happens within hours, 
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but conflicting reports suffer from similar experimental heterogeneity as for the reported 
uptake kinetics. How the remaining a-syn aggregates escape from the endosomal 
compartment before degradation is not known. However, the surrounding lipid membranes 
prevent access to endogenous a-syn, which is required to comply with the prion-like 
theory. 
Several cell surface proteins that can interact with a-syn were identified. Heparan sulfate 
proteoglycans (HSPG) is a potential binding partner for neurodegenerative hallmark 
proteins, including scrapie prion protein [273, 274], a-syn, and misfolded tau. [275]. 
HSPG initial interaction might be of non-specific electrostatic nature. Still, heparin can 
competitively inhibit internalization of a-syn fibrils [275]. Interestingly, internalization of 
larger a-syn amyloid aggregates but not non-amyloid oligomers is dependent on HSPG 
[276]. 
Recently, lymphocyte-activation gene 3 (LAG3), neurexin 1β and APLP1 were recognized 
as cell surface partners for a-syn preformed fibrils [277]. LAG3 most selectively bound to 
fibrils and co-endocytosed in cortical neuron cultures. Overexpression of LAG3 increased 
the uptake of fibrillary a-syn whereas knockdown of LAG3 prevented a-syn pathology. 
Similarly, internalization could competitively be blocked by LAG3-specific antibodies 
[277]. 
In addition to HSPG and LAG3, the a3-subunit of Na+/K+-ATPase (NKA) was identified 
as a potential binding partner for a-syn aggregates [278]. Similar to LAG3, NKA 
specifically interacts with a-syn fibrils but not with monomers. The authors demonstrated 
that NKA got trapped within clusters of a-syn assemblies on the cell membrane. This 
compromised the Na+ gradient in cultured neurons and may affect the relation with several 
other interaction partners.  
1.4.3 Neuronal Selective-Vulnerability 
With the increasing popularity of the a-syn pathogenic spread theory, there is also a 
growing resistance against the simplicity of the “prion-like” spreading mechanisms [55]. 
The principal alternative is a concept based on cell-autonomous factors which make certain 
neurons intrinsically more vulnerable to PD pathogenic processes. This older concept of 
selective neuronal vulnerability mainly conflicts with the oversimplification of non-cell-
autonomous mechanisms of the pathogenic spreading.  
Although the prion hypothesis provides an explanation for the progressive spreading 
pattern in PD brains, it fails to explain the observed staging of the Lewy pathology, on 
which the Braak stages are based. Besides that, the Lewy pathology cannot completely be 
correlated to all clinical states [53]. The idea of inter-neuron LB spread through the brain, 
driven by endogenous a-syn recruitment, cannot explain different spreading patterns and 
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affection of non-connected areas. The selective vulnerability hypothesis suggests cell-
autonomous mechanisms that drive the Lewy pathology and neuronal death; a-syn itself is 
not seen as a propagating pathogen [279]. To date, little is known about the selective cell 
death of similar neurons within the same brain regions [63]. However, a vulnerable neuron, 
which is susceptible to PD-associated factors like age, environmental toxins, mutations, 
and oxidative stress, is possibley also more vulnerable to a-syn pathology, including the 
pathogenic spreading. Albeit the prion hypothesis is simple and has its shortcomings, it can 
be combined with the selective vulnerability theory, which would explain a lot of the 
pathology in PD [280]. 
1.4.4 Strain Dependence 
Regarding a-syn as main pathological driver in synucleinopathies, basic differences in 
their pathology might be explained with different “strains” of toxic a-syn adopting 
different structural conformations [281]. It was hypothesized that the assemblies 
themselves, rather than the process of formation and spreading, may cause the toxic 
effects. Consequently, one protein but different strains could explain the various outcomes 
in different synucleinopathies. Additionally, the pattern of Lewy pathology, which can 
eventually be linked to clinical symptoms, can vary in different cases of the same disease. 
The reasons underlying these distinct clinical and pathological phenotypes within one 
disease remain unclear but might also be explained by the “strain hypothesis”. Recently, 
this hypothesis was supported with the characterization of two different a-syn assemblies 
[140]. These two a-syn polymorphs, fibrils and ribbons, had different levels of toxicity and 
showed different propagation properties in cell cultures. Following these findings, the 
same fibrils and ribbons were injected to the SN of rats [282]. It was shown that fibrils 
appear to be the major toxic strain, having a higher potential for degenerating 
dopaminergic neurons and causing motor deficits. In contrast, ribbons caused more 
deposition of a-syn in the brain. Furthermore, intravenous systemic administration of the 
same strains crossed the BBB. In the brain, ribbons but not fibrils led to the generation of 
glial cytoplasmic inclusions.  
Additionally, a-syn strains were discovered that showed different efficiencies in cross-
seeding tau aggregation [267]. Not only neuronal cell cultures but also a-syn inoculated 
mice showed signs of differentially induced tau pathology, depending on the a-syn strains. 
Overall, fibrillar a-syn polymorphisms were demonstrated to have different efficacies in 
the recruitment of endogenous a-syn as well as in their ability to promote tau inclusions. 
They exhibited different toxicities, binding efficiencies, and penetration efficiencies in cell 
cultures [185]. 
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1.5 Cell Culture Models for Parkinson’s Disease 
The field of PD has been struggling for a long time to find a disease-relevant animal model 
system that presents all the cardinal symptoms of PD. The multitude of the established 
animal models are rodent models, which only partially recapitulate the pathological 
features observed in humans. The growing importance of non-motor signs in PD patients is 
only poorly described in rodent models [283]. To study a single PD feature, cell culture 
models are an important alternative to animal models. Defined cell types in homogeneous 
isolation offers the advantage of studying specific cellular processes, which appear to have 
an important contribution to a disease, as it is the case for dopaminergic neurons in PD. 
Regarding our limited understanding of a-syn-mediated toxicity, it is important to 
investigate the cytotoxic mechanisms by reproducing the main aspect of disease spreading, 
including uptake, release, transport, and seeded aggregation of a-syn on easy cellular 
models. Since neither animal nor cellular models are able to fully recapitulate PD, 
dissecting the overall processes in simple molecular events is important to identify the 
main players in this disease [284]. However, the pathogenesis of a disease requires the 
interaction of several cell types, which to a certain degree can be established in cell culture 
systems but often can only be studied in animal models.  
Besides restricting the number of animal experiments for ethical reasons, cellular models 
offer several advantages: (i) easy access to genetic modifications for pharmacological 
testing; (ii) accessibility to imaging and biochemical analysis; (iii) experimental upscaling 
and high-throughput screening for pharmacological candidates and disease conditions 
[285]. Primary cell cultures only partially share these advantages, since they are derived 
from rat or mouse embryos and have a finite life span. This excludes their use in high-
throughput experiments and ethical questions still arise. Additionally, heterogeneous cell 
populations and differences among preparations are major drawbacks. 
The development of differentiated dopaminergic cell models is of particular interest in PD 
research. Although other types of neuronal cells in PD brains are known to degenerate, 
these cells are particularly vulnerable. Thus, the importance of dopamine depletion and 
motor-symptoms in PD puts dopaminergic neurons in the focus of many studies. Primary 
neuron cultures yield less than 10% dopaminergic neurons, whereas immortalized cell 
lines display the full range of advantages of cellular models and can present monocultures 
of dopaminergic neurons [285, 286]. Immortalized cell lines are generally easy to maintain 
with minimal equipment and their rapid proliferation makes them accessible to large scale 
studies [287]. In contrast to primary cell cultures, they can also originate from humans.  
In PD, several immortalized cell lines from human and mouse have been used, mainly 
HEK293, H4, SH-SY5Y, PC12, and LUHMES cells [284]. Although HEK293 cells do not 
have a dopaminergic phenotype [284], they are frequently used to study a-syn aggregation, 
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secretion, and transmission, since they are suitable for large scale screening and easy to 
cultivate [288, 289]. 
The human neuroblastoma cell line SH-SY5Y can develop dopaminergic neuron-like 
properties upon differentiation with retinoic acid [290]. They are easy to maintain which 
makes them suitable for large screening studies, but differentiation can be difficult and the 
cell response can be inconsistent [291]. Since the differentiated cells can exhibit 
dopaminergic, cholinergic, and noradrenergic phenotypes using various differentiation 
protocols, they are not considered as authentic dopaminergic neurons [292]. 
PC12 are another frequently used cell line in PD research. The cells from a 
pheochromocytoma of the rat adrenal medulla can be differentiated towards a neuron-like 
phenotype. They are often used to study PD toxins since they are susceptible to 6-OHDA, 
MPP+, rotenone, and paraquat [284]. 
Besides these cell lines and primary cell cultures, the development of hESC and iPSC have 
a great potential to model human diseases in vitro. Especially the fast progression in iPSC 
differentiation to midbrain dopaminergic neurons will be of great use as a PD model 
system [293, 294]. As they are generated from adult cells, they circumvent the ethical 
issues of hESC [295]. Additionally, sporadic and familial PD iPSC lines can be generated 
from PD patients, which makes them a unique model system [296]. However, 
differentiation to mature neurons is cost- and time-intensive and can result in 
heterogeneous populations. Future developments in iPSC technology will provide the PD 
field with a wide range of options to perform in vitro studies. For now, easily accessible, 
stable, and homogeneous cell cultures, as provided by immortalized cell lines, are still 
required. 
1.5.1 LUHMES Cell Line 
Lund human mesencephalic cells (LUHMES) are a subclone of MESC2.10 cells, which 
were generated from ventral mesencephalic tissue of an 8-week-old human fetus [297]. 
MESC2.10 were immortalized by transformation with a LINX-v-myc retroviral vector. 
The v-myc oncogene overexpression can be controlled with tetracycline. Thus, 
overexpression and proliferation of the cells can be stopped with tetracycline, resulting in a 
shut-down of the myc transgene and subsequent formation of post-mitotic neurons [298]. 
The addition of tetracycline, glial cell derived neurotrophic factor (GDNF), and cAMP 
promotes the morphological differentiation to dopaminergic neurons [297]. However, the 
MESC2.10 cell line was reported to show an unstable and heterogeneous TH expression 
[299]. Its subclone, the LUHMES cell line, features a similar behaviour compared to 
primary cell cultures when exposed to PD toxins and a more stable dopaminergic 
phenotype is achieved [300]. 
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With an optimized differentiation protocol, LUHMES cells became a suitable 
homogeneous cell line, with comprehensive characteristics with respect to morphology, 
neurite outgrowth, expression of neuronal markers, and electrophysiology [301, 302]. A 
strong dopaminergic phenotype with high TH levels, dopamine release, and synaptic 
marker expression that reaches its maximum after five days of differentiation was reported. 
Differentiated LUHMES cells appear to be highly sensitive to PD toxins, which has been 
exploited in several studies [303]. 
However, LUHMES cells cannot be regarded as completely differentiated neurons due to 
co-expression of several mature and precursor dopaminergic neuronal markers at all stages 
[301]. Additionally, conflicting results about heterogeneous expression of TH were 
reported [304]. 
Some efforts are required to perform genetic modification in LUHMES cells since 
classical transfection techniques have proven to be inefficient. Generally, lentiviral gene 
transfer in the proliferating state are used to perform experiments with the cells in 
differentiated states [305]. With this technique, several stable LUHMES models were 
developed, including models to study a-syn aggregation and models to study mitochondria 
motility [305, 306]. 
Recently, a co-culture model of LUHMES cells and astrocytes was developed to address 
functional questions of glia cells in neuropharmacological studies [307]. This new model 
should also enable studies on the astrocytes neuroprotective properties and on glia-cell 
derived neurodegenerative factors [308]. 
Supplemental to the standard adherent cultures, neurosphere formation and three-
dimensional cultivation of LUHMES cells was studied [309, 310]. With a slightly adapted 
differentiation protocols, this model allows the differentiation of LUHMES cells for more 
than 20 days, which allows long-term experiments with the advantages of the standard 
LUHMES cells. 
Microfluidic devices offer great advantages in cell cultivation, for example to study axonal 
transport of proteins. Although the cultivation of LUHMES cells in microfluidic devices 
has been mentioned in the literature, no such results were published to date [284, 311]. It is 
assumed that the cultivation of LUHMES cells is unstable in microfluidics and full 
maturity of the cells cannot be reached [312]. 
1.6 Microfluidic Cell Culture 
Since the development of cell culturing, the basic techniques have not changed [313]. The 
introduction of robotics has improved accuracy and increased throughput to allow large 
scale screening with minimal cell numbers, which became the last revolution in cell culture 
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technology. In the last few years, microfluidics allowed miniaturization of cell cultures 
down to a single cell level in devices with precisely defined geometries, substrates, and 
flow. Together with automatic manipulation and analysis this technology cleared the way 
for a biological lab-on-a-chip.  
Cultivating with microfluidics offers several advantages. Small volumes can be precisely 
regulated down to the fL-range and can be automated to a great extent [314]. This provides 
a highly-controlled environment for cell cultures without the need for manual intervention. 
This increases the reproducibility, which is important when high parallelization on a single 
chip performs a multitude of individually controlled experiments. Screening many 
conditions simultaneously with a single batch of cells improves consistency among assays. 
This high-throughput and controlled way of culturing is of great use, especially for 
demanding cell lines [315].  
Soft lithography of polydimethylsiloxane (PDMS) has become a standard technique for the 
manufacturing of microfluidic cell culture devices. It allows the integration of 
micromechanical valves, channels and assay chambers in compact devices. For optical 
analysis, PDMS offers the great advantages of being transparent with low levels of auto-
fluorescence and only containing small enclosed volumes. These excellent imaging 
properties and the high degree of control renders PDMS microfluidics ideal for live cell 
imaging.  
However, there are several issues that need to be addressed when working with cell 
cultures in PDMS microfluidics. Very often, revisions of the cell culture protocols are 
needed. Care must be taken in the production of PDMS devices, since improperly cured, 
non-cross-linked polymers might change the experimental conditions [316]. PDMS has 
very high gas permeability, which also can result in evaporation of cell media from the 
devices or can induce a different pH behavior compared to macroscale culturing. The small 
volumes in microfluidic devices compared to standard culturing dishes could also lead to 
different conditions, since consumption of nutrients and increase of waste products 
happens rapidly. Thus, a more frequent exchange of media is needed. Additionally, PDMS 
absorbs hydrophobic molecules, which complicates the evaluation of liquid content 
especially at these small volumes. Thus, the media composition may need to be adjusted 
[317]. Another important factor that needs to be considered in microfluidic devices is 
liquid flow, which can alter the growth of the cells and can induce shear stress, altering the 
outcome of the experiments [318]. 
A growing number of studies use microfluidic devices to culture neuronal cells and 
physically separate cell bodies from their axonal projections [250-253, 277, 319]. The 
fluidically isolated compartments ensure that transfer can only happen intracellularly 
through neurites, independent from flow and diffusion in cell media. Several of these 
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devices are commercially available. Studying intraneuronal transport, these devices can 
provide direct evidence that extracellularly-added peptides are taken up by soma or axons 
and transported in anterograde or retrograde direction respectively. The excellent optical 
properties of PDMS are ideal to monitor cell cultures and track fluorescently labeled 
protein assemblies using live cell light microscopy.  
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CHAPTER 2 
Dopaminergic Neuronal Model for Spreading of Fibrillar a-
Synuclein in Parkinson’s Using LUHMES Cells 
This chapter describes the development of a microfluidic device to co-culture fluidically 
isolated LUHMES cell populations for seeding experiments. Furthermore, LUHMES cells 
were evaluated for their use as a model in the prion-like spreading hypothesis of PD. This 
chapter is being prepared for submission. 
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Abstract 
We present a dopaminergic model system to study the prion-like cell-to-cell spreading of 
a-synuclein (a-syn) by combining Lund human mesencephalic (LUHMES) cell cultures 
with microfluidics, separating two cell populations only allowing neurite interactions. 
Aggregation of a-syn is a hallmark of Parkinson’s disease (PD). A prion-like spreading 
mechanism from one to the next cell could explain the stereotypic distribution of the 
protein aggregation in the brains of patients. The mechanisms underlying the long range 
axonal transport of a-syn aggregates and the cell-to-cell migration might be a key element 
in understanding the progression of PD. Unfortunately, in situ studies on a molecular and 
structural level are limited in patients, and model systems must be used. Cellular culture 
systems that allow spatial separation of cell bodies and neurites are of great use. We 
developed microfluidic chips and cell-culturing protocols to spatially control the cell 
growth and separate different populations of LUHMES cells, which can be differentiated 
to dopaminergic, neuron-like cells. We show that this combination of microfluidics and 
LUHMES cells can be used for direct observation of axonal transport of a-syn aggregates. 
The individual handling of cell populations without cross-contamination of testing agents 
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is possible. We observed that LUHMES cells transport a-syn fibrils with low efficiency in 
anterograde and retrograde directions.  
2.1 Introduction 
The loss of dopaminergic neurons in the substantia nigra is characteristic of PD. The 
symptomatic occurrence of aggregated a-syn, the putative main constituent of the so-
called Lewy bodies and Lewy neurites [33], suggests this protein plays a major role in PD. 
When Braak and colleagues reported a stereotypic spreading of the Lewy pathology in PD 
[47], a-syn itself was found to be a potentially infectious neurotropic protein. First 
evidence emerged from grafted fetal neurons implanted into the forebrain of PD patients 
for therapeutic reasons. These neurons also showed a Lewy body-like pathology in post-
mortem analysis several years after implantation [110, 111]. These observations combined 
with the Braak model of PD led to the “prion-like” spreading hypothesis, which is now a 
firmly established model for the disease progression of PD [320]. Although this theory is 
still controversial discussed [55], uptake, template misfolding, and cell-to-cell transmission 
has been shown for preformed a-syn fibrils in several in vivo and in vitro studies [253, 
319, 321]. To understand the mechanisms of prion-like PD progression it is essential to 
know how a-syn is transmitted from one cell to another. Transfer of aggregates is possible 
through extracellular space or by direct cell-to-cell contact. The first may involve active 
secretion strategies like exocytosis [260, 263], or passive processes by releasing naked 
protein aggregates to the culture media from intact and dead cells [322]. A release-
independent mechanism was reported where tunneling nanotubes mediate the transmission 
of aggregates from cell-to-cell. [257]. However, typical spatial distributions of Lewy 
bodies between axonally interconnected regions in the PNS and CNS suggest a long range 
axonal spread of a-syn. It has been shown in mice that injected a-syn fibrils induce 
endogenous a-syn to aggregate, even at a distant region from the injection site [255]. In 
cell cultures, several groups reported the transmission of exogenously-added, preformed a-
syn fibrils and oligomers along axonal projections in both anterograde and retrograde 
directions [250, 251, 253]. From axons, a-syn aggregates likely are not transferred in 
direct contact but secreted into the media independent of axonal lysis [251]. 
Microfluidic chambers are a useful tool to address the questions of neuron-to-neuron 
transmission [323]. To study axonal transport, cell populations are spatially separated by 
microchannels in such a way that only axonal projection can establish contacts between 
cells. A controlled media flow prevents transport other than through axons. In these studies 
primary cell cultures are mostly used [250-252, 324, 325]. These are only available with 
low yield, are not of human origin, and long differentiation times make large-scale 
experiments difficult. Other neuronal models are available more easily, such as PC12 rat 
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cells and SH-SY5Y neuroblastoma cell line. Unfortunately, they suffer from interspecies 
differences or are difficult to differentiate into post-mitotic neurons [285]. Therefore, the 
LUHMES cell line is a promising alternative [286, 298]. More easily available, 
homogeneous, and rapidly to differentiate, they play an increasing role in PD research 
[284]. Despite their use in neurotoxic screening and further development as a 3D model in 
neurospheres [309, 310], LUHMES cells were never cultivated in microfluidic devices to 
study a-syn spreading. Most likely this is due to poor growth in microfluidic devices or 
resistance against neurite guidance through the devices’s connecting parts.  
In this study, we developed a cellular tissue model system allowing large-scale 
experiments with homogeneously differentiated dopaminergic LUHMES cells. We 
designed a microfluidic device to create a viable environment for this cell type with two 
connected but flow-separated growth chambers. As a result, LUHMES cells can easily be 
made available for high throughput experiments with two isolated cell populations, e.g. for 
the testing of axonal transport upon a-syn aggregate incubation, or for toxin testing. Using 
this system, we tested the a-syn uptake and cell-to-cell transfer in LUHMES cells. 
2.2 Results 
An in vitro model system for the prion-like spreading of a-syn through neurites requires at 
least two components: firstly, a device (chip) that mechanically separates the two cell 
populations and restricts the interactions of the cells between their neurites, and, secondly, 
a dopaminergic cell culture growing in the chip. 
2.2.1 Chip Design and Fabrication 
The design principles of the microfluidic chip for the compartmented cultivation of 
neuronal cells are depicted in Figure 8A and are adapted from Dinh et al. [311]. Two cell 
growth chambers with a height of 30 µm are oriented towards a “communication region”, 
exhibiting small channels with a reduced height (~3 µm width, ~4 µm height) 
perpendicular to the growth compartments, solely allowing neurite outgrowth. 
Additionally, a central channel (80 µm width, 30 µm height) divides the communication 
region (Figure 8C 6). The chip exhibits three main channels, two supporting the cell 
growth compartment and a central channel crossing the “communication region.” Every 
channel consists of an inlet reservoir, an outlet reservoir, and a channel restriction to 
reduce the flow rate. Note that the flow rate of the central channel is higher to produce an 
underpressure in the central channel relative to the cell chambers. We used soft lithography 
and replica molding for the PDMS chip production. 
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Figure 8. Design of the microfluidics for the minimalistic tissue. (A) The arrangement of the individual chip 
components. Three independent channels each exhibit an inlet and outlet port (1). Two cell culturing 
chambers (2, blue) are symmetrically arranged towards a central channel (red). The cell culturing channels 
and central channel are separated by microchannels (not visible). All three main channels exhibit a flow 
which is controlled by resistive channels (3, 4). The flow in the central channel is higher since the restriction 
(4) is shorter. (B) Microfluidic chip bonded onto a glass plate, showing the channel ports (rendered image). 
(C) Details of the microchannels (5). The microchannels are arranged perpendicular to the cell growth 
chambers (2) and the central channel (6). (D) SEM of the microchannel region. Note the cell growth 
chamber (2) and the central channel have a height of approximately 30 µm, but the microchannels exhibit 
only a height of 4 µm, preventing the passage of the cell somas and only permitting the outgrowth of 
neurites. The inset shows the indicated region at higher magnification. (E) DIC image of LUHMES cells 
differentiated for 10 days. Nuclei DNA is stained by the DAPI fluorescence dye (yellow) in the cell growth 
chamber (2). Black arrows indicate some dendrites. Note the absence of nuclei in the central channel (6), 
demonstrating the specific permissibility of dendrite outgrowth through the microchannel region (5). Scale 
bars 50 µm. 
2.2.2 Flow Behavior and In-Chip Isolation of Fluidic Compartments 
The flow behavior of the chip was tested using fluorescent dyes (Figure 9). The hydrostatic 
pressure difference between the inlet and outlet port drives the buffer exchange of the cell 
media in the growth chamber, and after approximately 10 min upon filling the inlet port, 
the entire growth-media is replaced (Figure 9). After 24h the pressure difference between 
the inlet and outlet port drops to 0, the flow stops, and buffer exchange only happens by 
diffusion. By emptying the outlet ports every 24 h the buffer flow in the cell culture 
chamber and the central channel is maintained. Additionally, water evaporation must be 
considered to maintain a healthy growth environment in the microfluidic chip. The inlet 
ports ran dry within three days despite being stored in humidified cell incubators. 
Therefore, the chips were placed in a Petri dish along with two stripes of wet filter papers. 
In this condition cells can survive for three days without media change. 
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Figure 9. Hydrostatic-pressure driven flow through the channels and fluidic isolation between the individual 
channels. Central and left inlet ports were filled with PBS, whereas the right channel was filled with PBS 
complemented with 20 µM sulforhodamine B. The hydrostatic pressure difference is enough to start filling 
the cell growth chamber with the liquid within 10 min. Note the fluid isolation of the individual channels. 
Furthermore, the fluorescent experiments in Figure 9 demonstrate the isolation between the 
two cell-culturing chambers, preventing the diffusion of small molecules from one cell 
growth chamber to the other. Only slight traces of the fluorescent dye enter the center 
channels in the communication region by diffusion and liquid flow. Finite element 
simulations corroborate the experimental results (Supplemental Figure A.1). Although the 
central channel got a cross flow close to the outlet, cell chambers were isolated. 
2.2.3 LUHMES Cells Differentiation 
Three prerequisites for the cell cultures in our model systems must be fulfilled: (i) the cells 
can be differentiated to neuron-like cells, exhibiting the morphological shape of neurons; 
(ii) expression level and cellular distribution of selected markers, e.g. synaptophysin and 
tyrosine hydroxylase (TH), are comparable to the ones observed in primary cell cultures. 
Especially in neuronal cells with extended neurite networks, the localization of neuronal 
markers can give relevant information on the differentiation state; and (iii) a similar 
differentiation pattern among a cell population is needed for reproducible experiments in 
microfluidics due to low cell numbers. 
We tested LUHMES cells for the expression of general neuronal markers (Figure 10) and 
dopaminergic indicators (Figure 11A) using immunofluorescence labeling and confocal 
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light microscopy. Expression of the cytoskeletal protein β-III-tubulin (a general neuronal 
marker) was observed in 100% of the differentiating cells and appears not to increase with 
longer differentiation times (Figure 10A). After 12 days of differentiation, β-III-tubulin 
could only be found in neuritic extensions but not in the cell somas. Proliferating 
LUHMES cells also stained positively against β-III-tubulin to a small heterogeneous 
extent. 
The expression of synaptophysin (Figure 10B), a marker for neuroendocrine cells, was 
highly heterogeneous up to day 16 of differentiation. We found high expression levels in 
only a few cell groups, whereas most of the cells were not labeled at all. In later stages of 
differentiation, a regular expression pattern was found among the entire cell population and 
after day 18 of differentiation, definite labeling in 100% of LUHMES cells was observed. 
The expression of TH among the cell population was studied to examine the differentiation 
of dopaminergic neurons (Figure 11A). We detected weak labeling against TH before day 
12 of differentiation, with only a few cells expressing a lot of TH. Just after 20 days of 
differentiation, a uniform TH expression was found among the entire cell population.  
To study PD-related prion-like spreading a-syn expression levels must be considered 
(Figure 11B). The immunofluorescence levels of a-syn in proliferating LUHMES cells 
was low. After six days of differentiation, a uniform labeling of a-syn was visible and the 
fluorescent intensity remained at a similar level at longer differentiation times. All cells 
were labeled in soma and neurites. Interestingly, after longer differentiation, several 
neurites start to build up droplet-like inclusions, which stain highly positive against a-syn. 
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Figure 10. LUHMES cell differentiation monitored for general neuronal markers tubulin beta III (A) and 
synaptophysin (B) by confocal microscopy. Scale bars 10 µm. 
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Figure 11. Immunofluorescence microscopy of proliferating (prol) and differentiating LUHMES cells up to 
day 12 (d12) or day 20 (d20). A) Immunofluorescence signal of tyrosine hydroxylase (TH). B) Fluorescence 
labeling of a-syn. Scale bars 10 µm. 
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2.2.4 LUHMES Cell Differentiation in Microfluidic Devices 
In our hands, the standard protocols developed for LUHMES cultivation in dishes or well 
plates did not work in microfluidic chips. Therefore, heuristic optimization by adapting 
both the microfluidics and cultivation protocols was necessary for a stable co-culturing of 
LUHMES cells. 
Firstly, we adapted the microfluidic chip design from Dinh et al. [311] as described above. 
Secondly, the standard surface-coating protocols for LUHMES cultivation using poly-L-
ornithine and fibronectin [298] did not promote cell attachment in microfluidic devices 
(Supplemental Figure A.2). But Geltrex® was a suitable substrate for surface coating, 
leading to a homogenous adhering cell monolayer [309, 326]. 
Figure 12 shows the differentiation of LUHMES cells in the microfluidic chip. Cells 
displayed flat morphology a few hours after passaging. After four days, some cells started 
to attach to the PDMS and grew upside-down. Between day 3 and day 5, a meshwork of 
neurites began to build up. Subsequently, the neurites grew through the microchannels and 
started to interconnect the cell populations in the two cultivation chambers. Remarkably, if 
solely one cell pool was occupied, the neurite network through the microchannels 
developed slower. Importantly, the microchannels were designed with a height of 4 µm 
only (Figure 8D). An initial implementation of the chip was established with 3 µm wide 
and 10 µm height channels, through which cells could actively pass. Channels with a 
cross-section of 3 µm x 4 µm efficiently suppressed this behavior and built a substantial 
barrier for the cell somas. 
We observed that the liquid flow in the microfluidic chip influenced the outgrowth of the 
neurites (Figure 12, day 5 to 10). By comparing the neurite growth-pattern with the 
simulated fluid stream (Supplemental Figure A.1), we recognized that the neurites tend to 
align along the streamlines and that faster local liquid flow promotes longer neurite 
outgrowth. Interestingly, this also happens against the stream, and some neurites grew into 
the supplying channels. 
After approximately 8 days, large bundles of neurites are formed in both cell cultivation 
chambers and in the middle of the central channel. Reducing the flow in the central 
channel by a longer resistance pipe (Figure 8A-4), the bundle formation is reduced, and the 
neurites grow more directly to the other cell pool. As observed in cell cultivation in flasks 
or well plates, the cell somas in microfluidics move closer together and build clusters after 
8 days. 
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Figure 12. Differentiation of LUHMES cells in the microfluidic chip for days 1 to 10. The overviews show 
the complete cell population, the insets have three times larger magnification including the central channel 
region. Scale bar 200 µm. 
Chapter 2  49 
 
2.2.5 Exposure of LUHMES Cells to a-Synuclein Fibril Fragments 
Seeding experiments in 12-well plates were performed to optimize a-syn fibril-fragment 
preparation, cell-incubation times, and fibril concentrations. Filaments of overexpressed 
and purified a-syn were fragmented using a sonicator and labeled with a fluorescent dye. 
Figure 13A depicts a negative-stain preparation of fragmented filaments in the 
transmission electron microscope (TEM). The overview image shows fragments where 
80% of the fragments exhibit a length between 40 and 100 nm and a thickness of approx. 8 
nm or 16 nm respectively. Note, that smaller pieces were also visible in the background. 
Most filament fragments seem to consist of two filaments (note the darker strip in the 
middle along the filament axis). LUHMES cells after 3 days of differentiation were 
exposed (“seeded”) for 24 h with a-syn filament fragments. Incubation with varying 
concentration of seeds (Supplemental Figure A.3) showed that the seed readily associated 
with the cells. Some of the a-syn fibril fragments were internalized into the cell as shown 
by confocal microscopy (Figure 13B). The number of seeds taken up by the cell depends 
on the incubation time and seed concentration in the cell media (Supplemental Figure 
A.3A). At low levels of 0.05 µg /ml (monomer concentration) few cells took up the fibrils 
within an hour. At ten times higher fibril concentrations, the seeds cover the cells almost 
completely after 1 day of incubation. Subsequent seeding experiments were performed 
using a seed concentration of 0.1 µg /ml and an incubation time of 24h.  
To study the retrograde transport of a-syn fibrils, cell media containing fluorescently 
labeled fibrils was added to the central channel of the microfluidic device. Care had to be 
taken to load the seed solution after the other ports were filled and to empty the inlet with 
fibril solution first. Otherwise, crossflow might occur. For both retrograde and anterograde 
transport, the neurites were regularly observed by fluorescent microscopy and fixed at 
different chasing times to be analyzed by confocal microscopy. Figure 13C shows an 
example of retrograde transport of seeds in the chip. Seeds (0.1 µg/ml) were supplied to 
the central channel and after 24 h the media was exchanged to remove unbound seeds. 
After a chasing time of 4 days, we fixed and analyzed the cells in the microfluidic chip by 
confocal fluorescence microscopy. Whereas neurites readily took up the seeds, only a few 
seeds were transported through the microchannel. Intracellular transfer of a-syn seeds 
happened only with low efficiency and for short distances of below 200 µm.  
Similar experiments (Supplemental Figure A.5) were performed to study anterograde seed 
transport with comparable results as described above. Note that we did not detect any 
toxicological effects or morphological changes of the LUHMES cells in all our seeding 
experiments.  
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Figure 13. Internalization of a-syn fibrils by LUHMES cells. Alex546 labeled fibrils (red) were added at a 
concentration of 0.1 µg/ml (monomer concentration). (A) TEM image of sonicated fibrils used for seeding 
experiments. (B) Representative confocal image of LUHMES cells after 3 days of exposure to a-syn fibrils 
showing internalized seeds. Nuclei are shown in yellow and actin labeling is shown in blue. (C) Retrograde 
transport of fibrillar a-syn seeds from (A). Black scale bar 100 nm. White scale bars 10 µm. 
2.3 Discussion 
Cell models are an important alternative to animal experiments to tackle specific questions 
in PD pathogenesis and progression. The LUHMES cell line is a human, immortalized cell 
line and represents the advantages of cell culture models to a great extent. In contrast to 
primary cell cultures, studies using LUHMES cells cultivated over one week in 
microfluidic devices were not published till now. Here we describe a microfluidic chip 
design and cultivation protocols allowing LUHMES neuron differentiation and cell growth 
for more than two weeks. 
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To assess the suitability of the LUHMES cell line as a dopaminergic model in 
microfluidics, we first studied its differentiation to a “dopaminergic monoculture.” 
Previous reports showed that also proliferating LUHMES cells stain against β-III-tubulin 
and mRNA levels do not increase substantially after two days of differentiation [301]. 
Thus, β-III-tubulin correlates with the earliest phase of differentiation. Our results 
corroborate these findings. Confocal microscopy of immunolabeled differentiating 
LUHMES cells showed a steady and uniform pattern of β-III-tubulin and the fluorescent 
signals did not further increase after 6 days of differentiation. However, after 12 days we 
found β-III-tubulin-III labeling only in neuritic projections and not in the cell somas 
having implications for guidance and maintenance of the neurites. The neurite outgrowth 
and proper β-III-tubulin labeling make LUHMES cells suitable for intraneuronal transport 
studies in microfluidics and analysis by optical microscopy. 
We found a heterogeneous expression of TH in LUHMES cell cultures in the early days of 
differentiation. Such an unstable expression was already reported for MESC2.10 cells 
[299], from which LUHMES cells were sub-cloned, and this was recently observed to be 
the case for LUHMES cells too [304]. Longer differentiation times of 20 days were needed 
with our protocols to reach homogenous TH expression levels. Using higher cAMP levels 
in the cell media could accelerate the maturing of TH expression.  
It was reported that a-syn co-localizes with synaptophysin in the presynaptic terminals of 
mature primary neurons [164]. Additionally, LBs show immunoreactivity against 
synaptophysin [327]. Therefore, we tested LUHMES cells for stable expression of 
synaptophysin. Mostly no positive labeling against synaptophysin was found up to day 16 
of differentiation, except for intense heterogeneous labeling of a few regions per well. This 
finding is consistent with previous studies where LUHMES cells were grown in 3D for up 
to 21 days, finding a similar increase in synaptophysin levels from day 12 to 21 of 
differentiation [310]. In another study, high synaptophysin mRNA levels were observed 
after day 6 of differentiation [301, 305], however, mRNA levels do not necessarily 
correlate with the expression levels of proteins [328].  
To assess LUHMES cells as a platform for seed-induced aggregation and transmission of 
misfolded a-syn species, a stable endogenous a-syn level in wt-LUHMES is required. 
Optionally, the overexpression of different types of a-syn was already demonstrated in 
LUHMES cells, whereas controversial results regarding a-syn-induced cytotoxicity were 
presented [304, 305]. The possibility of a reduced tolerance against high levels of a-syn is 
not compatible with long differentiation times, which might be needed for an increased 
maturity of LUHMES cells. In our hands, strong and uniform labeling of a-syn was 
detected after six days of differentiation, which did not rise any further with longer 
differentiation times. This finding is different from observations where a-syn was weakly 
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labeled at the beginning of the differentiation, but where increasing levels of a-syn up to 
day 9 of differentiation were observed [305]. Combined with the synaptophysin results, we 
conclude that differentiating LUHMES cell cultures for an extended period seems to be 
essential for synaptogenesis in LUHMES cells.  
The expression of critical cell differentiation markers and the neurite length of LUHMES 
cells makes them a good cell line to study the prion-like behavior of fibrillar a-syn in 
microfluidic devices. Despite no media change for two days, no cross flow from one 
chamber to the other was observed (Figure 9). Fluid isolation and constant stream were 
maintained over two weeks with minimal effort and equipment. Due to high cell motility, 
there was no need to array the cells along the connecting microchannels as proposed before 
[311]. Restricting the cell mobility to only a small band in front of the microchannels 
promoted cell clustering in front of the microchannels, and the underpressure in the central 
channel imposed shear stress to the cells. We only could achieve a stable cell growth of 
LUHMES cells in the microfluidic chips using Geltrex® for the surface coating, and 
employing higher concentrations of media supplements. More supplements were useful, as 
supplement concentration in media can be reduced in PDMS devices, likely due to 
diffusion and absorption of small molecules like growth factors into the PDMS, lower 
volume to cell ratio, and media dilution when chips were kept in an incubation chamber 
over two days without media replacement [316]. Increasing the size of the cell pools had a 
positive effect on cell growth, likely due to the aversion of cells to grow in low numbers. 
Additionally, the significant pools led to a reduction of the stream, which reduced the 
alignment of the neurites to the flow. Still, constant flow in the microfluidic device seemed 
to have a strong influence on the cell network but not on the cell morphology (Figure 12). 
On about day 4 of differentiation, a neurite meshwork started to build up through the 
microchannels which connected the two fluidically isolated cell populations. Since cells 
could be reliably differentiated for two weeks in microfluidic devices, this left about 10 
days to perform pulse-chase experiments or toxicity studies. 
Several studies reported the uptake and axonal transport of a-syn fibrils in primary mouse 
neurons [250, 251, 319]. The anterograde transport was stated to be more efficient than the 
retrograde axonal transport [251]. Our data suggest that studies on intracellular transport 
could also be conducted on the human LUHMES cell line. The transport of seeded fibrils 
was observed in both directions, although only for short distances of less than 200 µm and 
in only a few events. From our results we cannot conclude that transport in one or the other 
direction is more efficient. The rate-limiting steps could not only be the transport itself but 
also the uptake and release of the fibrils. The internalization of the fibrils could easily be 
observed and increased by higher fibril concentrations or incubation times, as LUHMES 
cells don’t show any adverse effect on this type of fibrils. Fluorescent fibrils mostly 
attached to the cells and were not internalized, which was shown by washing cells with 
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trypsin to remove a great amount of the membrane-bound fibrils. In microfluidic devices, 
the constant flow seemed to have a big influence on the uptake, especially on the neurite 
site. While the binding of the fluorescent fibrils to the cell membrane looked similar in the 
cell growth chamber and on 12 wells, much lower concentrations were detected on neurites 
in the central channel, likely due to the higher flow. On neurites in the central channel no 
bigger aggregates or elongated assemblies were found. Thus, retrograde transport was 
especially limited by the uptake rate of fibrillar a-syn. Regarding the anterograde 
transport, the few events could be explained with the longer distance to the separating area, 
as soma often arranged around the center of the growth chambers. However, similar 
studies using primary neurons reported fluorescent fibril transmission over distances of 1 
mm [252]. 
Another limiting factor might be the secretion of the previously internalized fibrils. In 
general, a higher number of fibrils were observed on the background after a few days of 
seed incubation, even when membrane-bound fibrils were removed with trypsin. Thus, 
fibrils were released, although it is likely that a substantial amount came from apoptotic 
cells. In the case of microfluidic co-culturing, the release without immediate uptake of 
second order neuronal cells leads to a decrease of fibril concentration because of the 
constant flow. This was less the case in 12-well plates where we observed a slow decrease 
of the fluorescent signal.  
Degradation of internalized fibrils could decrease the number of seed transmission events 
even further. Lysosomal degradation of a-syn fibrils could be a significant limitation, and 
no studies exist about lysosomal degradation in LUHMES cells. Studies about degradation 
kinetics using other cell cultures reported that most internalized fibrils are degraded, 
although there are controversies [246]. However, intracellular a-syn assemblies in 
LUHMES cells were observed more than 14 days after incubation, and several studies 
show high concentrations of transmitted a-syn fibrils in primary cell cultures after several 
days of incubation [253, 319].  
In general, we have shown that LUHMES cells can be used to monitor the anterograde and 
retrograde transport of possible prion-like proteins. As only one type of fibril was tested 
here, comparisons to other kinds of fibrils, oligomers, and different types of prion-like 
proteins would eventually reveal strain-dependent transport behaviors.  
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2.4 Conclusion and Outlook 
In this paper, we demonstrate the integration of the LUHMES cell line into microfluidic 
devices for separating soma and neurites. Therefore, no additional surface patterning or 
guidance molecules were needed. Besides the production of the microfluidic chips, the 
effort for cultivation is comparable with standard protocols and can be done in every cell 
culture lab without additional equipment. LUHMES cells exhibit a strong dopaminergic 
phenotype, and therefore, seem to be ideal for testing Parkinson’s disease-related agents. 
Since the system is a low-cost application, it is ideal for high throughput experiments for 
testing several different strains of a-syn assemblies to measure transmission efficiencies. 
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CHAPTER 3 
Testing Key Steps for Prion-Like a-Synuclein Hypothesis in 
LUHMES Cell Line  
This chapter addresses questions about the required steps of a-syn seed propagation, 
namely internalization, transport, and release of a-syn assemblies. It is a continuation of 
the previous chapter with additional experiments and discussions concerning the prion 
hypothesis in LUHMES cells.  
3.1 Introduction 
In the previous chapter 2, LUHMES cells were systematically tested for dopaminergic 
characteristics in order to evaluate their use to serve as an in vitro model system for the 
study of the prion-like spreading hypothesis of PD. Furthermore, a co-culturing device was 
developed which allows the co-cultivation of LUHMES cells with soma and neurites 
physically separated. Both dopaminergic characteristics and co-cultivation of LUHMES 
cells are required to conduct experiments that address the different steps of a-syn 
pathological spreading – internalization, transport, and release of a-syn fibrils – which are 
central for the prion-like hypothesis. A detailed review of these steps can be found in the 
introduction of this thesis (section 1.4.2). In this chapter, we pursued seeding experiments 
using mostly preformed a-syn fibrils. Furthermore, seeding experiments with differently 
prepared a-syn assemblies were performed, since recent findings have indicated that 
distinct a-syn strains might be responsible for the heterogeneous pathological patterns of 
synucleinopathies [329]. 
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3.2 Results and Discussion 
3.2.1 Internalization of a-Syn Assemblies 
Figure 14. Time course of internalization of fluorescent a-syn seeds in LUHMES cells on day 8 of 
differentiation. Fibrillar seeds were added at a concentration of 0.1 µg/ml and cells were fixed after the 
indicated time passed. Left panel shows maximum intensity z-projections of confocal stacks. In the right 
panel, projections of sub-stacks (corresponding to 1 µm in z-direction) were selected to only show a 
volume that is cutting through the cells. Scale bars 20 µm. 
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Internalization of a-syn fibrils was previously demonstrated by confocal microscopy 
(section 2.2.5). In general, this is assumed to be a fast process after initial binding of fibrils 
to various structures on the cell membrane [277]. Among different studies, the kinetics of 
seed uptake appear to vary, which could be explained by unequal cellular models and 
conditions, strain differences in a-syn fibril samples, and in different seed-preparation 
techniques [246]. To get insights into seed internalization of LUHMES cells, we analyzed 
the uptake of fluorescent a-syn fibrils in time course experiments (Figure 14). After 1 h 
incubation time at an a-syn fibril concentration of 0.1 µg/ml several fluorescent puncta 
were found within cells (Figure 14, right panel). Interestingly, the intracellular 
concentration of seeds only increased up to 2 h of incubation and not gradually for 24 h. 
The overall concentration of seeds sticking to the cell membrane and to the growth 
substrate increased constantly because seeds in solution had more time to settle (Figure 14, 
left panel). In a similar experiment (Supplemental Figure A.3), cells were incubated for 1 h 
with fluorescent seeds but were cultivated for another 3 days instead of immediate fixation. 
More fibrils were detected in this previous experiment, indicating that LUHMES cells 
internalized the membrane-bound fibrils during the additional 3 days of cultivation. Since 
the intracellular concentration does not show a significant increase at 24 h of incubation 
(Figure 14, right panel), it is suggested that after a rapid initial internalization, large 
amounts of seeds follow a slower internalization mechanism. 
It was reported that seed uptake into neuronal cells reaches a maximum level between 6 h 
and 24 h, and that the majority of endocytosed fibrils are degraded [257, 269]. It is likely 
that the uptake and degradation kinetics largely depend on the cell type [246]. Thus, the 
observed uptake kinetics into LUHMES cells does not contradict the published findings. 
Focusing on fluorescent puncta after long cultivation times, we saw a decrease of fibrils 
associated to cellular structures, but mostly an increasing background of fluorescent fibrils 
(Supplemental Figure A.3B). It seems that the fibrils were not necessarily degraded but 
rather secreted from the cells. Indeed, we could not observe a co-localization of a-syn 
fibrils with lysosome-associated membrane protein (LAMP) 1 and 2 (Figure 15A and B). 
To verify these results, a pulse-chase experiment using fluorescently labeled wheat-germ 
agglutinin (WGA) was done. WGA is a widely-used lectin which binds to glycoproteins 
and is often used for cell membrane and Golgi labeling. When used in live cells at 37°C, it 
rapidly enters the endosome-lysosome pathway where fluorescent signals can be observed 
in early endosomes after 10 min, in late endosomes after 30 min, and in lysosomes after 1 
hour [330]. When seed-loaded LUHMES cells were incubated with fluorescent WGA, no 
significant co-localization was observed (Figure 15C). It is possible that fluorescent dyes 
dissociate from the fibrils in the lumen of the endocytic compartments and, therefore, no 
co-localization of a-syn fibrils and lysosomes is observed. However, this would imply that 
fluorescent puncta only consist of aggregated fluorophores and that they are not located in 
58 Andrej Bieri 
the endosome-lysosome compartments. Still, this would not explain why other studies have 
observed co-localization and high levels of fluorescent puncta, even after long cultivation 
times [253].  
Figure 15. Localization of a-syn fibrils and lysosomes in LUHMES cells. Cells were incubated with seeds 
from a-syn fibrils. Fixed cells were immunofluorescent labeled with LAMP1 (A) and LAMP2 (B). Alternatively, 
cells were incubated with fluorescent WGA which is known to co-localize with LAMP positive structures (C). 
Scale bars 20 µm. 
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Consistent to co-localization with endosomal markers and degradation of internalized a-
syn fibril, a decrease of extracellular fibrils was reported, indicating that the fibrils are 
being cleared from the media by endocytoses [269]. To verify these findings in LUHMES 
cell cultures, cell lysate was prepared on three different days after seed incubation. In 
addition, supernatant of the detached cells was collected prior lysis; one set of cells was 
detached with trypsin and the other by gently rinsing with PBS. Trypsin was used to 
efficiently remove membrane-bound a-syn aggregates. The supernatant was analyzed by 
dot blot immunolabeling, and cell lysate was analyzed by reverse phase protein arrays 
(RPPA), whose development is described in section 4.2.3. Cell lysate from cells which 
where incubated with fibrils for two days showed high levels of a-syn, but only when cells 
were not trypsinized before lysis (Figure 16, top panel d8). This indicates that membrane-
bound fibrils exceeded the concentration of endocytosed fibrils by far, even after 2 days of 
incubation. The signals equalize after 4 days of cultivation (Figure 16, top panel d10), 
which supports the theory that LUHMES cells require longer time for internalization after 
initial seed binding. At this point, membrane-bound fibrils appear to be less abundant than 
intracellular seeds. After 6 days of incubation (Figure 16, top panel d10), the a-syn signal 
in trypsinized cells was higher than when detached without trypsin. Since the latter 
represents endocytosed and membrane-bound fibrils combined, a higher signal from only 
endocytosed fibrils is contradictory. However, since the control with simple cell media 
shows an increased signal too, the findings on day 13 of differentiation are not reliable.  
Figure 16. Immunoblot analysis of LUHMES cell lysate and media supernatant after a-syn fibril seeding. 
Top panel shows a reverse phase protein array of LUHMES cell lysate prepared on three different days of 
differentiation. Bottom panel shows a dot blot analysis of the supernatant which was collected from the 
supernatant of the pelleted cells before they were lysed.  
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Dot blot analysis of the supernatant of the very same experiment shows a decreasing signal 
of fibrils in the supernatant (Figure 16, bottom panel). This is in agreement with the 
increased number of internalized fibrils. Since the cell media was exchanged several times 
before analysis, this represents only the fibrils which were secreted or membrane-bound 
and then released into the media. Interestingly, when no trypsin was used, there was still a 
weak signal of extracellular fibrils up to 6 days after seed incubation. Insufficient washing 
could explain the higher signal during the first harvesting on day 8 of differentiation 
(Figure 16, bottom panel). But it is unlikely that initially seeded fibrils are in the media 
after three washing steps before day 13 of differentiation. This indicates that some fibrils 
are released back into the media without degradation.  
Figure 17. LUHMES cells were incubated with 0.5 µg/ml a-syn for one hour on day 7 of differentiation and 
fixed on day 10 of differentiation. Seeds are represented in magenta, endogenous a-syn in green, and 
seeds which were recognized by anti-a-syn-antibodies in white. Scale bar 20 µm. 
When fixed LUHMES cells were immunofluorescence labeled with anti-a-syn antibodies, 
both endogenous a-syn and seeds were labeled (Figure 17). Since seeds are already 
fluorescently marked, double-labeling results in a distinct color in the additive color 
system. In Figure 17, antibodies labeled both endogenous a-syn (green) and seeds (white). 
a-Syn fibrils which were not recognized by the antibodies do not result in an additive 
signal (magenta). An incomplete labeling was observed with all the tested antibodies, 
while some only poorly recognized seeds (Supplemental Figure B.2). However, even 
antibodies with good labeling efficiency against seeds did not bind to all a-syn fibrils 
(Figure 17, insets). The reason that not all a-syn fibrils are recognized by the antibodies 
remains unknown. It might be due to changed or hidden epitopes on a-syn, or due to 
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dissociation of the dyes from a-syn as mentioned above. It appears that most of the evaded 
seeds are located within cell bodies or neurites, but not antibody bound seeds without 
association to cellular structures were also present. These extracellular blank seeds, and a 
thorough permebilization of the cells before immunolabeling, excludes the option of 
shielding organelles, such as lysosomes, which could prevent the contact with antibodies. 
It can only be hypothesized that a-syn fibrils were modified during aggregation within the 
cells, which made them undetectable. Since evasion from degradation and release from 
cells is required to fulfill the prion-like spreading hypothesis, it might explains the 
potentially modified fibrils outside of cells.  
Although we did not find any signs for fibril degradation by the endosome-lysosome 
pathway, we cannot implicate a complete evasion of the used a-syn fibrils from this 
system. It was shown that a-syn are immediately internalized, but a possible saturation is 
only reached after several days of incubation. Furthermore, a part of the seeded fibrils is 
not recognized by antibodies. There are many open questions regarding a-syn fibril 
internalization and escape from degradation [246]. 
3.2.2 Release of a-Syn Fibrils and Intercellular Transfer 
Cell-to-cell transfer of a-syn fibrils can be established by direct cellular contacts or via 
transport through extracellular space. Recently, direct transfer through tunneling nanotubes 
was demonstrated [257]. Although this was claimed to be a highly efficient process, it is 
expected that the majority of intercellular transfers involve a vesicle-free release from the 
donor cells to extracellular space [252].  
In most of our seeding experiments, a lot of a-syn fibrils were found in the background not 
associated to soma or neurites, and this number increased the longer the cells were 
cultivated after seeding (Supplemental Figure A.3B). Mostly the background signals 
derived from membrane-bound fibrils, since trypsin treated samples showed largely 
reduced numbers of fibrils in the background. However, fibrils could still be found in the 
background of trypsin-treated samples (Supplemental Figure A.3B). These were either 
secreted or released from dying cells.  
To see if a-syn fibrils are transferred between LUHMES cells, a-syn fibrils were 
separately labeled with two different dyes and seeded onto two separate cell cultures. After 
one day, both cell populations were trypsinized to remove membrane-bound fibrils, and 
mixed together for further cultivation. After 10 days of incubation, we did not detect a 
single cell which contained both types of fibrils (Figure 18). Extracellular seeds were often 
found in close proximity to cellular debris, as they could be recognized by the contracted 
nuclei in Figure 18. This indicates that most of the free a-syn fibrils were not secreted but 
were exposed to cell media after the a-syn harboring cell died. Interestingly, regardless of 
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the fact that they derived from dead cells, released a-syn fibrils did not enter intact cells. It 
is likely that intercellular transfer is a relatively rare event. In similar experiments, a 
transfer efficiency below 20% for cells which are not in close contact was reported [257]. 
It is also worth noting that published studies which used different cell types and different 
seed preparation protocols also reported different levels of uptake and transfer [257, 270, 
288]. 
Figure 18. Seeding experiment on LUHMES cells using two differently labeled seeds (green and magenta) 
of the same filament sample. Separate cell cultures were incubated with the particular seeds on day 1 of 
differentiation. The next day, cells were trypsinized and combined for cultivation until day 11 of 
differentiation. Nuclei (blue) and bright field image were adjusted for the merged figure to highlight the 
seeds. The channel represented by the green color is leaking to the magenta channel. Scale bar 20 µm. 
3.2.3 Recruiting Endogenous a-Syn 
Template recruitment of endogenous a-syn by misfolded seeds should be discernable in 
the fluorescent pattern of immunolabeled a-syn, as was demonstrated in several studies 
[253, 267, 319]. In our seeding experiments, the endogenous a-syn labeling never showed 
any difference between a-syn fibril-induced samples and control cell cultures. The 
endogenous a-syn was mostly homogeneously distributed in soma and neurites 
(Supplemental Figure B.2).  
Usually a-syn seeds aggregate with each other after a few days of incubation in cell 
cultures. When comparing Figure 14, where cells were fixed after short incubation times, 
and most other experiments, where cells were further cultivated after seeding (e.g. Figure 
17), we see an increase in size of the fluorescent puncta. Thus, preformed fibrils still 
aggregate, although the concentration is extremely low. Since many of these aggregates 
can be found in association with cellular material, we hypothesize a local increase of seed 
concentration on the cellular membranes, which assists the formation of larger a-syn 
fibrils aggregates. Although aggregate formation of the added seeds was common, 
additional a-syn labeling with antibodies did not reveal a growth of the original seeds. 
This indicated that endogenous a-syn was not recruited by misfolded a-syn templates. The 
Chapter 3  63 
 
reasons that no changes were observed could be various. Eventually, template recruitment 
is only visible after long cultivation times, which is not manageable for LUHMES cells. 
Furthermore, cellular model systems in general can have different responses to a-syn 
seeding and since a-syn strains might play an important role in synucleinopathies, various 
seeds might trigger aggregation with different efficiencies. Thus, the weak response in this 
study might be attributed to the strain of a-syn we used, fluorescent modification of the 
seeds, or to LUHMES cells themselves. 
3.2.4 Strains of a-Syn: Fibrils, Ribbons, and Oligomers 
For the majority of the seeds produced in this thesis, an adapted version of a published 
protocol was used [189] (Figure 19,A). Additionally, we adapted three published protocols 
which aim for a-syn fibril, ribbon, and oligomer production [140, 331, 332]. A 
representative selection of the fibrils, which were produced based on these protocols can 
be seen in Figure 19 and in Supplemental Figure B.1. All fibril-formation protocols use 
similar protein concentrations, incubation temperatures, and pH. The main differences 
among them was the type of buffer and salt concentration. As a result, structurally different 
fibrils were formed. Although the standard fibrils were incubated for 7 days, batches of 
fibrils could already be found 30 h after incubation (Supplemental Figure B.1). The fibrils 
were of heterogeneous length and seemed to be ruptured. It is likely that incubation on a 
shaker caused this fragmentation, since the initial protocol used a rotating wheel in which 
longer fibrils were formed [189]. By using the same buffer, extremely long filaments could 
be formed over long incubation times, even at RT (Supplementary Information B.1). Such 
long networks were also observed when using Tris buffer. There, prolonged incubation 
times led to large insoluble aggregation which are difficult to detected by TEM, since 
aggregates cleared all the free fibrils from the solution and concentrated in big precipitates 
(Supplemental Figure B.1). 
Figure 19. Representative images of negatively stained a-syn fibrils and oligomers produced with different 
protocols. These protocols manly differ in buffer composition. (A) Standard fibrillization protocol for this 
thesis using PBS according to ref. [189]. (B) Oligomers were formed based on common protocol from ref. 
[332]. (C) Fibrils made in sodium phosphate buffer at high salt concentrations. Triggering the initial fibril 
formation was omitted from the protocol [331]. (D) In Tris buffer, a-syn assemble to ribbon like fibrils [140]. 
Scale bars 200 nm.  
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When using phosphate buffer at high salt concentrations, usually less fibrils were formed 
and were often decorated by oligomers (Figure 19C). In Tris buffer, a similar decoration 
was observed but fibrils developed a ribbon-like structure. As this decoration looks like 
oligomers, they might be related to the fibril formation process. Interestingly, we did not 
find any oligomers during the standard procedure. This is remarkable, since oligomer and 
standard fibril formation followed the same protocol, except oligomers were harvested 
after two days of incubation from a threefold-higher concentrated a-syn solution, followed 
by separation from already formed fibrils and subsequent up concentration. Thus, 
oligomers in Figure 19B represent the precursors of those fibrils. Overall, a high 
heterogeneity of fibrils can be formed by changing one of the many conditions. This is 
important, regarding reproducibility of experiments, but also in the context of PD 
progression. Even minor changes in certain cells can completely alter the environment for 
toxic a-syn formation. 
Figure 20. Representative confocal microscopy images of seeding experiments using oligomers which 
were either added on day 3 of differentiation (A) or on day 6 of differentiation. LUHMES cells were fixed on 
day 13 of differentiation. Scale bar 20 µm. 
Besides the already mentioned seeding experiments with sonicated a-syn fibrils, 
LUHMES cells were incubated with fluorescently labeled oligomers on either day 3 
(Figure 20A) or day 6 (Figure 20B) of differentiation and were cultivated for an additional 
10 or 7 days respectively. Comparing those two preparations, less oligomers could be 
found in the background of day 3 seeded cells. Additionally, fluorescent spots are bigger 
Chapter 3  65 
 
and often concentrate on cell debris. Overall, similar levels of fluorescence were observed 
in both preparations, which indicates that oligomers were not cleared from the background 
by internalization and degradation. Rather, they accumulated to big aggregates and even 
completely occupied whole cells (Figure 20A). Whether or not oligomers were responsible 
for the cell death of the fully fluorescent cells remains to be tested. It needs to be explained 
why those cells internalized such amounts of seeds whereas cell soma and neurites of 
neighboring cells display virtually no fluorescent seeds. In context with the selective 
vulnerability theory, it almost seems that those cells selectively internalized the seeds.  
Examining cell preparations where oligomers were added 3 days later (Figure 20B), signs 
of aggregate formation start to appear. Still, the fluorescent signals are more diffuse and 
although there are dead cells, none of them accumulated big amounts of seeds. 
Furthermore, seeds are distributed evenly on soma and neurites. Whether these differences 
among the two preparations result from the longer exposure to seeds, or if the 
differentiation status on time of seeding plays a role, remains to be determined. As 
LUHMES cells change their differential status rapidly within the days of differentiation, it 
is likely that the timepoint of seeding is important. 
In general, large accumulations in live and dead cells were also observed in seeding 
experiments with a-syn fibrils, and thus are not a unique strain-dependent feature (see 
section 3.2.3).  
Figure 21. Seeding experiments using oligomers which were added to one of the cell growth chambers in 
the neuron co-culturing device. Most oligomers (magenta) stick to the PDMS and do not co-localize with 
the actin filaments (green) of the neurites. Scale bar 20 µm. 
Big differences were observed when oligomers and fibrils were applied to microfluidic 
devices. Whereas a-syn fibrils were internalized by cell bodies and neurites, and 
transmitted in anterograde and retrograde directions (Figure 13), oligomers were barely 
detected on cellular structures (Figure 21). Most oligomers bound to the PDMS walls of 
the microchannels and not to cells. Fibrils usually also attached to the PDMS, but also 
covered cell bodies and neurites. Low concentrations of oligomers associating with cellular 
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material could be due to a steady fluid flow in the microfluidics device, which would 
indicate that oligomers have a much lower binding affinity to cell membranes than fibrils. 
This is not in agreement with most published data, where a high oligomer adsorption to 
cell membranes was reported [332]. It is important to note that oligomers with different 
potentials to trigger aggregate formation can be produced [199]. Although we followed a 
protocol for highly potent oligomer formation, it is possible that changes in microfluidic 
culture conditions altered the oligomer binding capacity. 
Although conformational strains of a-syn might play an important role in explaining the 
pathologic variability of synucleinopathies, there is not much known about their 
ultrastructure. Most studies which use artificial a-syn aggregates for seeding experiments, 
including this one, prepare their assemblies without thorough characterization or 
purification. These protein solutions might consist of a polymorphic mixture of 
monomeric, oligomeric, prefibrillar, and fibrillar a-syn. Thus, when conducting 
experiments about the prion-like nature of a-syn, valuable information about the influence 
of each species is lost. Extracting individual assemblies from the cell for characterization, 
or even direct characterization in cells, would be beneficial. Differences in fibril formation 
protocols, sonication techniques, or storage could then also explain the different 
controversial results of different studies.  
3.3 Conclusion 
In this chapter, seed internalization and secretion was demonstrated in the LUHMES cell 
model using confocal microscopy and dot blot analysis. Immunofluorescent labeling 
showed only incompletely marked fibrils, which suggests morphological changes of the 
initial seeds, hidden epitopes during aggregate formation, or dissociation from fluorescent 
dyes. In all experiments, LUHMES cells showed weak responses to incubation with a-syn 
assemblies regarding seed propagation of a-syn. It is suggested that different cell types 
might display different susceptibilities to a-syn seeds. Furthermore, a huge variety of a-
syn fibrils can be produced in vitro, although the exact structure of the seeds which are 
finally used for the experiments remains unclear. Thus, additional studies with different a-
syn assemblies are needed to demonstrate a strain dependence in different neuronal model 
systems. In LUHMES cells, differences in seeding experiments between oligomers and 
fibrils were marginal. Only when seeded in microfluidic chips did oligomers seem to have 
a different binding affinity to cell membranes than fibrils.  
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CHAPTER 4 
Making Microfluidics Accessible to Electron Microscopy and 
Single-Cell Analysis 
This chapter evaluates additional techniques to make neuronal co-culturing microfluidic 
devices accessible to analysis by electron microscopy. Three main approaches were tested 
for feasibility, of which two include the integration into the visual proteomics pipeline 
which was developed and constantly improved in this group. 
4.1 Introduction 
A part of this section has been published and was reprinted and modified with permission 
from reference [333]. Copyright (2017) Creative Commons License 4.0 
Arnold S.A., Albiez S., Bieri A., Syntychaki A., Adaixo R., McLeod R.A., Goldie K.N., 
Stahlber H., Braun T., J Struct Biol, 2017. 197(3): p. 220-226. 
Microfluidic cell cultures aim for a small number of cells per condition down to single-cell 
experiments. Often biological analysis techniques lack sensitivity on a single-cell level. A 
seamless integration of microfluidic cell culture would require the handling of small 
volumes. Therefore, a direct integration of cellular microfluidics to EM sample preparation 
techniques would benefit from both small sample volumes and cell numbers, as well as 
high sensitivity. Currently, we are developing a modular microfluidics pipeline with the 
aim of integrating sample extraction, purification, and analysis preparations in one 
workflow. As of now, this platform provides working modules for single-cell lysis [334], 
sample conditioning for EM [335] and lossless cryo-EM grid preparation [333]. Modules 
for purification and additional handover to other analysis methods are in progress. 
However, analysis by cryo-EM would have a great impact on the proteomic analysis of 
small volumes and rare events which could happen in microfluidic cell culturing. 
In recent years, transmission electron microscopy of vitrified specimens [336] has become 
a powerful technique for the high-resolution structural analysis of biological matter, and is 
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now increasingly recognized as a mainstream tool in biology [337-339]. Several technical 
achievements have made this development possible, the most prominent being the recent 
introduction of direct electron detection cameras [340-342] and the availability of 
improved data processing algorithms [343-345]. 
Cryogenic sample-grid preparation and imaging methods ensure that biological specimens 
withstand the ultra-high vacuum inside electron microscopes, allowing their investigation 
while trapped at physiological conditions that conserve the structural arrangement of the 
biomolecules and reduce the effect of radiation damage [336, 346]. However, these 
preparation methods have not improved significantly over the last 20 years and have some 
major drawbacks: A 2-4 µl sample volume is required, and 99.9% of the sample volume is 
lost during grid preparation, due to an extensive blotting step using filter paper [347]. 
Furthermore, blotting with filter paper can lead to protein aggregation or denaturation. The 
current state of the art sample preparation methods are recognized as one of the most 
significant limitations in cryo-EM [348]. 
Improved cryo-EM grid preparation strategies that reduce sample consumption are now an 
essential requirement. A device that combines ink-jet picoliter dispensing with a plunge-
freezing apparatus was presented in 2012 [349], and was recently refined by the use of 
self-blotting grids to allow cryo-grid preparation in combination with ink-jet spotting 
[350]. Recently, we presented a blotting- and spotting-free method that requires total 
sample volumes of just a few nanoliters (e.g., 3-20 nl) [333]. It uses a microcapillary to 
directly ‘write’ the sample on holey carbon EM grids and subsequently vitrifies the 
deposited liquid, producing thin layers of vitrified specimen in the holes of the carbon film. 
In this chapter, we try to benefit from the lossless preparation methods and attempt to 
integrate microfluidic cell culturing into the single-cell analysis platform (Figure 22A). 
Regarding neuronal co-culturing devices, the visual proteomics approach of individual 
cells which were only in contact by their neuronal projections would give insight into 
several cellular processes, including response to prion-like proteins, susceptibility to PD 
toxins, and intercellular differences in general. 
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Figure 22. (A) Modular microfluidics pipeline to make small volumes accessible to different analysis 
methods. New modules can be implemented or skipped. (B) Implementation of co-culturing devices would 
allow easy transition of the small output volumes and cell lysate. The main instrument includes fluorescence 
microscopy and a humidity chamber. (C) Antibodies bound to magnetic beads can enrich target proteins 
from cell lysate. (I) Cell lysate is flushed across the magnetically trapped beads. (II) Target structures can 
bind and get separated from the other lysate. (III) After washing, UV-light cleaves the antibodies from the 
beads. (IV) And the target protein is released for further processing. (D) Conditioning, like buffer exchange or 
negative staining for EM, can be done with nanoliter sample volumes. (E) The sample is handed over to 
different substrates, depending on the analysis method. As of now, sample preparation for negative stain 
TEM, cryo-TEM, reverse-phase protein arrays, and mass spectrometry is possible. Reprinted and modified 
with permission from ref [333, 335]. Copyright (2016) American Chemical Society. Copyright (2017) 
Creative Commons License 4.0. Panel (A, C) courtesy of Thomas Braun and Claudio Schmidli, C-CINA, 
University of Basel. 
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4.2 Results and Discussion 
4.2.1 Making Co-Culturing Microfluidics Accessible to Single-Cell Lysis 
In the previous chapters 2 and 3, co-cultivation of LUHMES cells was demonstrated and 
transmission of fibrillar a-syn was observed. The main analysis method therein was 
fluorescence microscopy, a powerful tool to perform live cell microscopy and track the 
transmission of possible toxic protein assemblies. However, this technique requires 
antecedent fluorescent labeling of the protein of interest and no conclusion about structural 
modifications of the initial seeds can be drawn. With increasing evidence that 
polymorphisms of a-syn assemblies modify the pathology of synucleinopathies [185], the 
direct analysis of the seeded fibrils compared to the transmitted fibrils in the second order 
neurons would give insight to the toxic variants of these proteins (see section 3.2.4). 
LUHMES Cells Grown on ITO Slides.  
To be able to compare the initial a-syn fibrils with those potent enough to be transmitted, 
the second order neurons must be lysed and analyzed by EM. Therefore, an integration to 
the in-house developed single-cell lysis setup for visual analysis by EM is ideal (Figure 22) 
[334]. This system is designed for electrical lysis of individual adherent cells. It is 
therefore required to grow LUHMES cells on indium tin oxide (ITO)-coated microscopy 
slides which act as electrodes. For initial testing of the growth performance on ITO, cells 
were cultivated on standard glass slides and on ITO glass slides with a PDMS ring as a 
boundary. LUHMES cells develop a different morphology on ITO-coated glass slides than 
on normal glass, with both being pre-functionalized with fibronectin and PLO 
(Supplemental Figure C.2). On ITO, cells don’t spread and tend to form larger cell 
assemblies. In general, LUHMES cells acquire a round morphology on ITO in 
combination with standard functionalization and often die within 8 days. Growing 
LUHMES cells on Geltrex®-coated ITO slides, however, only show marginal differences 
compared to cultivation on uncoated glass slides. This is not surprising, as Geltrex® forms 
a hydrogel-like layer on the surface, through which cells are not likely to have contact with 
the ITO coating. Compared to other cell lines like HEK293 cells and BHK cells, the 
cultivation of LUHMES cells is generally more challenging. 
LUHMES Single-Cell Lysis Evaluation. 
Before trying to make the co-culturing devices directly accessible to the lysis setup, single-
cell lysis experiments were performed on ITO-coated microscopy slides as described in 
Arnold et al. [335]. After LUHMES cells were successfully grown on this substrate, these 
initial lysis experiments should show if LUHMES cells can be used in a similar way to 
HEK293 cells with the single-cell instrument setup. As shown in Figure 23A and B, cell 
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lysate from BHK and HEK293 cells were successfully prepared with a custom-built setup 
and made accessible for TEM [334, 335]. Compared to those cell lines, LUHMES cells 
were more challenging to lyse. Because LUHMES cells cannot be passaged at too low 
confluency, preparing well-separated, healthy cell layers is difficult. It is therefore rare to 
find an isolated proliferating LUHMES cell (Figure 23C). Additionally, for an efficient 
lysis, more pulses at a higher amplitude were required, which also affected the surrounding 
cells. The reason for the lower lysis efficiency is not clear. The Geltrex®-coated surface 
might be an important factor, as the hydrogel-like surface isolates the cells more from the 
ITO surface than it does with the PLL coating, as in the case of the BHK and HEK293 
cells. It might also be possible that LUHMES cells are of a more resistant nature. 
Conducting HEK293 lysis experiments on Geltrex®-coated substrates would give more 
insight into this hypothesis. In the case of differentiated LUHMES cells (Figure 23D), the 
mentioned issues become more severe. The formed neurite network interferes with the 
aspiration of the cell lysate, since it detaches easily and can clog the microcapillary. To 
prevent this, more intense lysis was required to separate the neurites from possible cell 
debris, or completely isolated cells were required. Unfortunately, preparing isolated single 
cells is even more difficult with differentiating than with proliferating LUHMES cells, 
since they start to form clusters. Hypotonic buffers increase the lysis efficiency and weaker 
electric fields might be used. The morphology of the cells alters as water is forced into the 
cells (Figure 23D). This, however, might also alter the proteome within a really short 
timeframe, making parameters difficult to adjust and the experiments less reproducible.  
Figure 23. Comparison of different cell types for single-cell lysis. Phase contrast light microscopy images 
of cells grown on ITO microscopy slides before (top row) and after (bottom row) a sequence of electrical 
pulses was applied. On B-D, the microcapillary which serves as second electrode is visible from the left 
side. (A) Adherent BHK21 cells in HEPES buffer. Only a ghost imprint of the cell is left after lysis and 
aspiration. (B) HEK293 cells before and after lysis. A bubble is formed after electrical pulses were applied. 
Since cells were grown at high confluence a burst of electrical pulse also affected surrounding cells. (C) 
Proliferating LUHMES cells were better suited for lysis experiments compared to cells at a high stage of 
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differentiation (D), as no neurite network is formed yet. LUHMES cells were generally difficult to lyse, likely 
due to the Geltrex®-coated surface. (D) Differentiated LUHMES cells on Geltrex® in hypotonic PBS buffer. 
Hypotonic buffer helped for cell lysis. Still LUHMES cells required longer electrical pulses with higher 
amplitudes for lysis. The formed network became a problem for aspiration and at differentiated stage, 
isolated cells were difficult to find. Scale bars 20 µm. (A) was reprinted and modified from ref [334]. 
Copyright (2013) Creative Commons 3.0. 
LUHMES Accessibility in Microfluidic Devices.  
The design for the co-culturing device offers no open access for a microelectrode to be 
placed close to the target cells. To the best of our knowledge, there is no PDMS-based 
microfluidic device which would allow such access while keeping different cell 
compartments isolated. In principle, the initial PDMS device we produced (Supplemental 
Figure C.1) would give access to the cell somas in the center of the inlet ports. However, it 
was not possible to guide neurites of LUHMES cells in this device to other compartments.  
The second option would be to lift off the PDMS boundary, exposing the adherent cells in 
its growth pattern on the glass slides. Since the PDMS is not plasma-bonded to the glass 
surface, the devices could easily be disassembled as demonstrated in other studies [351]. 
However, our system required in-channel coating, since the hydrogel-like character of 
Geltrex® does not allow pre-coating of glass slides before device assembly. In-channel 
coating made not only the glass surface, but also the PDMS surrounding, a suitable surface 
for LUHMES cell attachment. To render PDMS resistant to cell adhesion, two 
polyethylene glycol (PEG)-based surface functionalization methods were tested. PEG is 
regularly used as an anti-fouling coating and to prevent non-specific biological material 
binding to surfaces. Regarded as a gold standard, poly-L-lysine PEG copolymers (PLL-g-
PEG) in buffered solution are probably the widest and easiest procedure to render a surface 
non-fouling [352]. Coating of the microfluidics device was solely done on the PDMS 
replica in order to prevent PLL-g-PEG grafting to the glass surface. After PEG 
functionalization, devices were prepared as usual for cell experiments. We then labeled the 
cells with calcein acetoxymethyl ester (calcein-AM) to visualize cell rupture caused by the 
disassembly of the device. After separation, the glass and PDMS surface were kept humid 
and were imaged under a fluorescent microscope. Unfortunately, the adherent LUHMES 
cells preferentially attached to the PDMS walls of the microfluidic channels (Figure 24). 
The cells did not show any signs of physical stress, as morphology and neurite network 
corresponded to those of healthy cells, and all cells displayed an even calcein labeling 
(Figure 24B). These results indicate that Geltrex®-coated PDMS provides better growth 
conditions than Geltrex®-coated glass, even when LUHMES cells have to grow upside-
down. Although microfluidic devices with channel heights of only 10 µm were used in 
these experiments, the preference to PDMS of the flat cells is still surprising. Apparently, 
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PLL-PEG coating is not potent enough to avoid the formation of a Geltrex® layer. It is 
proposed, that Geltrex® forms a sort of a basal lamina, which comprehensively covers the 
whole area. This hydrogel-like layer is eventually at first repelled by PEG, but with 
progressive thickening of the hydrogel it stabilizes itself and does not need direct contact 
with the surface. However, chances are that PLL-PEG surface packing density is not 
formed highly enough at RT, even after 20h of incubation [353]. Higher incubation 
temperatures were tried, but at a recommended temperature of 60°C the solution diffuses 
into the PDMS to a large extent.  
Figure 24. PLL(20)-g[3.5]-PEG(2) functionalized PDMS replica after disassembly from the glass surface. 
This was not the final design of the co-culturing device and channels had a height of about 10 µm. (A) 
Bright field light microscopy image of LUHMES cells attaching to the PDMS boundary. (B) The same section 
as in top panel but cells were labeled with calcein-AM to show that cells detached from the glass surface 
without being ruptured. Scale bars 100 µm.  
The second PEG coating method we tested was not solely based on electrostatic 
adsorption, but PEG was covalently bound to the PDMS surface via a silane reaction. It 
was reported that this surface modification of PDMS results in nicer packing density, and 
reduced hydrophobic recovery renders the surface resistant to nonspecific adsorption for 
extended periods [354]. Indeed, one week after the coating reaction, surface contact angle 
measurements indicated a stable PEG-coated surface layer (Figure 25). The control PDMS 
was subject of the same modification procedure, including oxygen plasma treatment, but 
with 100% acetone incubation. Although, this plasmaoxydized surface was hydrophilic in 
the short term, it regained its hydrophobicity after one week (Figure 25A, bottom panel). 
After standard Geltrex® coating of the modified surface, minor differences in growth 
74 Andrej Bieri 
behaviour of LUHMES cells compared to a control surface was found (Figure 25B), but in 
general, LUHMES cells grew on both surfaces. On pegylated PDMS, the cell monolayer 
was less continuous with a few areas on which LUHMES cells could not adhere at all 
(Figure 25B, top panel). This indicates that Geltrex® did not form a continuous, basement 
membrane-like substrate. Thus, PEG-silane functionalization could improve resistance to 
adsorption of PDMS, but not significantly change cell adhesion compared to PEG-PLL 
coating.  
Figure 25. Effect of PDMS surface modification with a PEG functional silane. (A) Surface angle 
measurements of functionalized PEG. The PEG-coated surface (top panel) is hydrophilic a week after the 
procedure, whereas the control surface regained a normal hydrophobic characteristic. Both surfaces were 
initially oxygen plasma treated. (B) LUHMES growing on Geltrex®-coated PDMS, only on minor areas, 
LUHMES growth performance changes between surface modified (top panel) and control (lower panel) 
PDMS. 
Both approaches, PLL-PEG and PEG-silane coating, did not hinder LUHMES cells to 
grow on PDMS, mainly due to the excellent coating properties of Geltrex®. Omitting 
Geltrex® is not an option, as standard fibronectin/PLO coating is not suitable for LUHMES 
cells in microfluidic devices (Supplemental Figure A.2). We looked for ways to incubate 
only the glass surface with Geltrex®, leaving the pegylated PDMS exposed to the cell 
cultures. Due to the proteinous nature of Geltrex®, the coating only worked in fully 
assembled chips. Incubating only the glass surface required the coating to dry before the 
PDMS could be assembled, but this destroyed the continuous basement membrane and 
cells only grew on few clusters. Additionally, to be able to flood the small channels of the 
device, a liquid with low surface tension had to be applied prior to cell culture media. As 
we used ethanol for this task, the Geltrex® layer completely denatured.  
Also, increasing the height of the microfluidic chambers up to 25 µm did not solve the 
tendency of LUHMES cells to grow on PDMS. Although most of the cells remained on the 
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glass surface, this approach would not resolve the problem close to the walls or in the 
neurite microchannels of the device, with a required height of only 4 µm (Figure 26). 
Figure 26. Overview of a whole microfluidic co-culturing device with a height of 25 µm. Red arrowheads 
show LUHMES cells which do not grow on the glass surface. Scale bar 200 µm. 
Overall, making LUHMES cells in co-culturing microfluidic devices accessible to single-
cell lysis is challenging, mainly due to the need of Geltrex®-coated surfaces. As Geltrex® 
forms a thick, extracellular, matrix-like layer it seems to completely isolate all surfaces. 
Thus, it interfered with the electrical lysis efficiency as the conductive ITO surface was not 
in close contact with the cells. It also interfered with a usually highly inert PEG surface by 
simply covering it. 
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4.2.2 Fishing a-Synuclein Fibrils 
The experiments in this section were done in collaboration with Claudio Schmidli, C-
CINA, University of Basel. 
A trapping module to extract protein complexes from cell lysate is currently being 
developed for later integration into the single-cell lysis setup (Figure 22C). This is a crucial 
step in the pipeline, as the identification of protein complexes in crude cell lysate is 
difficult. Initial experiments with a-syn fibrils were performed to evaluate if a-syn 
assemblies could be extracted from LUHMES cell lysate.  
Figure 27. Proof-of-principle study for microfluidics in-line purification of a-syn fibrils. (A) Sequential images 
(from left to right 10 minutes) of beads being trapped by a magnetic field in a microcapillary, which can be 
seen by the growing aggregate in the center of the capillary. (B) Starting mixture of streptavidin-coated 
beads and biotinylated fibrils. From this mixture, biotinylated fibrils should be separated from fibrils which 
were fluorescently labeled (C). After fibrils were trapped, a washing fraction was collected and then the 
purified fibrils were released. Scale bars 500 nm. 
The working principle is similar to immunoprecipitation. The a-syn fibrils were 
functionalized with a photo-cleavable biotin and mixed with non-biotinylated fibrils. After 
incubation with streptavidin coated beads, the solution was loaded to the system via a 
capillary of 250 µm inner diameter. By passing the magnetic field gradient, the beads, 
together with bound a-syn fibrils, were trapped (Figure 27A). After flushing PBS across 
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the trapped particles to remove unbound fibrils, the magnetic trap was switched off to 
release the purified fibrils bound to nanoparticles. Alternatively, illumination with UV 
light breaks the photo-cleavable crosslinker from fibrils in the magnetic trap, and isolated 
a-syn fibrils can be removed from the microcapillary. 
As shown in Figure 27B, not all functionalized nanoparticles bound to a-syn fibrils. It is 
unlikely that there were no biotin binding sites, as an excess of biotin-NHS was used in the 
reaction. It is possible that there was still free biotin in the sample, which competitively 
blocked the interaction with a-syn fibrils.  
When the fibrils passed the magnetic field, they were efficiently trapped and formed a big 
cluster (Figure 27C). After the washing step, this cluster did not dissociate even when no 
magnetic field was applied. Only after harsh pipetting could the sample be made available 
for TEM. It is possible that streptavidin beads bound to several filaments simultaneously, 
and filaments themselves tend to form big clusters. This will not be a problem in later 
applications, as this high number of fibrils will not be available in cell lysate. The washing 
fraction (Figure 27C, top right panel) still contained bead-decorated fibrils. However, less 
free nanoparticles were found, indicating that magnetic trapping is not strong enough for 
bigger protein aggregates with only few beads to withstand the flow.  
When the fibrils were separated by UV light, the elute mostly contained bead-free a-syn 
fibrils, but the concentration was drastically reduced (Figure 27C, bottom panel). Thus, 
cleaving the photo-crosslinker is not efficient. It is likely that the beads interfere with the 
incoming light. With lower fibril and bead concentrations, this effect will be reduced. 
Overall, the initial microfluidic in-line extraction experiments with a-syn showed potential 
to isolate a-syn assemblies from cell lysate. The major drawbacks mentioned above, were 
mostly the result of the high fibril concentrations, leading to a big plaque. However, it 
remains to be proven if the system is efficient enough to trap a few fibrils from a single-
cell lysate.  
4.2.3 LUHMES Cells for Reverse-Phase Protein Arrays 
The experiments in this section were done in collaboration with Stefan Arnold, C-CINA, 
University of Basel. 
Miniaturization of single-cell protein analysis is crucial regarding the small cell numbers in 
microfluidics and the stochastic nature of biological processes in a putative homogeneous 
cell population. As mentioned above, efforts were made to analyze LUHMES cells on a 
single-cell level by visual proteomics. Since the setup used has a modular organization, the 
same instrument can be used for sample handover to other analysis techniques (Figure 
22E). Instead of writing the sample on an EM grid, it can be spotted on a nitrocellulose or 
hydrogel-coated glass slides. Upon immunofluorescent labeling, the spots can be analyzed 
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by a microarray scanner, which is in principle a miniaturized dot-blot platform based on 
reverse-phase protein (RPPA) technology [355]. Because the integration of co-cultured 
LUHMES cells in the single-cell lysis setup was not reproducible, we performed RPPA 
with LUHMES batch lysate.  
Figure 28. Multiple arrays of 4x4 spots of LUHMES cell lysate was spotted on a hydrogel-coated glass 
slide and immunofluorescent labeled with various antibodies against a-syn. (A) The signal intensity varied 
depending on the primary antibody. (B) 10 nl of cell lysate from differentiating LUHMES cells and 
proliferating LUHMES cells at a concentration of 5 x 106 cells/ml was spotted.  
A solution was prepared which contained the lysate of 5 million cells per milliliter. By 
using 10 nl of sample, each spot contained an equal of 50 lysed cells. Multiple arrays of 16 
spots were prepared with lysate of proliferating and differentiating LUHMES cells. With 
an incubation chamber module, each set of 4x4 spots could be immunofluorescent labeled 
individually. The aim of this initial experiment using LUHMES cells and the miniaturized 
dot blot application was, (i) testing labeling performance of different antibodies against a-
syn, (ii) comparing a-syn expression of proliferating and differentiating LUHMES cells, 
(iii) estimating the detection limit for a-syn with this method.  
The five primary antibodies showed significant differences in labeling efficiencies (Figure 
28A). This is not surprising, as all of them target different epitopes. Still, all of them are 
recommended for detection of a-syn by western blot analysis. The reduced sensitivity 
might be related to secondary antibody binding, but could not be assessed with this 
experimental design. Interestingly, the ratio between a-syn signals of lysate from 
differentiating and proliferating cells is not constant among the antibodies.  
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The MJFR antibody was demonstrated to be the least efficient, showing the weakest signal. 
However, regarding the previously mentioned signal ratio, it is the most specific. Given 
that the lysate of 50 cells was concentrated per spot, it his hardly possible to use this 
antibody for single-cell lysis detection of a-syn. Although other antibodies were more 
efficient, the detection of a-syn on low cell numbers is difficult with this technique. When 
using the same antibodies for immunofluorescent labeling in confocal microscopy, the 
efficiency does not coincide with the RPPA experiments (Supplemental Figure B.2). In 
those fixed samples, the BD antibody was the least efficient and the MJFR antibody 
showed high specificity also for a-syn fibrils. It is normal that some antibodies only work 
for specific assays. 
Consistent with the literature, differentiating LUHMES cells have an upregulated 
expression of a-syn [305]. The amount of a-syn which we detected in proliferating cells 
was quite high and, depending on the antibody, almost reached the level of differentiating 
LUHMES cells. Although we also detected some a-syn in proliferating cells by 
immunofluorescence labeling and confocal microscopy analysis (chapter 2.2.3), the signals 
here are clearly too strong. This indicates nonspecific labeling of the cell lysate 
independent of the state of differentiation. Since there is only a weak signal when the 
primary antibody was omitted, the nonspecific labeling could be assigned to the primary 
antibodies.  
The miniaturized dot-blot experiments are a promising approach for detection and 
quantification of proteins. However, in the case of measuring endogenous a-syn with this 
method, some antibodies already reached the detection limits with 50 cells per spot. It is, 
therefore, unlikely to detect less abundant proteins on a single-cell level with this 
technique. Different strategies to enhance the sensitivity have been demonstrated. It was 
shown that novel nanostructured plasmonic gold substrates enhanced the near-infrared 
fluorescence signals of protein microarrays up to 100-fold, allowing protein detection in 
the femtomolar range [356]. Recently, another study, based on surface-enhanced Raman 
scattering, reported immunoassays also with femtomolar sensitivity [357]. A third 
approach could make use of signal amplification by sequential incubation of fluorescently 
labeled secondary antibodies [358]. Such improvements in microarray sensitivity, together 
with improvements on the single-cell lysis setup to prevent further dilution of the sample, 
would allow the detection of less abundant proteins down to single cell level. 
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4.2.4 LUHMES Cells for Liquid Chromatography-Mass Spectrometry 
The experiments in this section were performed in collaboration with Stefan Arnold, C-
CINA, University of Basel.  
Similar to RPPA experiments, LUHMES lysate could be handed over for mass 
spectrometry (MS). Batch lysate was differently prepared based on a urea buffer and 
special cyclic olefin copolymer (COC) microscopy slides were used as substrate to spot the 
samples. Small volumes in the range of 2-18 nl with 2 nl increments were spotted on COC 
slides. The spots were eluted using a thin layer chromatography interface and fed into the 
liquid chromatography-MS device, where a targeted mode was used to detect glutamic 
acid. As seen in Figure 29, the peak area increased linearly with the deposited volume. 
Theoretically, the smallest spot contained only lysate from 2–3 cells. Although cells were 
thoroughly rinsed prior to lysis, traces of glutamic acid could still be introduced by the 
original cell media. Additionally, lysis buffer based on urea is not ideal for mass 
spectrometry, as it causes a lot of ion suppression. An alternative lysis buffer might further 
increase the sensitivity. Nevertheless, the experiments showed that with this system, 
single-cell sensitivity could potentially be reached. With further optimization of the setup 
and instrumentation, even less abundant metabolites should be detectable at the single-cell 
level. 
Figure 29. Testing LUHMES batch lysate for glutamic acid. The detected amount increased linearly with 
the amount of spotted lysate. Reprinted with permission from ref [359]. 
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4.3 Conclusion 
Attempts were made to integrate LUHMES co-culturing devices to the in-house developed 
single-cell lysis instrument. Therefore, initial experiments at several modules of the single-
cell proteomic pipeline were performed to test the suitability of LUHMES cells for further 
integration.  
At the beginning of this pipeline, culturing LUHMES cells on conductive surfaces for 
electrical lysis and access to the isolated cells within a microfluidic chip was required. 
Growing the cells on ITO was successful. However, slight interference between the growth 
substrate and electrical lysis was assumed. In general, LUHMES cells are more 
challenging for single-cell lysis compared to other cell types.  
The need for Geltrex® appeared to be an obstacle also for exposing cells by lifting off the 
PDMS replica. As it forms a continuous basement membrane matrix, it renders most 
surfaces suitable for culturing LUHMES cells, even when coated against fouling. To 
overcome this problem, a new surface coating must be found which in the best case can 
run dry to pretreat only the growth surface, not the PDMS replicas. 
Proof-of-concept experiments for inline protein isolation showed, that in principle, a-syn 
fibrils could be fished from protein lysate. This would be an interesting application for 
seeded transmission experiments, to isolate transmitted a-syn assemblies from recipient 
cells and hand over to TEM for strain analysis. However, the low single cell volume and 
low fibril number compared to a system volume several orders of magnitudes bigger would 
require an extremely high efficiency.  
Finally, RPPA and MS with LUHMES cell lysate revealed that other analysis methods 
than TEM would be suitable at the end of the single-cell lysis pipeline. However, 
sensitivity must be increased in both cases to detect proteins and metabolites on a single-
cell level. 
 
 
 
  
82 Andrej Bieri 
 
Chapter 5  83 
 
CHAPTER 5 
Correlative Light and Electron Microscopy to Study Mitochondrial 
Degeneration in Native Environment 
This chapter describes the primary evaluation of correlative light and electron microscopy 
(CLEM) for the in situ study of LUHMES cell organelles. This approach aims for fast 
sample preparation without inducing changes in neuronal cells. 
5.1 Introduction 
Differentiated neurons develop a complex arbor of neurites which are responsible for 
distribution and collection of information. Some axonal projections form extensive 
networks and connect different brain regions. Increasing evidence indicates a spreading of 
Lewy pathology based on the prion-like behavior of a-syn, therefore it seems likely that 
pathological a-syn species undergo a neuron-to-neuron transfer along these axonal 
projections [280]. Hence, it is crucial to know the neuronal architecture and structure of 
potential organelles which are involved in this axonal transport.  
Electron microscopy offers a unique possibility to study neurons and their connections as 
its resolution is high enough to structurally characterize cellular contents at nanometer 
scale. However, due to limited penetration of the electron beam, most conventional EM 
techniques require sectioning of previously dehydrated and resin-embedded cells or tissue 
[360]. This harsh chemical procedure can induce changes from their native state. Although 
there are sophisticated techniques to preserves the physiological state of a biological 
sample by sectioning vitrified specimens, there might be compression artefacts introduced.  
Since the thickness of neurites does not exceed the limits of cryo-EM, several studies 
demonstrated the growth, vitrification, and visualization of neurons grown directly on EM 
grids [361-366]. The advantage therein is to preserve the neurites in a close-to-
physiological state. Light microscopy can be used to guide the EM search for structures of 
interest. Advanced CLEM techniques allow automatic position mapping in light 
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microscopy and spatial correlation to the EM control software, allowing for high 
throughput and automated image acquisition. Thus, with specific fluorescent labeling, this 
technique is ideal to study neurite architecture and interaction sites of labeled, internalized 
a-syn fibrils. 
Here, we present the applicability of frozen-hydrated LUHMES cells to direct visualization 
by light and electron microscopy. As an example, we focused on mitochondrial 
architecture upon incubation with a-syn fibrils. Additionally, a method is suggested to 
combine microfluidics co-culturing devices with cryo-EM to study intra-neurite transport. 
5.2 Results and Discussion 
5.2.1 LUHMES on-Grid Preparation for CLEM 
The general steps for growing and vitrifying neurons on EM grids were thoroughly 
described elsewhere [361]. As we have seen in other applications, preparation of 
LUHMES cell cultures can be challenging, depending on the required surface (see 
Chapter 4.2.1). Thus, an adapted protocol for LUHMES cell preparation on EM grids was 
developed. 
Growing LUHMES Cells on EM Grids 
Disinfected and glow-discharged gold EM grids were placed in the center of miniaturized 
Petri dishes which were made from PDMS rings on standard microscopy slides. Unlike 
other protocols [361], we did not experience any advantages from flame-sterilization as 
gold grids are highly fragile. The heat often bent the grids and destroyed the holey carbon 
film. Re-exposure to the environment after glow-discharging was not considered a risk for 
contamination, as the wells were sterilized with ethanol once the grids were in position. 
Additionally, we experienced a better coating with glow-discharged grids. 
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Figure 30. LUHMES cells growing on EM gold grids. (A) Supportive layer of Geltrex® was used. (B) Gold 
grids were coated with fibronectin and PLO. Scale bar 200 µm. 
In general, we faced the same problems with the standard fibronectin/PLO coating as in 
microfluidic devices or on ITO coated glass, (i) weak spreading and attachment, (ii) slow 
neurite network formation, (iii) formation of cell aggregates after few days of 
differentiation, (iv) differentiated cells detached easily, (v) cells did not grow at low cell 
numbers. Additionally, the formed network was often guided along the bars of the EM 
grid, where they could not be imaged (Figure 30B). However, Geltrex® coating allowed for 
plating at lower cell density, and with cells still forming networks without being influenced 
by grid bars (Figure 30A). Since cell bodies are too thick for cryo-EM, cell density should 
be kept as low as possible. With Geltrex® coating, it was possible to grow cells at a 
concentration as low as 200’000 cells/ml. While loading 300 µl of cell suspension in each 
well, an absolute cell number of about 60’000 cells per well was loaded. Fewer cells often 
resulted in less stable cell cultures. This cell number exceeds the recommended cell density 
fourfold [361], which influenced the vitrification quality (see section 5.2.2). 
Vitrifying LUHMES Cells on EM Grids 
For the plunge freezing process, two commercial vitrification devices were used. At first, a 
vitrobot (ThermoFisher Scientific, USA) was used in a manual mode, as one-sided manual 
blotting was preferred. The normal mode of the vitrobot performs a both-sided blotting, 
which completely ruptured the cell monolayer. Manual blotting from the backside of the 
grid for 10 seconds gave reproducible results. Unlike described in the literature, using 
calcium free blotting paper did not make any difference [361].  
As second device, a Leica EM GP (Leica Microsystems GmbH, Germany) was used. 
Although this machine performs one-sided blotting, it resulted in more damaged grid 
windows than when manually performed. Adjusting the parameters for only slight contact 
often resulted in not properly blotted grids. Therefore, manual blotting is recommended. 
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Different types of gold EM grids were tested. Finder grids can assist with correlating light 
and electron micrographs. Here, only manual correlation based on prominent features was 
done. This was also possible with normal gold grids. 400 mesh grids appeared to be more 
stable due to smaller window sizes. However, 200 mesh grids were preferred since the 
chances of finding neurites in good conditions are enhanced despite increased damage. 
Similarly, 3.5 µm dimeter holes offered more field of view compared to R2/2 holey carbon 
films.  
5.2.2 Correlative Light and Electron Microscopy 
Observing sample grids by light microscopy prior to EM can be of great use to find the 
regions of interest, to identify labeled targets, and to assess the grid quality. Here, we 
correlated light micrographs of vitrified and life cell monolayers to EM. In order to make 
sure that the grid could be correlated to the EM images and to avoid lacking data when 
parts of the carbon film crack, the whole grid was imaged.  
Cryo-Light Microscopy Mapping 
To record light microscopy images of frozen grids, an upright light microscope equipped 
with a cryostage was used. The tongue of the cryoholder was immersed in LN2 for the grid 
transfer of up to 9 grids. As no transfer station was available for this type of cryostage, a 
polystyrene box was modified to fit the grid holder. The transfer process was kept as short 
as possible to avoid ice contamination.  
In bright-field mode of the light microscope, cell bodies were clearly visible through the 
vitreous ice (Figure 31 top panels). This mode is useful to assess the ice quality. In general, 
when cells were clearly visible, as in Figure 31A’s leftmost windows, the vitreous ice was 
thin enough for cryo-EM. Thicker ice often displayed cracks, as it can be seen in the other 
windows. Since we were interested in imaging neurites, exact localization on grids was 
required. Because neurites were hardly visible in bright field, viable cells were labeled 
with calcein-AM prior to vitrification. As it can be seen in the lower panel of Figure 31, 
calcein fluorescence is strong enough for the detection of neurites through vitreous ice. 
Still, compared to the fluorescent brilliance in liquids (see Figure 30), samples in vitreous 
ice showed a weaker signal and could appear blurry. This might be explained by quenching 
effects and increased scattering of light, leading to reduced fluorescence and poor focus. 
Thus, correlating small or rare features require strong fluorescent labeling.  
High cell numbers could impact the ice quality negatively. With many cells on a grid 
window, the ice was still too thick, even with increased blotting times over 15 s. In this 
case, over-blotting was hardly possible as water was trapped in close proximity to the cells 
(Figure D.2.). Ideally, cell bodies grow on grid bars with only neuronal projections 
crossing the windows. Since the position could not be directed, the cell density was kept as 
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low as possible. This increased the field of view and decreased the ice thickness. Using 
concentrations of 100’000 cells per well corrupted the vitrification of the whole grid 
(Figure 31B). Reducing the cell concentration to 60’000 cells per well resulted in a stable 
cell monolayer but still made large parts of the grid unusable (Figure 31A). Unfortunately, 
loading even less cells could lead to a poor neurite network formation. This however, is a 
trade-off that was considered beneficial for a good ice quality, as the grids were examined 
and selected before vitrification. 
Figure 31. Representative light microscopy images of frozen-hydrated LUHMES cells on EM grids. Upper 
panels show the grid in bright-field mode and lower panels shows the same cells by fluorescence 
microscopy of calcein. (A) About 60’000 cells were seeded per well, resulting in a quite high cell density. (B) 
About 100’000 cells were seeded per well. Cells almost entirely cover the grid, leaving almost no window to 
perform cryo-EM measurements.  
Although examining vitrified grids for latter correlation in cryo-TEM is useful to assess the 
quality of the frozen grids, it was often favorable to map the grids in liquid state based on 
the following issues. The used setup increased the risk of ice contamination and defects on 
the grid with each manipulation step. The intensity of the fluorescent signal and image 
quality is much better in liquid samples. When mapping was done right before vitrification, 
the cell state would not change significantly. Overloaded grids, damaged grids, and grids 
without fluorescent target signal could be discard before vitrification. Possible changes 
during the freezing process were recognized manually. Additionally, the focus in this study 
centered on the identification of mitochondrial alteration upon a-syn fibrils incubation. 
Since both mitochondria and a-syn fibrils were highly abundant, light microscopy 
mapping was rather to control sample integrity than to localize target features. 
However, for future studies using LUHMES cells and CLEM where rare events or cell 
features should be observed a correlation with frozen grids is beneficial. 
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Live-Cell Light Microscopy Mapping 
Sample preparation for live-cell imaging was nearly identical as for cryo-light microscopy, 
except for the vitrification step. Additionally, LUHMES cells were incubated with 
fluorescently labeled a-syn fibrils 24 h prior to imaging. To obtain a whole image at a 
resolution where fluorescent a-syn fibrils could be correlated to cellular features, several 
images at high magnification were recorded and later stitched together. Since light 
microscopy work was done at RT, image acquisition had to be performed fast. Afterwards, 
grids were immediately frozen to prevent changes in the cellular arrangement. This process 
could be improved significantly by using live-cell imaging incubation chambers and 
automatic image mosaicking on the light microscope.  
Neurites could clearly be located in bright field images, as it can be seen in the inset of 
Figure 32A. Therefore, no calcein staining was required. Fluorescent labeled a-syn fibrils 
were detected mostly co-localizing with cell bodies (Figure 32B). Furthermore, 
mitochondria were labeled to assist the search in cryo-EM. However, the resolution was 
not high enough to discriminate individual mitochondria (see Figure 32D). Using higher 
magnification objectives was not advantageous as imaging time at RT would have 
increased. In this case, the exact location of mitochondria was irrelevant, as they were 
highly abundant in neurites.  
The light microscopy images were mirrored to match the orientation of EM projections 
(Figure 32C). When comparing Figure 32 C-E, a neurite can be detected in bright field and 
fluorescent microscopy and finally by cryo-TEM. Several high magnification micrographs 
were recorded based on an overview image of this neurite (Figure 32F). There, the 
positions where the mitochondria were found are labeled with asterisks. Since no 
mitochondria can be seen on this overview, TEM images were recorded randomly along 
the neurite.  
This basic workflow for CLEM of mitochondria in LUHMES neurites could be 
substantially reduced. In principle, no correlation would be necessary at all regarding the 
abundance of mitochondria and a-syn fibrils. Still, for observing the integrity of neurites 
and co-localizing a-syn fibrils with target cells, light microscopy correlation was 
maintained. For further studies using LUHMES cells with CLEM, where rare events or 
organelles should be observed, high resolution light microscopy is indispensable. 
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Figure 32. LUHMES cells differentiated for 6 days on EM grid and incubated with 2 µg/ml fluorescent a-
syn fibrils 24h prior vitrification. Grids were mapped by light microscopy before vitrification. (A) Bright field 
image representing parts of an EM finder grid in non-frozen state. Inset was recorded at higher 
magnification for correlation with cryo-TEM micrographs. (B) Fluorescence microscopy was used to 
determine co-localization of fluorescent fibrils and cells. (C) Inset of A was mirrored on the horizontal axis. 
This is necessary for comparison with TEM micrographs, since TEM produces projections of the sample. 
(D) Fluorescent images of the same section but labeled with mitotracker. (E) Cryo-TEM images correlated to 
the previously shown light microscopy images. (F) Cryo-TEM images of the neurite of interest, as this neurite 
labeled positive for mitochondria in D and the connected cell labeled positive for a-syn fibrils in B. (*) 
Asterisks label the positions where images of mitochondria were recorded (high resolution micrographs 
follow the same order). White scale bars 50 µm. Black scale bars 500 nm. 
5.2.3 a-Syn Fibrils and Mitochondrial Dysfunction 
Both mitochondria and a-syn seem to play an important role in the pathogenesis of PD 
[367]. It was suggested that the mitochondrial dysfunction enhances the formation of 
misfolded a-syn aggregates [216], although no study was found which supports this 
theory. On the other hand, several studies suggest a function of a-syn in the control 
mechanisms of mitochondria [368]. Therefore, a perturbation of this relation is likely to 
have an effect on mitochondrial function. Overexpression of a-syn affects the normal 
90 Andrej Bieri 
function of respiratory chain complexes in vivo [369] and induces mitochondrial 
fragmentation in vitro [213, 214]. Additionally, oligomeric [215] and fibrillar species [370] 
of a-syn could cause mitochondrial impairment. Direct association of a-syn to 
mitochondrial membrane was demonstrated, but the exact localization remains unclear 
[371]. According to our knowledge, direct interaction of any internalized a-syn assemblies 
have not been demonstrated. To study interaction sites of a-syn and its effect on 
mitochondria shape, the adapted protocol for visualizing mitochondria in dopaminergic 
LUHMES cell neurites could be of great use.  
According to the developed protocol described in the previous section, LUHMES cells 
were differentiated on gold EM grids. Specifically for the presented data in Figure 33, cells 
were incubated with 2 µg/ml a-syn fibrils on day 6 of differentiation. Samples were 
mapped on day 10 of cell differentiation and subsequently vitrified. Fewer fluorescent 
fibrils were detected after four days of incubation than after 24 h of incubation (compare 
Figure 33A and Figure 32B). It is possible that fibrils were removed during media 
exchange or were released as discussed in section 3.2.2. Otherwise, cells did not show any 
morphological signs for a-syn-induced toxicity (Figure 33A).  
Cryo-TEM images were acquired using the Serial EM software [372]. First, an atlas of the 
EM grid was recorded, based on which regions of interest were correlated manually with 
the light microscope map, and windows with thin ice were selected. Montages of 
overlapping images of these windows were prepared (Figure 33C). On these montages, 
random coordinates along neuronal projections were programmed to automatically record 
the neurite architecture. Most of the programmed spots contained mitochondria (Figure 
33D).  
All mitochondria displayed a short, almost round shape (Figure 33D). This type of 
structure was reported for mitochondria in a-syn overexpressing mammalian cells, 
whereas wild type cells displayed long and thin mitochondria [214]. Regarding the 
ultrastructure of the mitochondria, no obvious effect of a-syn fibrils was detected. Cristae 
are of regular order with narrow intermembrane spaces, which is not consistent to 
observations in a-syn overexpressing cells, where irregular and enlarged intercristal spaces 
were observed [151]. 
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Figure 33. CLEM of LUHMES cells on day 10 of differentiation. Cells were incubated with 2 µg/ml a-syn 
fibrils for 4 days. (A) Merged bright field and fluorescent image locating the fluorescent seeds on the cells. 
(B) Same region in cryo-TEM recorded as an atlas in serial-EM. (C) Region of interest recorded as individual 
images and stitched together with the polygon function of Serial-EM. (D) Mitochondria were imaged on 
random spots which were selected on the overview map in C. White scale bar 100 µm. Black scale bars 
100 nm. 
In comparison with earlier structural data (Figure 32 asterisk), the ultrastructure of cristae 
and the round shape was mostly identical, although the samples from Figure 33 were 
exposed to a-syn over a longer period. Interestingly, all of the mitochondria with longer a-
syn exposure contained electron-dense granules. In samples with 24 h fibril incubation we 
did not find any intra-mitochondrial granules. Since they appeared in only one condition, a 
systematic artefact from sample preparation cannot be excluded. It is also possible that 
granules are formed in older mitochondria, since there were no granules in cells which 
were vitrified on day 6 of differentiation.  
Several conflicting reports exist about the presence of such electron-dense granules. They 
were considered to be the result of pathological conditions or due to sample preparation 
artefacts [373]. Some studies exclude a link to cellular stress or toxicity [361]. In general, 
it is agreed that the granules are involved in the regulation of the ionic environment in 
mitochondria [373, 374]. Furthermore, it has been reported that the intracellular calcium 
concentration in old neurons is significantly elevated compared to young neurons [375]. 
Thus, if granules regulate the internal ionic environment of mitochondria by deposition of 
the divalent ions in granules, it would explain our data, where granules were only detected 
in older LUHMES cells. Whether these granules are linked to a-syn toxicity or to age 
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remains to be systematically tested. But given the above considerations, it is likely the 
neurons in some of our preparations did not display mitochondrial electron-dense granules 
as a result of a-syn toxicity.  
Figure 34. Influence of a-syn fibrils on mitochondria in LUHMES cell cultures. Seeds were applied on day 
2 of differentiation and cells were fixed on day 10 of differentiation. Mitochondria are labeled in green, seeds 
are labeled in magenta. (A) LUHMES cells without incubation of a-syn fibrils. (B) Fibrils are incubated on day 
2 of differentiation. (C) LUHMES cells were cultivated in a co-culturing device and seeds were applied to the 
central channels. Mitochondria were labeled with mitotracker. (D) Cell viability test of LUHMES cells 
incubated to different seed concentrations. Scale bars 20 µm 
Confocal microscopy studies with LUHMES cells prepared under the same conditions as 
for the CLEM studies did not reveal any effect of a-syn fibrils on mitochondrial 
morphology. Immunofluorescent labeled mitochondria in fixed samples display the same 
pattern in LUHMES cells which were incubated with fibrils and in the control sample 
(Figure 34A and B). Unlike the reported tubular and connected pattern of mitochondria in 
wild type mammalian cells [214], the mitochondria appeared small, in a punctuated 
pattern. This would be consistent with the round shape of the mitochondria in the cryo-
TEM data (Figure 33D). Interestingly, when mitochondria in live cells were labeled using 
mitotracker, the fixed sample showed a tubular mitochondrial pattern (Figure 34C). 
Additionally, using both labeling methods, a-syn fibrils did not co-localize with 
mitochondria (Figure 34B and C). It has been shown in many experimental models that 
monomeric a-syn is localized to mitochondria [371]. The direct interaction of bigger a-syn 
assemblies was not demonstrated. It remains unclear how a-syn fibrils might indirectly 
affect mitochondria. 
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Additionally, we tested what concentration of a-syn fibrils is needed to induce a 
substantial toxic effect in LUHMES cells. The resazurin assay is particularly interesting in 
this matter, as it gives us information about cell viability based on dehydrogenase activity 
in mitochondria. Therefore, it also provides insight into mitochondrial respiratory function. 
Here, we did not observe any significant decrease in reduction of resazurin, even at high a-
syn fibril concentrations (Figure 34D). This indicates that neither did cells die from a-syn 
toxicity nor was there a reduced mitochondrial activity. Several controversial reports about 
a-syn fibril toxicity exist. In some, only the oligomeric, not monomeric or fibrilar form of 
a-syn, can induce mitochondrial dysfunction which is consistent with our results [215]. 
Other studies reported mitochondrial impairment in cell cultures as a direct effect of a-syn 
fibrils [370]. Either way, mitochondrial changes do not inevitably lead to detectable 
mitochondrial dysfunction [214]. Therefore, absence of overt cellular toxicity in LUHMES 
cells does not necessarily conclude that a-syn fibrils have no effect in cellular integrity.  
The results from this chapter are in agreement with observations from chapter 2 and 3, 
where no obvious toxic effect from a-syn fibrils was observed. Supported with cell 
viability tests and mitochondrial ultrastructure, most seeding experiments indicate that 
LUHMES cells are not susceptible to a-syn pathology of this strain of fibrils.  
5.2.4 Microfluidics Co-Culturing on EM Grids 
With the development of automated high-resolution CLEM, sample preparation remains 
the main bottleneck in this technique. Regarding the preparation of LUHMES cells on EM 
grids, the main problem is the relatively high cell number which is required to grow a 
healthy monolayer. This conflicts with the need in cryo-TEM for a thin ice layer, since a 
continuous cell monolayer interferes with the vitrification. As only cell bodies are an 
obstacle in this method, a separation from neurites and somas would be beneficial. Initial 
evaluation of this concept was done, combining microfluidic co-culturing devices with 
CLEM.  
PDMS replicas for the co-culturing devices were prepared as described previously 
(chapter 2.2.1) Instead of assembling the devices, replicas were bisected along the central 
channel, dividing the two cell-growth chambers in separate replicas. A pair of those were 
placed in Petri dishes with enough distance to place a gold grid in the central space (Figure 
35). From this point, devices were processed according to standard LUHMES cell 
culturing in microfluidic devices. No difference in growth behavior between the normal 
and these bisected devices were observed. Indeed, this application even offers a few 
advantages. As there is no central channel, the big space between the two halves had to be 
filled with cell media, which meant the whole space in the dish around the device was 
filled with media. In this huge excess of media, cells could easily survive for 4 days 
without media change. 
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For seed transfer experiments in anterograde direction, Petri dishes must be filled to at 
least the same level as the inlet ports of the growth chambers, otherwise seed transport 
would occur with the stream through the neurite channels. This high level of media often 
detached the devices due to good buoyance of PDMS and weak interaction with plastic 
Petri dishes. To perform experiments which don’t allow a stream from the growth pool to 
the central space, the PDMS needed to be weighted. 
Figure 35. Combining microfluidics and CLEM. (A) An EM holey carbon gold grid (ø 3.05 mm) was place 
in-between a bisected microfluidics co-culturing chip. (B) Fluorescence microscopy image of neurites 
growing through the microchannels onto the gold grid. (C) Neurites from individually cultured LUHMES cells 
meet at the center of a gold grid. Scale bars 0.5 mm. 
As in normal co-culturing devices, neurites begin to grow through the microchannels after 
three days of differentiation. Grids could also be inserted at this point, when it is certain 
the cells are growing regularly. Unfortunately, as gold grids have a thickness of 20 µm and 
can be slightly bent, neurites mostly grow underneath the grid (Figure 35B). Interestingly, 
neurites didn’t stick to the Geltrex®-coated plastic surface, but instead they formed a dense 
network upside-down on the bottom side of the gold grids. Thus, EM grids should be 
positioned upside-down. 
To have enough neurites in the field of view for cryo-TEM, neurites must push towards the 
center. With exactly aligned PDMS replicas and EM grids, neurites still have to grow over 
a distance of 1.5 mm. However, after 10 days of differentiation with a high cell number in 
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the growth pools, there were enough neurites in the central region of the grid, with some 
even crossing the center (Figure 35B). This then even allows the study of direct interaction 
sites of two different cell populations.  
The vitrification of the sample also follows the presented CLEM procedures, whereas 
neurites could be imaged on live-cells or after the vitrification. It was difficult to mount the 
grid on the tweezer, while the grid was pushed around in the dish. With the first contact 
between the grid and the tweezer, the neurites get injured and crush. From this moment, 
the fine structure of the neurites start to change. Since this is not a problem when cells are 
grown together with their neurites on the grid, we thought that this new method would be 
less physiological. However, the time between first contact with the grid and final plunge 
freezing can be below 30 seconds. Time for the part distal to the injury to degenerate can 
only be estimated. It was reported, that after crush trauma, Wallerian degeneration starts in 
the distal part of the neurites. The progressive anterograde degeneration begins usually 
within 24 hours [376]. Mitochondrial swelling and disintegration, and ER degradation are 
early changes, followed by microtubule depolymerization. However, it was shown that 
both ends die back within 30 min for several hundred micrometers from the site of injury 
[377]. This acute degeneration is similar to Wallerian degeneration but affects both ends.  
Taking this into account, parts of the neurites which reach the center of the grid should still 
be intact after hours. But to avoid taking chances, vitrification of the grid should be done 
rapidly after first contact with the tweezer, especially since the described degeneration 
processes were studied in vivo, whereas neurites in cell cultures might respond differently. 
However, even if mounting the grid can take several seconds, and subsequent blotting time 
takes 10 seconds, the whole plunge freezing process can be managed within 30 seconds. 
Thus, neurites at grid center still should display a physiological neurite architecture. 
Overall, this technique offers several advantages. Neurites and soma can be treated 
independently, which allows experiments on neuronal transport of a-syn fibrils. Since 
neurites can span half of the grids, projections of two independently-treated cell 
populations can be studied. No large cell bodies grow on the grid which would interfere 
with the vitrification. Thus, sample preparation should be more reproducible, and fewer 
expensive gold grids would be required. In contrast to on-grid cell cultivation, grids can be 
positioned when neurites start to grow through the channels. This again reduces the loss of 
grids due to poor cell conditions. In general, grids should display a cleaner background 
since secreted vesicles, apoptotic cell debris, and other cellular residuals mostly remain in 
the microfluidic chambers. 
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5.3 Conclusion 
Here we have presented a protocol of how LUHMES cells can successfully be made 
available for CLEM studies of neurites in near-physiological state. Initial findings 
indicated that a-syn fibrils do not induce a significant reaction in these cells. In general, 
LUHMES cells do not seem to be susceptible to fibrils. 
The main problem in sample preparation was poor vitrified ice due to a high number of 
cell bodies on the EM grids. To avoid this problem, we presented initial results of a 
concept where only neurites grow on the grids, by using microfluidic co-culturing devices. 
With the development of automatic correlation between light microscopy and EM, 
automatic image acquisition in cryo-TEM, and sophisticated microscopes to record high-
resolution images, many steps were taken already for high throughput experimentations. 
However, there is plenty of space for optimization in the CLEM process. Here, the 
protocol would profit further from automatic mapping in light microscopy with automatic 
z-stack recording at high magnification and image stitching.  
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CHAPTER 6 
General Conclusion and Outlook 
The overall aim of this thesis was the co-cultivation of LUHMES cells in microfluidic 
devices as a minimalistic in vitro model system for PD-related research on the prion-like 
spreading of a-syn. As a far-reaching aim, a flawless integration of several single-cell 
lysate analysis techniques and of CLEM was pursued. 
First, LUHMES cell cultures were established. The decision to use these cells was based 
on the lack of alternative stable, dopaminergic neuronal cells of human origin, and on the 
suitability of LUHMES cells as a model for PD-related studies [301]. This human cell line 
was developed to fill the gap between animal models, where often the disease phenotype of 
PD is missing, and cellular models, which often don’t meet the dopaminergic 
requirements, or are not of human origin. Since the creation of LUHMES cells in 2005 
[298], several studies have used this cell model to reveal DA-related cell death 
mechanisms, often due their suitability for MPP+ toxin-induced neurodegeneration [300, 
305, 378], and LUHMES cells were well-characterized in this process [301]. However, so 
far, no studies were published using LUHMES cells as a model for seeded aggregation and 
transmission of a-syn. Therefore, LUHMES cells needed to be characterized upon 
incubation with a-syn fibrils. Uptake and release of extracellularly added fibrils was 
observed by confocal microscopy. The internalization of fibrils in LUHMES cells is a 
process which starts immediately after incubation and does not reach saturation within 24 
h. Most of the a-syn fibrils thereby remain on the cell surface. Furthermore, extracellular 
added fibrils seem to form aggregates, inside the cell and on the cell membrane. Unlike as 
reported in several studies using other cell lines, we could not observe any seeded 
aggregation of endogenous a-syn [253, 379]. Regarding release, there were some 
indications that a-syn fibrils are secreted from LUHMES cells, although it seems that most 
fibrils are released after cell death. Degradation of a-syn fibrils by endosome-lysosome 
pathways could not be verified since corresponding markers did not co-localize with seeds. 
While studying seed propagation of a-syn, we continuously prolonged the cultivation 
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times of adherent LUHMES cells for up to 20 days of differentiation. Compared to the 
reported 12 days of differentiation [301], a further increase of some neurological markers 
was detected, making LUHMES cells at longer differentiation times a more complete 
dopaminergic model to study PD. Additionally, we found an improved differentiation 
within shorter time when using a different surface coating.  
In the second step a co-culturing microfluidic device was developed to study the 
transmission of a-syn through neuronal projections – a further key element of the prion-
like spreading hypothesis in PD. In general, fluidic separation from axons and soma of 
neuronal cells is an established technique. Although attempts to cultivate LUHMES cells 
in microfluidic devices were made in the past [312], so far no published data is available 
on this matter. To improve growth and neurite guidance of LUHMES cells in PDMS-on-
glass devices, the cultivation protocol and surface coating were heuristically adapted. The 
design of the microfluidic device was improved for stable cell cultivation with no cross-
contamination of different cell populations. The developed devices were used to study 
intra-neurite transmission of a-syn fibrils, which seems to be less efficient in LUHMES 
cells compared to other cell lines. In general, LUHMES cells seem only slightly 
susceptible to a-syn pathology, which does not make them a bad model system, as many 
experimental parameters, including a-syn strains, seed concentration, and cellular 
heterogeneity need to be clarified by further testing. As the efficiency of uptake and 
transmission is only low, it is even more important to make microfluidics devices 
accessible to other analysis techniques which allow for detection of rare events. 
On these grounds, attempts to connect microfluidic co-culturing devices with a single-cell 
lysis device were made. This instrument has a modular structure, which allows the 
integration of different modules at several steps of the pipeline, and can handover the final 
sample to several analysis methods, including cryo-TEM, MS, and RPPA. The initial 
sample-loading can be done by directly lysing and aspirating single cells. Therefore, 
LUHMES cells were successfully grown on ITO slides and provided for electrical lysis, 
which is the main task for further processing at a single-cell level. Direct lysis from 
microfluidic chips was evaluated, and failed mainly due to the need for adherent LUHMES 
cells to grow on Geltrex®-coated surfaces. Further steps in the single-cell lysis pipeline 
were successfully tested, particularly the handover to complementary single-cell analysis 
methods like RPPA and MS. These results demonstrated the feasibility of single-cell 
analysis with LUHMES cells, although more work will be necessary for a flawless 
integration of co-culturing devices. 
In the final part, protocols were established to visualize LUHMES cell neurites by CLEM. 
With the importance of mitochondria degeneration in PD in mind, correlating light 
microscopy and EM with LUHMES cells can be of great use in studying the influence of 
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a-syn to dopaminergic cells. An improved cultivation procedure was tested which 
combines LUHMES co-cultivation with CLEM, thereby reducing the damage caused by a 
cell monolayer to the holey carbon EM grids, and allowing the study of seed transmission 
through neurites. 
Overall, many methods were presented in this thesis, with all of them involving the 
cultivation of a stable LUHMES cell monolayer. The benefits of stronger adhesion to a 
particular substrate would be high, especially in single cell lysis experiments to avoid 
aspirating cell debris, and in CLEM to avoid altering the morphology of the neuronal 
network during vitrification. But also for longer differentiation times, LUHMES cells need 
an improved substrate to avoid detachment during washing steps. By using Geltrex® an 
improvement was made in this respect. Additionally, the use of Geltrex® demonstrated that 
LUHMES cells might be able to differentiate into a more complete neuronal cell line. We 
showed that a monolayer growth of up to 20 days is possible and increased SP levels were 
detected. Development of better growth substrate and media composition would be 
necessary for a complete polarization of this cell line. To this effect, co-cultivation of 
LUHMES cells with astrocytes, and long-term cultivation in a 3D model was already 
demonstrated [307, 310]. Regarding the prion-like spreading of a-syn, a better 
differentiated and more mature cell culture would possibly lead to different behavior of the 
cells and a more developed a-syn pathology. Thus, it might be possible to detect 
endogenous a-syn template recruitment. 
Seeding experiments can be done with an endless number of possibilities, using different 
seeds to study strain dependence of spreading, using cells at various stages of 
differentiation to study cell development dependence, and using co-cultivation models with 
other cell types to study protective mechanisms of neurodegeneration. Live-cell fluorescent 
microscopy at high resolution could improve these experiments. Real-time analysis of seed 
uptake, release, and transmission would give important insights into the mechanisms of 
prion-like spreading. Especially for assessing the influence of different strains, a 
fluorescent analysis of the individual cells is fundamental, e.g. to evaluate the cell’s 
condition with respect to the selective vulnerability theory.  
Direct implementation of the microfluidic co-culturing device into the single-cell lysis 
setup would allow a whole new analysis perspective for a-syn fibrils. Initial seeds could be 
compared directly to seeds which were isolated from second order neurons. Handover to 
EM can be used to directly characterize a-syn fibril or oligomer structure and possible 
seeding parameters, as transmission efficiency and toxicity can be correlated in 
combination with live-cell microcopy.  
Future improvements will also involve the seeded a-syn fibril localization in a native 
neuron by CLEM. Electron tomography can give exact structural data of organelles and the 
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position of a-syn fibrils. Improved cultivation on EM grids in combination with co-
cultivation microfluidics gives a higher yield of proper vitrified grids. Furthermore, 
advanced cryo-light microscopy will allow fast and automatic correlation with cryo-TEM 
image recording. Especially with experiments where only rare events take place, light 
microscopy is crucial to aid the search for exact locations in EM. Additionally, evaluation 
of fluorescent markers for dopaminergic cells might give insights into the selective 
vulnerability of certain cells which then can be analyzed by cryo-EM. 
Finally, microfluidic devices can be highly automated, controlling the flow rate, time point 
of media exchange, or addition of seeds. Additionally, a better fluidic separation over long 
incubation times would be guaranteed, as no hydrostatic pressure equalization would invert 
the flow. 
This thesis has clearly demonstrated that LUHMES cells can be stably cultivated in a 
microfluidics co-culturing device and can be used to study the prion-like spreading of a-
syn. 
 
Closing remarks 
The initial goal of this project was the assessment of different a-syn fibrils regarding their 
transfer efficiency to second order neurons by comparing the structure of initial seeds and 
those transmitted. When I started my Ph.D. no cell cultures were maintained, no clean-
room was accessible, no a-syn fibrils were generated, and no cryo-CLEM was performed. 
Starting from scratch, each technique needed to be established in order to finally realize 
that the bottleneck is, as so often, the challenges that lie in cell cultures. However, all the 
methodologies are now available and can be used to tackle questions in the field of 
Parkinson’s disease.  
 
 
 
 
Chapter 7  101 
 
CHAPTER 7 
Experimental Section 
In this chapter, all experimental procedures which were used in this thesis are described. 
Some were reproduced and modified with permission from the corresponding references 
[334, 335].  
 
LUHMES Cell Maintenance Standard Procedure. The LUHMES cell line was kindly 
provided by Prof. Dr. Marcel Leist (University of Konstanz, Germany). Apart from the 
cells in microfluidic devices, cell cultivation and differentiation was performed following 
the original protocol [301]. Only NunclonTM Delta treated cell culture flasks and multi-
well plates (Thermo Fisher Scientific, USA) were used. For confocal microscopy cell 
preparation, 0.18 mm thick glass slides were additionally added into 12-well plates 
(Mänzel-Gläser, Thermo Fisher Scientific). All dishes were pre-coated with 50 µg/mL 
poly-L-ornithine (PLO, Sigma-Aldrich) and 1 µg/mL fibronectin (Sigma-Aldrich) in 
culture grade H2O (Sigma-Aldrich) overnight. Prior cell transfer coated dishes were rinsed 
twice in PBS (Sigma-Aldrich) and air-dried. For maintenance in proliferation state, 
adherent cell monolayer was briefly rinsed with PBS- and then dissociated with 0.05% 
trypsin-EDTA solution (Thermo Fisher Scientific). After 3 min incubation, trypsin was 
deactivated with 10 ml Advanced DMEM/F-12, pelleted at 100 rcf for 5 min and 
resuspended in proliferation media. Proliferation media was freshly prepared with 
Advanced DMEM/F-12 containing 2mM GlutamaxTM supplement (Sigma-Aldrich), 1 x 
N2 supplement (Gibco) and 40 ng/ml recombinant human FGF basic (R&D systems). To 
keep cells in proliferating state they were passaged 1:5 every second day or when they 
reached 80% confluency. For pre-differentiation, 2 x 106 proliferating LUHMES cells were 
splitted in a T-25 flask containing proliferation media. After one day, differentiation was 
started by media exchange to differentiation media consisting of Advanced DMEM/F-12 
supplemented with 2mM GlutamaxTM, 1 x N2 supplement, 1 µg/mL tetracycline (Sigma-
Aldrich), 1 mM dibutyryl cAMP (Sigma-Aldrich) and 2 ng/mL recombinant human GDNF 
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(R&D Systems). After two days of differentiation cells were trypsinized, pelleted at 100 
rcf for 5 min, and resuspended in differentiation media. For further differentiation in 12-
well plates, cells were diluted to 4 x 105 cells/ml and 1 ml was added per well.  
Immunofluorescence Labeling for Confocal Microscopy. The labeling procedure was 
the same for cells grown in 12-well plates and in microfluidic devices. Cell monolayer was 
washed three times with prewarmed (37°C) PBS+ and fixed in 4% PFA (Sigma-Aldrich) 
for 30 minutes at RT. After washing three times in Modified Hank’s buffer (MHB; Ca2+-
free, 137 mM NaCl, 5 mM KCl, 1.1 mM Na2HPO4 x 12 H2O, 0.4 mM KHPO4, 4 mM 
NaHCO3, 5.5 mM glucose, 2mM MgCl, 2mM EGTA, 5 mM MES, pH 6.5) plates were 
sealed with parafilm and stored at 4°C until further use.  
Incubation with the primary antibodies was done for 2 h after 10 min cell permeabilization 
with 0.25 % Triton X-100 in MHB. After 2 x 10 min washing in cell buffer secondary 
antibodies were applied for 2h. In some cases, cells were stained with DAPI or phalloidin 
after these steps. After 3 x 10 min washing in MHB, glass coverslips where embedded in 
mowiol and dried for 24 h before imaging. Due to narrow channels in microfluidic devices, 
a mounting media with lower viscosity was needed. We used either ProLong™ Diamond 
Antifade Mountant (Thermo Fisher Scientific) or ProLong™ Gold Antifade Mountant 
(Thermo Fisher Scientific). For confocal microscopy, a Leica SPE was used. 
Antibodies for Immunofluorescence and WB. The following commercial available 
primary antibodies were used in this thesis: 
 
Antigen Name Supplier Dilution CLSM Dilution WB Species 
a-syn (AA 120-202) SC211 Santa Cruz Biotechnology 1:200 1:1000 mouse 
a-syn (AA 118-123) MJFR1 Abcam 1:150 1:1000 rabbit 
a-syn (AA 115-122) LB509 abcam 1:500 1:2000 mouse 
a-syn (AA 15-123) BD BD Bioscience 1:500 1:2000 mouse 
a-syn S129 abcam 1:200 1:1000 rabbit 
β-III-tubulin TUJ Sigma-Aldrich 1:500 - rabbit 
synaptophysin SP Sigma-Aldrich 1:300 1:500 mouse 
VDAC1 VDAC Abcam 1:500 - mouse 
LAMP1 LAMP1 Abcam 1:300 - rabbit 
LAMP2 H4B4 LAMP2 Abcam 1:400 - mouse 
Thyroxin hydroxylase TH Santa Cruz Biotechnology 1:500 - rabbit 
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Microfluidic Co-Culturing Device Production. The design for the microfluidic device 
was adapted from Dinh et al. 2013 [311] and allows stable LUHMES cell growth and 
neurite connections between two cell populations, which can be handled independently. 
The microfluidic devices were prepared by replica molding with PDMS (Sylgard 184, 
Down Corning) on a multi-height SU-8 master on a silicon waver, allowing two different 
channel depths. Therefore, the three-way microchannels from a chrome mask (Delta Mask, 
the Netherlands) were exposed on a ~4 µm thick SU8-3005 (MicroChem) layer. A second 
layer of SU8-3025 (MicroChem) was then additionally spin coated to a depth of ~30 µm 
on which the big flow channels were exposed from a foil mask (Selba S.A, Switzerland). 
In the PDMS replicas (Sylgard 184, Down Corning) 3 mm in diameter inlet ports and 1.5 
mm in diameter outlet ports were made with biopsy punches (Harris Uni-Core™). Replicas 
were then sonicated in ethanol for 10 minutes, thoroughly rinsed with deionized water, air 
dried and assembled with thin microscopy cover slips to the final microfluidic device. The 
glass slides need to be suitable for confocal microscopy. 
Microfluidic Device Testing. Due to possible production variances, all devices were 
tested for fluidic isolation. Therefore, equal volumes of PBS were applied to the inlet ports 
and fluorescent dye (sulforhodamine B, 20 µM) was alternately supplemented in the liquid 
of one port till possible cross-contaminations from the cell-growth chambers could be 
excluded. After inlet ports were filled the devices were stored in cell humidity chambers 
for two days and monitored frequently in a fluorescent microscope (Zeiss Axio Imager 
M2). 
LUHMES Cell Cultures in Microfluidic Devices. Microfluidic co-culturing devices were 
coated with Geltrex® (Thermo Fischer Scientific) according to producer’s protocol at a 
dilution of 1/100 in PBS+. Assembled devices were flushed with EtOH absolute and PBS+ 
before Geltrex® in PBS was applied for 1 hour at 37°C. Neuronal differentiation in 
microfluidic devices did not require a pre-differentiation of LUHMES cells. Proliferating 
cells were trypsinized, centrifuged and resuspended in differentiation media at a 
concentration of 3 x 106 cells/ml. 20 μl cell suspension was loaded into the flanking inlets 
of the microfluidic device and slight vacuum with a cell culture aspiration system at -400 
mbar compared to atmospheric pressure (vacusafe, integra bioscience) was applied at the 
outlet ports. Afterwards, inlet ports where washed with PBS+ and filled with 50 μl 
differentiation media. Microfluidic devices were placed in rectangular 4-well plates with 
one well being filled with water and filter paper to prevent inlet ports from running dry. All 
cells in flasks, plates, or microfluidic devices were stored in a humidified cell culture 
incubator at 37°C and 5% CO2 atmosphere. 
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WGA Pulse-Chase Experiments. LUHMES cells were differentiated in microfluidic 
devices as usual and incubated with fluorescent a-syn seeds. After the particular 
cultivation time, cells were incubated with 5 μg/ml WGA-Alexa488 (Thermo Fisher 
Scientific) in differentiation media for 30 min, followed by 2 min washing with PBS+ and 
4 h further cultivation in differentiation media. Cells were fixed and immunolabeled as 
described before. 
Cell Culture for Single-Cell Lysis Experiments. For single-cell experiments, the 
standard cell culture procedures were performed, but cell suspension was seeded in 
miniaturized Petri dishes on ITO-coated glass slides (Diamond Coatings UK, 8-12 
/square). The miniaturized Petri dishes were made from PDMS (Dow Corning SYLGARD 
184) rings and pressed onto the ITO surface to form sample wells. The PDMS rings were 
filled with 300 µl of the particular cell culture media with total 104 cells. The cell cultures 
were incubated as usual at 37°C and 5%CO2 atmosphere. Prior single-cell lysis 
experiments, adherent cells were washed with HEPES, PBS or hypotonic PBS buffer, 
depending on lysis protocol. 
PEG Surface Functionalization. Two different approaches were used to coat the PDMS 
surface with PEG. First, PLL-g-PEG with a PLL (20kDa) to PEG (2kDA) ratio (g) of 3 to 
4 (SuSoS AG, Dübendorf, Switzerland) was dissolved at a concentration of 1mg/ml in 
10mM HEPES buffer (pH 7.4). Solution was sterile filtered and aliquots were stored at 
4°C. Thawed aliquots were diluted to 100 µg/ml with HEPES buffer before use. PDMS 
devices were plasma activated on the channel side, immersed in the PLL-PEG solution and 
incubated for 20 h in the range of 20 to 60°C. Devices were washed in nanopure water for 
10 min, dried with N2, and stored at RT till further use. 
PEG-silane coating was performed according to previously published protocols [354]. 3-
[Methoxy(polyethyleneoxy)propyl]trimethoxysilane, tech-90, 6-9 C2H4O units, was 
purchased from abcr GmbH (Karlsruhe, Germany). Extra dry acetone 99.99 (EMS, 
Hatfield, USA) was used to make a 50% (v/v) PEG-silane solution immediately prior use. 
The oxygen plasma activated PDMS device was immersed and allowed to react for 1h at 
RT. The devices were washed 2 x 10 min in MQ water and dried at RT till further use.  
Single-Cell Lysis Procedures. LUHMES single-cell lysis experiments were performed 
according to our previously published protocols [334, 335]. In brief, cells on ITO wells 
were placed in the slide holder on the inverted microscope of the cell lysis setup and put to 
electrical ground. An individual cell was selected under the microscope, and the 
microcapillary tip was immersed into the buffer and placed 20 µm above it. Three to five 
short voltage pulses (250 µs at 16–20 V) were delivered via the microcapillary electrodes 
to the targeted cell. The cell lysed within milliseconds, and its content was directly 
aspirated into the microcapillary electrodes tip in 3 nl of liquid by the syringe pump. The 
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outer surface of the microcapillaries was with 2 nm of Ti/W and 200 nm of Pt by sputter 
deposition, and subsequently functionalized by immersion into a 1 M ethanolic solution of 
1-dodecanethiol for 24 h to increase the hydrophobicity. 
LUHMES Batch Lysate for MS and Sample Preparation. To prepare batch lysate, the 
cells cultivated in a T-25 flask were washed with PBS (Dulbecco’s Phosphate Buffered 
Saline, Sigma Aldrich, Switzerland) and lysed with a solution of 8 M urea, 75 mM NaCl in 
50 mM Tris buffer, pH 8.2, supplemented with protease inhibitor cocktail (complete mini, 
Roche, Switzerland), 1 mM -glycerophosphate, 1 mM sodium orthovanadate, 10 mM 
sodium pyrophosphate, and 1 mM phenylmethylsulfonyl fluoride (PMSF), all from Sigma 
Aldrich, Switzerland. 50 µl aliquots of batch lysate at a concentration of 5 mio cells/ml 
were stored at -20 °C. To print slides, an aliquot was diluted in 150 µl H2O, yielding a 
concentration of 1250 cells/µl. 
Sample deposition was performed similar to RPPA experiments. As substrate, COC slides 
were used (ChipShop GmbH, Germany), dried after spotting and stored under argon gas 
till further use.  
LUHMES Batch Lysate for Western Blot. LUHMES cells were prepared according to 
standard protocol. When cells reached the desired day of differentiation, the monolayer 
was washed twice with PBS- (Dulbecco’s Phosphate Buffered Saline, without MgCl2 and 
CaCl2, Sigma Aldrich, USA) and the whole flask was shock frozen in LN2 and stored at -
20°C till further use. Cells were thawed on ice and incubated for 10 min with lysis buffer 
(MHB with 1x cOmpleteTM protease inhibitor cocktail, 1mM PMSF, 1 mM Na3VO4, 
0.25% sodium deoxycholate, 1% NP40) on ice. After removal of membranes and cell 
debris via centrifugation at 10000 rcf for 10min, protein concentration was determined 
using the BCA assay. 
Western Blot. An equal of 35 µg protein from the cell lysate was prepared of each sample, 
mixed 1:5 with sample buffer, boiled for 5 min at 95°C, and separated by SDS-PAGE. 
Gels were transferred onto nitrocellulose membranes by semi-dry transfer (TE77XP, 
Hoefe). After blocking in 10 % BSA in TBS (0.05 M Tris and 0.15 M NaCl, pH 7.6), 
membranes were incubated with primary antibodies for 2 h in TBS with 0.1% Tween20 
and 5% BSA. After 3 x 10 min washing in TBS, secondary antibodies were incubated in 
the same buffer (IR-antibodies, LI-COR,). Nitrocellulose membranes were scanned with an 
odyssey infrared imaging system (LI-COR, USA) 
Dot Blot Analysis. Dot blot experiments were performed using a 96-well Bio-Dot® 
microfiltration apparatus (Bio-Rad Laboratories, USA). Assembly and cell lysate loading 
was done according to manufacturer’s instructions. Immunoassay procedure followed the 
same instructions as for western blots, with minor differences. First blocking step, primary 
antibody incubation and washing steps were done in the wells of the apparatus. 
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Subsequently, the apparatus was dismantled and the nitrocellulose was passed into a dish 
for immunolabeling following the western blot protocol. 
a-Syn Expression and Purification. Early experiments in this thesis were performed with 
lyophilized a-syn powder which was kindly provided by C. Eichmann and P. Kumari. 
Some purified a-syn in solution was provided by I. Mohammed. Further a-syn was 
produced according to their protocols using the same plasmids. BL21(DE3) Competent E. 
coli were transformed with plasmids and grown in lysogeny broth at 37°C and shaking at 
120 rpm up to OD 0.8. After adding Isopropyl -D-1-thiogalactopyranoside (Sigma-
Aldrich) to a concentration of 1 mM, cells were grown for additional 4 h at the same 
conditions. Bacteria were collected by centrifugation and a-syn was extracted and purified 
according to ref [380].  
a-Syn Fibril and Seed Formation. Standard seeds (Figure 19C), which were mainly used 
in this thesis, were produced in PBS+. Lyophilized a-syn monomers were dissolved at a 
concentration of 1-10 mg/ml and pH was adjusted to pH 7 using 1 M NaOH solution. 
When the solution was clear and the pH adjusted, aliquots were frozen in LN2 and stored at 
-20°C. Proteins started to form oligomers and fibrils when stored at RT. To have consistent 
protocol from the same starting product, monomer solution was thawed and immediately 
ultra-centrifuged at 100,000 rcf for 30 minutes (TL-100, Beckman Coulter, USA). Only 
supernatant was collected, ensuring that no seed nuclei were present and fibrillization was 
initialized similarly throughout all experiments. Other types of fibrils were produced 
according to the standard fibril formation procedure but a-syn monomers were dissolved 
in different buffers. Ribbons were formed in tris buffer (50 mM Tris, 150 mM KCl, pH 
7.5). The fibrils which can be seen in Figure 19C were produced in 20 mM sodium 
phosphate buffer with a 1M NaCl concentration (pH 7.4). 
a-Syn oligomer (Figure 19B) formation procedure is similar to the fibril formation. A 12 
mg/ml a-syn monomer solution was incubated at 37°C, but without agitation and seeds 
were already harvested after 24 h. Already formed fibrils were separated from oligomers 
by ultracentrifugation for 1 h at 247,000 x g ((TL-100, Beckman Coulter, USA). 
Monomers and small multimers were removed by repeated filtration using centrifugal 
filters with a 100 kDa cutoff (Amicon Ultra, MerckMillipore). Up-concentrated oligomers 
were frozen in LN2 and stored at -20°C until further use.  
To produce seeds of sheared a-syn fibrils, the fibril solution in 2 ml Eppendorf tube was 
sonicated for 1 h at 4°C in a UP200St VialTweeter block sonitrode (Hielscher, Germany) 
at full power and half second intervals just prior use. 
Protein Labeling. Before seeds were formed, a-Syn fibrils were prepared at a 
concentration of 4 mg/ml in PBS+ and labeled via amine groups using N-hydroxy 
succinimidyl ester (NHS) conjugates. For fluorescent labeling, Alexa Fluor®546 
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(Invitrogen, USA), Oregon Green®488 carboxylic acid (Invitrogen, USA) and Sulfo-
Cyanin 5 (Lumiprobe, USA) NHS-ester conjugates were used according to established 
protocols from the manufacturer. Alternatively, fibrils were biotinylated using photo-
cleavable N-hydroxysuccinimidobiotin (PC-Biotin-NHS, AmberGen Inc., USA). A 5-fold 
excess of NHS-ester conjugates from a previously prepared and aliquoted stock solution 
was added the fibrils solution. After shaking for 2 h at RT, free conjugates were removed 
from labeled proteins on HiTrap desalting columns (Sephadex G25) using the 
corresponding running buffer. The labeled proteins were stored in aliquots at -20 °C. 
Alternatively, labeling solution was repeatedly sedimented at16,000 rcf in an Eppendorf 
centrifuge and the a-syn fibril pellet was washed four times in the corresponding buffer.  
Protein Concentration Determination with Nanodrop. Protein concentrations were 
determined spectrophotometrically using a NanoDrop microvolume spectrophotometers 
(ThermoFisher Scientific, USA). For a-syn, an extinction coefficient of 5960 M-1 cm-1 at 
280 nm was used [288].  
Protein Concentration Measurement with Bicinchoninic Acid (BCA) Assay. Protein 
concentration was determined with a commercial available BCA kit (PierceTM BCA 
Protein Assay Kit, ThermoFisher Scientific, USA) according to manufacturer’s protocol. 
In brief, diluted BSA standards were prepared from a provided stock solution in a range of 
25 µg/ml to 2000 µg/ml. Standards were aliquoted and kept a -20°C to speed up repeated 
measurement procedures. No difference was found between frozen aliquoted standards and 
freshly prepared standards. Proteins of interest were diluted to be in the range of the 
standards. Since measurements were performed on a NanoDrop microvolume 
spectrophotometers (ThermoFisher Scientific, USA) a sample to working reagent ratio of 
1:10 was used. Samples were incubated for 30 min a 37°C. When cooled to RT, 
absorbance was measured at 562 nm. Measurements were performed using the NanoDrop 
BCA quantification module. 
Microfluidics In-line Protein Extraction. Photo cleavable N-hydroxysuccinimidobiotin 
(PC-Biotin-NHS, AmberGen Inc., USA) was prepared in anhydrous DMF at a 
concentration of 50 mM and stored at -20°C. For biotinylation, 0.5 mg/ml a-syn fibrils 
were prepared in PBS and PC-Biotin-NHS stock was added to a concentration of 100 µM. 
After 1 hour incubation at RT in an Eppendorf shaker at 600rpm, fibrils were washed four 
times by centrifugation at 100000g for 30 minutes. Superparamagnetic streptavidin beads 
(Ocean NanoTech, USA) were mixed 1/100 with the fibril solution and incubated at RT. 
After 1 hour, 2.5 µl of the sample was aspirated in the capillary of 250 µm in diameter. By 
passing the magnets, the fibrils which interacted with magnetic beads were trapped. The 
trapped assemblies were washed with 4 µl of PBS which was aspirated in the setup before 
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the sample and this washing fraction was collected. To release the fibrils, either the magnet 
was switched off or the crosslinker was cleaved by UV light.  
Buffers for Revers-Phase Protein Array. For PBS-T, PBS+ buffer (Dulbecco’s 
Phosphate Buffered Saline, 2.7 mM KCl, 1.5 mM KH2PO4, 136.9 mM NaCl, 8.9 mM 
Na2HPO4•7H2O, pH 7.4, Sigma Aldrich, USA) was supplemented with 0.2% or 0.1% 
(v/v) Tween20 (Sigma Aldrich, Switzerland). TBS-T buffer (0.05 M Tris and 0.15 M 
NaCl, pH 7.6, 0.01% Tween20 (Sigma Aldrich, Switzerland)) was prepared in advance, 
sterile filtered and stored at RT. Blocking buffer consisted of a 1:1 mixture of LiCor 
ODYSSEY blocking buffer (LI-COR Biotechnology GmbH, Germany) and PBS-T 0.2%. 
A 1:10 dilution of blocking buffer in PBS-T 0.1% was used for washing. The final wash in 
a 50 ml Falcon tube was done in TBS-T 0.1%. 
Revers-Phase Protein Array Principle and Analysis. The same instrument was used for 
RPPA slide preparation that was also used for single-cell preparation for EM [333]. Instead 
of performing single-cell lysis of LUHMES cells and writing the sample on EM grids, 
batch lysate was prepared and spotted on nitrocellulose coated glass slides (UniSart® 3D 
slide, Sartorius AG, Germany) or on hydrogel coated glass slides (NEXTERION® Slide H, 
SCHOTT Technical Glass Solutions GmbH, Germany). An openBEB macro script was 
prepared with defined flow rates, aspiration volumes, deposition volumes and spot 
positions. To wash the microcapillary between new samples, the tip of the microcapillary 
was inserted in a detergent solution (1% Alconox, Alconox Inc., USA) and flushed in and 
out with a high flow of detergent inside and around the tip of the microcapillary. The tip 
was then flushed with clean ddH2O.  
After spotting, the nitrocellulose glass slides were blocked for 10 min at RT with blocking 
buffer in a 16-well incubation chamber (ProPlate 16 Well Slide Module 204862, Grace 
Bio-Labs, USA). Subsequently, each well was incubated with 100 µl of primary antibody 
solution for 18 h at RT. After washing with 200 µl washing buffer, secondary antibody 
solution was applied for 1 h at RT and again washed twice. Finally, slides were quickly 
immersed in TBS-T in a 50 ml Falcon tube, dried with nitrogen and kept at RT till used for 
microarray scanning. 
For the analysis, two different scanners were used. Nitrocellulose coated slides were 
scanned with an odyssey infrared imaging system (LI-COR, USA). The hydrogel coated 
glass slides were scanned with an MS 200 Microarray Scanner (Roche NimbleGen, USA) 
with 10 µm/pixel at 532 nm and 635 nm. Images were processed with GenePix Pro 6.0 
software (Molecular Devices, LLC, USA) and intensity data was exported and analyzed 
with TIBCO Spotfire software (TIBCO, USA). 
TEM Negative Stain. Sample aliquots of 4 µl were adsorbed for 60 s on glow discharged 
carbon coated electron microscopy grids. Subsequently, grids were blotted, washed four 
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times on drops of deionized water and negatively stained by floating them twice for 10 
seconds on 2% (w/v) uranyl acetate. The excess of liquid was blotted away between all 
washing and staining steps with Whatman® 1 filter paper. Grids were imaged with a T12 
electron microscope (FEI) operating at 120 kV and equipped with a TVIPS F416 CMOS 
camera. 
CLEM: Growing LUHMES Cells on EM Grids. LUHMES cell culturing and pre-
differentiation was done according to a published protocol [301] and described above. 
Following types of gold EM grids were used: type NH2 200 mesh finder grids R 3.5/1, 200 
mesh R3.5/1 and 400 mesh R2/2, all from Quantifoil® (Quantifoil Micro Tools GmbJ, 
Germany). All of them are suitable to perform CLEM. However, finder grids, in case the 
letters are not entirely covered, can assist with the orientation in both manual and software 
assisted correlation. Grids were sterilized in pure EtOH, glow-discharged for 20 s in air 
plasma and placed in PDMS rings (ID of 1 cm) on microscopy slides and again washed 
with EtOH. Prior adding Geltrex® solution, dishes were emptied and rinsed with PBS. 
Grids must never run dry, otherwise the carbon layer sticks to the glass surface. For the 
Geltrex® to cure, dishes were placed in rectangular culture dishes and incubated for 1h at 
37°C.  
Pre-differentiated LUHMES cells (after 24 hours of differentiation) were counted with a 
hemocytometer counting-chamber and 6 x 105 cells in 300 µl differentiation media were 
loaded in each dish. Cells were incubated at 37°C, 5% CO2 and cell media was changed 
every second day.  
CLEM: Vitrifying LUHMES Cells on EM Grids. Cryo-EM grids for CLEM were 
prepared using Vitrobot Mark IV (ThermoFisher Scientific, USA) with manual blotting or 
a Leica EM GP (Leica Microsystems GmbH, Germany). For manual blotting, vitrobot 
humitdity chamber was set to 100% humidity at 32°C and blot time was set to zero 
seconds. Filter paper was cut into small pieces and bent to 90°C, to be a able to hold one 
end with a tweezer and blot with the other perpendicular to this direction. Liquid ethane 
was prepared. Grids with LUHMES cells were taken from the cell culture incubator and 
washed once with PBS. Grids were grabbed by the special vitrobot tweezer and mounted to 
the vitrobot. 5 µl of 1/10 in PBS diluted ProteinA gold 10 nm was applied on the grid the 
grid was retracted to the humidity chamber. From the side window, grids were blotted for 
10 seconds with the prepared L shaped filters and plunge frozen.  
CLEM: Imaging Vitrified Grids with Light Microscopy. We used an upright 
microscopy (Axio Imager M2, Carl Zeiss AG, Jena, Germany) with an AxioCam Mrm 
camera (Carl Zeiss AG, Germany). Digital acquisition and image analysis was done with 
AxioVision software (Carl Zeiss AG, Germany). The long working distances of the 
objectives allowed the application of a CLM77K cryostage (Instec, Inc., USA). A 
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thermocouple on the grid holder tongue and the cryostage allowed for monitoring the 
temperature at all times. The temperature of the stage was controlled by the Instec mk1000 
temperature controller (Instec, Inc., USA) linked to a liquid nitrogen pump with reservoir. 
A stream of nitrogen was directed to the top and bottom window of the cryostage to 
prevent ice formation.  
CLEM: Mapping Live Cells on EM grids.  
To record a map at RT, a similar procedure was follow as when using vitrified grids. The 
advantage was to see the state of the cell before vitrification. Additionally, grids get lost or 
were destroyed easily while using the light microscopy cryostage. Since we used an 
upright microscopy the glass slides with the grids needed to be imaged upside-down. 
Spacers made from PDMS were placed on both sides of a second glass slide on which the 
sample grids were placed. Forming a ‘sandwich’ like that, the miniaturized PDMS 
Petridish was not in contact with the second slide and cell media was retained in the dish 
by surface tension. Image were recorded using a Zeiss Axiophot microscope. 4 x 4 images 
were recorded per grid and stitched together with the grid/collection stitching plugin in Fiji 
software. Mounting and recording was done within 5 min, as samples were at RT. 
Subsequently, suitable grids were plunge frozen immediately. 
CLEM: Cryo Electron Microscopy. Vitrified LUHMES cells were imaged on two 
different EM. First, a Philips CM200 equipped with a field emission gun was used. The 
microscope operated at an acceleration voltage of 200kV and images were acquired on an 
UltrascanTM1000 CCD camera.  
Other samples were recorded on a Titan Krios (ThermoFisher Scientific, USA) which 
operated at 300kV, and equipped with an Gatan Quantum-LS Energy Filter (GIF, 20eV 
energy loss window; Gatan Inc.). Images were recorded with a K2 Summit direct electron 
detector (Gatan Inc., ) in dose fractionation mode (50 frames) using Serial EM software 
[372] at a magnification of 33,000 x. Micrographs were drift-corrected and dose-weighted 
through the Focus interface [381]. 
Resazurin Assay. LUHMES cells were cultivated in 96-well plates according to standard 
protocol. Specifically for this assay, 40’000 predifferentiated cells in 100 µl differentiation 
media were loaded in each well. To test the effect of a-syn fibrils on cell viability, 
differentiation media with different concentrations of fibrils were prepared and 100 µl of 
the particular solution was added per well on day 4 of differentiation. Resazurin assay was 
performed on day 12 of differentiation. Till then, 100 µl of differentiation media was 
exchanged in each well every second day.  
Resazurin sodium salt powder (Sigma-Aldrich, USA) was dissolved in PBS (Dulbecco’s, 
Sigma-Aldrich, USA) to a final concentration of 1 mg/ml. The resazurin solution was 
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diluted in differentiation media to a final concentration of 5 µg/ml. Media from wells was 
replaced with staining solution and cells were incubated at 37°C, 5% CO2 2 hours. Then, 
50 µl supernatant of the reduced solution was replated to a second well plate and 
fluorescent intensity was measured at 530 nmex and 570 nmem / 600 nmem using the 
fluorescent intensity scanning mode on a Tecan Infinite M1000® microplate reader (Tecan, 
Switzerland). 
Mitochondria Labeling with MitoTracker. Labeling with MitoTrackerTM was done 
according to manufacturer’s protocol with minor changes. In brief, 1 mg/ml stock solution 
was prepared from lyophilized MitoTrackerTM Green FM (ThermoFisher Scientific, USA) 
at RT in anhydrous DMSO. Aliquots of 10 µl were stored at -20°C. For staining, stock 
aliquots were thawed and diluted in LUHMES differentiation media to either 40 nM for 
live cell imaging or 200 nM when cells were fixed. After incubation for 15 min at 37°C, 
5% CO2, staining media was replaced with normal differentiation media and cells were 
immediately observed on a fluorescent microscope. For fixed samples, normal fixation 
procedure was followed immediately after incubation. 
Computational Fluid Dynamics Simulation. The computational fluid dynamics (CFD) 
module of the software COMSOL Multiphysics 5.2 (COMSOL Inc, Burlington, USA) was 
used to evaluate the fluidic isolation between the two cell compartments of the 
microfluidic co-culturing device. The static laminar state right after applying media to the 
inlet ports was described by solving the incompressible Navier-Stokes-equation. We 
assumed a Newtonian fluid with properties of water at RT. PDMS was chosen as boundary 
material from COMSOL’s material library. To simulate the hydrostatic pressure driven 
flow, an atmospheric pressure of 101325 Pa was assigned to the outlet ports and a pressure 
of 101364.24 Pa to the inlet ports, which corresponds to a 4 mm column of water. 
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APPENDIX A 
Supporting Information: Chapter 2 
 Computational Fluid Dynamics Simulation 
Figure A.1. CFD analysis of fluid flow through the microfluidic co-culturing device with different pressures 
applied. Flow rates are pictured in colored spectra. (A) Black lines represent stream lines. A pressure 
difference corresponding to a 4 mm water column in all three inlet ports was applied. (B) Same conditions 
as in A. Size of the arrows is proportional to the flow velocity and their direction is aligned to the stream. (C) 
An underpressure of -400 mbar was applied to the outlet port of the right channel. (D) An under-pressure of 
-400 mbar was applied to the outlet port of the central channel. 
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Flow velocities in microfluidic co-culturing devices were simulated by the CFD module in 
COMSOL Multiphysics 5.2. A pressure difference of about 40 Pa between the inlet and 
outlet ports resulted in a velocity of under 3 µm/s in the center of the cell growth 
compartments (Figure A.1A). This maintains a constant media change without disturbing 
cell growth. Still, neurite alignment was observed at this low velocity (Figure 12 ). Using 
the same parameters, a slight inflow from the cell compartments through the central 
channels was simulated (Figure A.1B). This does not influence the fluidic separation 
towards the second growth chamber, as the same inflow occurs and the central channels 
high flow rate acts as a fluidic barrier. During cell loading a vacuum is applied to the outlet 
ports of the growth chambers. Comparing Figure A.1C and D, it becomes clear why no 
vacuum should be applied to the central channel, as high velocities press the cells to the 
microchannels, resulting in shear stress and cell damage. 
  Geltrex® Coating vs. Fibronectin / PLO Coating 
Figure A.2. Comparison of LUHMES cells growing on Geltrex® (A) or fibronectin/PLO (B) coating in 
microfluidic devices. Cells were taken directly from proliferating stated and resuspended in differentiation 
media. Images were taken 1 h after cells were loaded.  
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 Evaluation of Optimal Seed Concentration 
Figure A.3. (A) Seeds were added to LUHMES cells at different concentrations and media solution was 
replaced after 1 h or 1 day. After seeding, cells were cultivated for an additional 3 days. (B) Seeding 
experiments with different concentrations, incubations times, and cultivation times. Scale bars 20 µm. 
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Seed dilution and incubation time series were made to assess seeding conditions using 
LUHMES cells. It appears that seeds attach to cell membranes within 1 hour (Figure 
A.3.A, top panel) and seed concentration increases with longer incubation time, as a-syn 
fibrils have more time to settle (Figure A.3.A, bottom panel).  
When cells grow for longer periods after depletion of a-syn fibrils in the culturing media, 
it appears that the amount of fluorescent signal decreases (Figure A.3B). This may be due 
to internalization and seed degradation, or seeds detaching from the membranes and being 
removed during media change. However, most of the a-syn fibrils seeds stick to the 
membrane, as they can be easily removed by washing the cells with trypsine (Figure A.3B, 
bottom right). Additionally, labeled fibrils can be found on the background, not covering 
any obvious cell body or neurite. This can also be observed after trypsinizing and washing 
the cells, indicating that some a-syn fibrils are secreted or released from apoptotic cells.  
 Seed Uptake and Aggregate formation 
Figure A.4. (A) Confocal images of LUHMES cells incubated with fluorescent seeds. (B) Same cells as in A 
but intensity isosurface rendered in Imaris 9. Scale bars 5 µm. 
Aggregate formation of extracellularly added seeds can be observed inside cell soma and 
neurites, and extracellularly on the cell membrane. This is usually only the case after 
incubation times of more than one day and at high seed concentrations (Figure A.3B). 
Whether the extracellular aggregates are formed in solution, on the cell membrane, or 
intracellularly followed by release remains to be determined. However, intracellular 
aggregates can be observed at seed concentrations of 0.1 µg/ml after 4 days of cultivation 
(Figure A.4). The aggregates appear much brighter in confocal microscopy than the 
average of small puncta in the background (Figure A.4A). Aggregates can also be found in 
neurites, where they adapt an elongated shape. 
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 Anterograde Transport of a-Syn Fibrils 
Figure A.5. 3D Volume of LUHMES cell neurites growing through microchannels. A 0.5 µg/ml seed 
solution was applied to the inlet of one growth chamber on day 2 of differentiation. Cells were fixed after 8 
days of cultivation. Scale bar 20 µm. 
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APPENDIX B 
Supporting Information: Chapter 3 
 Strains of a-Syn Assemblies 
Figure B.1. Additional selection of negatively stained a-syn fibrils. Crucial protocol steps are linked to the 
figures. 
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 Immunolabeling of Endogenous a-Syn 
Figure B.2. Confocal images of LUHMES cells with immunolabeling against a-syn. Four different 
antibodies were tested. Antibody labeled a-syn can be seen in green and fluorescent seeds are in 
magenta. When antibodies co-localize with seeds, it appears in white color. Scale bar 20 µm. 
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APPENDIX C 
Supporting Information: Chapter 4 
 Simple Microfluidic Co-Culturing Devices 
Figure C.1. (A) Scheme of a basic microfluidic co-culturing device designed by M.K. Lewandowska. (B) 
LUHMES cells labeled with calcein-AM. (C) Neurites of LUHMES cells never grew completely through the 
connecting microchannels in this microfluidic device. Scale bars 100 µm. 
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 LUHMES Cell Growth on ITO Glass 
Figure C.2. Comparison of LUHMES cells differentiating on ITO-coated glass and non-coated glass. When 
the surface is coated with Geltrex®, cells differentiated also on ITO-coated glass slides. Scale bar 40 µm. 
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APPENDIX D 
Supporting Information: Chapter 5 
 CLEM: Cryo-TEM Images of Neurites 
When LUHMES cells are cultivated on EM grids, almost the whole grid is covered with 
neurites, cell bodies, and cellular material. In cryo-TEM, cell bodies are visible as black 
areas, since they are too thick for the electrons to pass. Between cell bodies of 
differentiating cells, an extensive neurite network is built (Figure D.1A). At low 
magnification, this network looks disordered and neurites cross each other from all 
directions. At higher magnification, it is revealed that several thinner neurites grow in 
parallel (Figure D.1B). The fine structures in the neurites can clearly be discerned (Figure 
D.1D), allowing the study of microtubule and luminal particles [362]. 
In Figure D.1C, an expanded end of a neurite can be seen, which is filled with vesicles in 
the range of 40-60 nm. Their size match the reported dimensions of synaptic vesicles 
[382]. Indeed, this neurite resembles the synaptic compartments which were recently 
imaged by a similar CLEM technique as it was used in this thesis [366]. However, 
LUHMES cells were reported to be an incompletely differentiated cell line [301]. 
Although MESC2.10 cells, the precursor of LUHMES cells, display excitatory and 
inhibitory postsynaptic potentials, indicating functional synapsis [297], no functional 
synapses were assumed in the LUHMES cell line using the standard differentiation 
protocol [301]. However, so far no cryo-EM studies were conducted using LUHMES cells. 
To make LUHMES cells accessible for CLEM, Geltrex®-coated EM-grids were used. As 
mentioned before, LUHMES cells acquire neuronal morphology much faster on Geltrex® 
compared to PLO/fibronectin coating. Thus, the synaptic maturity of LUHMES cells 
cannot be excluded and requires further investigation. 
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Figure D.1. Selection of cryo-TEM micrographs of LUHMES cell neurites. (A) Low magnification image of 
crossing neurites. (B) Neurites of grow parallel to each other. (C) Vesicle size at the end of a neurite is 
between 40 and 60 nm, which correspond to the size of synaptic vesicles. (D) Microtubules in neurites. 
 CLEM: Extended Blotting 
Blotting times appear to be less crucial for vitrified sample preparation of on-grid 
cultivated cells as compared to protein solutions, for example. Cell bodies and the 
extended neurite network seem to retain liquid on the grid, even at long blotting times of 
17 s (Figure D.2.C). Although large parts of the grids are dry, larger neurite bundles are 
nicely frozen for cryo-EM. However, whether or not long blotting times affect the neurite 
integrity remains to be tested.  
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Figure D.2. (A) Bright field and (B) fluorescence microscopy of LUHMES cells growing on an EM finder 
grid. The grid was vitrified after light microscopy imaging. Blotting time before vitrification was extended to 
17 seconds. (C) Cryo-TEM image of the same grid at low resolution. (D) Inset image recorded at higher 
resolution. 
126 Andrej Bieri 
 
 
 
 
 
  
Bibliography  127 
 
BIBLIOGRAPHY 
1. Gammon, K., Neurodegenerative disease: brain windfall. Nature, 2014. 515(7526): p. 299-300. 
2. World Health Organization, Neurological Disorder: Public Health Challenges. World Health 
Organization, Geneva, 2006. 
3. Parkinson, J., An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci, 2002. 14(2): p. 
223-36. 
4. Tysnes, O.B. and Storstein, A., Epidemiology of Parkinson's disease. J Neural Transm (Vienna), 
2017. 124(8): p. 901-905. 
5. Hirsch, L., et al., The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. 
Neuroepidemiology, 2016. 46(4): p. 292-300. 
6. Reeve, A., Simcox, E., and Turnbull, D., Ageing and Parkinson's disease: why is advancing age the 
biggest risk factor? Ageing Res Rev, 2014. 14: p. 19-30. 
7. Alcalay, R.N., et al., Frequency of known mutations in early-onset Parkinson disease: implication for 
genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol, 
2010. 67(9): p. 1116-22. 
8. Marder, K.S., et al., Predictors of parkin mutations in early-onset Parkinson disease: the consortium 
on risk for early-onset Parkinson disease study. Arch Neurol, 2010. 67(6): p. 731-8. 
9. Poewe, W., et al., Parkinson disease. Nat Rev Dis Primers, 2017. 3: p. 17013. 
10. Van Den Eeden, S.K., et al., Incidence of Parkinson's disease: variation by age, gender, and 
race/ethnicity. Am J Epidemiol, 2003. 157(11): p. 1015-22. 
11. Baldereschi, M., et al., Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher 
incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology, 2000. 
55(9): p. 1358-63. 
12. Pringsheim, T., et al., The prevalence of Parkinson's disease: a systematic review and meta-analysis. 
Mov Disord, 2014. 29(13): p. 1583-90. 
13. Postuma, R.B., et al., MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord, 2015. 
30(12): p. 1591-601. 
14. Gelb, D.J., Oliver, E., and Gilman, S., Diagnostic criteria for Parkinson disease. Arch Neurol, 1999. 
56(1): p. 33-9. 
15. Postuma, R.B. and Berg, D., The New Diagnostic Criteria for Parkinson's Disease. Int Rev 
Neurobiol, 2017. 132: p. 55-78. 
16. Hughes, A.J., Daniel, S.E., and Lees, A.J., Improved accuracy of clinical diagnosis of Lewy body 
Parkinson's disease. Neurology, 2001. 57(8): p. 1497-9. 
17. Rizzo, G., et al., Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-
analysis. Neurology, 2016. 86(6): p. 566-76. 
18. Buchman, A.S., et al., Nigral pathology and parkinsonian signs in elders without Parkinson disease. 
Ann Neurol, 2012. 71(2): p. 258-66. 
19. Garnett, E.S., Firnau, G., and Nahmias, C., Dopamine visualized in the basal ganglia of living man. 
Nature, 1983. 305(5930): p. 137-8. 
128 Andrej Bieri 
20. Seifert, K.D. and Wiener, J.I., The impact of DaTscan on the diagnosis and management of 
movement disorders: A retrospective study. Am J Neurodegener Dis, 2013. 2(1): p. 29-34. 
21. Pyatigorskaya, N., et al., A review of the use of magnetic resonance imaging in Parkinson's disease. 
Ther Adv Neurol Disord, 2014. 7(4): p. 206-20. 
22. Klein, C. and Westenberger, A., Genetics of Parkinson's disease. Cold Spring Harb Perspect Med, 
2012. 2(1): p. a008888. 
23. Lill, C.M., Genetics of Parkinson's disease. Mol Cell Probes, 2016. 30(6): p. 386-396. 
24. Chen-Plotkin, A.S., Unbiased approaches to biomarker discovery in neurodegenerative diseases. 
Neuron, 2014. 84(3): p. 594-607. 
25. Førland., M.G., et al., Evolution of cerebrospinal fluid total -synuclein in Parkinson's disease. 
Parkinsonism & Related Disorders, 2018. 49: p. 4-8. 
26. Caslake, R., et al., Changes in diagnosis with follow-up in an incident cohort of patients with 
parkinsonism. J Neurol Neurosurg Psychiatry, 2008. 79(11): p. 1202-7. 
27. Dickson, D.W., et al., Neuropathological assessment of Parkinson's disease: refining the diagnostic 
criteria. Lancet Neurol, 2009. 8(12): p. 1150-7. 
28. Damier, P., et al., The substantia nigra of the human brain. II. Patterns of loss of dopamine-
containing neurons in Parkinson's disease. Brain, 1999. 122 ( Pt 8): p. 1437-48. 
29. Iacono, D., et al., Parkinson disease and incidental Lewy body disease: Just a question of time? 
Neurology, 2015. 85(19): p. 1670-9. 
30. Bernheimer, H., et al., Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, 
morphological and neurochemical correlations. J Neurol Sci, 1973. 20(4): p. 415-55. 
31. Hornykiewicz, O., Basic research on dopamine in Parkinson's disease and the discovery of the 
nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener Dis, 2008. 5(3-4): p. 114-
7. 
32. Roy, S. and Wolman, L., Ultrastructural Observations in Parkinsonism. Journal of Pathology, 1969. 
99(1): p. 39-44. 
33. Spillantini, M.G., et al., -Synuclein in Lewy bodies. Nature, 1997. 388(6645): p. 839-40. 
34. Baba, M., et al., Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and 
dementia with Lewy bodies. Am J Pathol, 1998. 152(4): p. 879-84. 
35. Duffy, P.E. and Tennyson, V.M., Phase and Electron Microscopic Observations of Lewy Bodies and 
Melanin Granules in Substantia Nigra and Locus Caeruleus in Parkinsons Disease. Journal of 
Neuropathology and Experimental Neurology, 1965. 24(3): p. 398-414. 
36. Ishizawa, T., et al., Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. Journal of 
Neuropathology and Experimental Neurology, 2003. 62(4): p. 389-397. 
37. Olanow, C.W., et al., Lewy-body formation is an aggresome-related process: a hypothesis. Lancet 
Neurology, 2004. 3(8): p. 496-503. 
38. Wakabayashi, K., et al., The Lewy body in Parkinson's disease and related neurodegenerative 
disorders. Mol Neurobiol, 2013. 47(2): p. 495-508. 
39. Forno, L.S., Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol, 1996. 55(3): p. 259-
72. 
40. Mackenzie, I.R.A., The pathology of Parkinson’s disease. BCMJ, 2001. 43(3): p. 142-147. 
41. Halliday, G., Lees, A., and Stern, M., Milestones in Parkinson's disease--clinical and pathologic 
features. Mov Disord, 2011. 26(6): p. 1015-21. 
42. Parkkinen, L., et al., Disentangling the relationship between lewy bodies and nigral neuronal loss in 
Parkinson's disease. J Parkinsons Dis, 2011. 1(3): p. 277-86. 
43. Schulz-Schaeffer, W.J., The synaptic pathology of alpha-synuclein aggregation in dementia with 
Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol, 2010. 120(2): 
p. 131-43. 
44. Jellinger, K.A., Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 
(Vienna), 2004. 111(10-11): p. 1219-35. 
45. Terry, R.D., Do neuronal inclusions kill the cell? J Neural Transm Suppl, 2000. 59: p. 91-3. 
Bibliography  129 
 
46. Gaig, C., et al., G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies. J 
Neurol Neurosurg Psychiatry, 2007. 78(6): p. 626-8. 
47. Braak, H., et al., Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 
2003. 24(2): p. 197-211. 
48. Del Tredici, K., et al., Where does parkinson disease pathology begin in the brain? J Neuropathol 
Exp Neurol, 2002. 61(5): p. 413-26. 
49. Braak, H., et al., Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology 
associated with sporadic Parkinson's disease reconsidered. Mov Disord, 2006. 21(12): p. 2042-51. 
50. Jellinger, K.A., A critical reappraisal of current staging of Lewy-related pathology in human brain. 
Acta Neuropathol, 2008. 116(1): p. 1-16. 
51. Burke, R.E., Dauer, W.T., and Vonsattel, J.P., A critical evaluation of the Braak staging scheme for 
Parkinson's disease. Ann Neurol, 2008. 64(5): p. 485-91. 
52. Beach, T.G., et al., Unified staging system for Lewy body disorders: correlation with nigrostriatal 
degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol, 2009. 117(6): p. 613-
34. 
53. Jellinger, K.A., Formation and development of Lewy pathology: a critical update. J Neurol, 2009. 
256: p. 270-9. 
54. Attems, J. and Jellinger, K.A., The dorsal motor nucleus of the vagus is not an obligatory trigger site 
of Parkinson's disease. Neuropathol Appl Neurobiol, 2008. 34(4): p. 466-7. 
55. Walsh, D.M. and Selkoe, D.J., A critical appraisal of the pathogenic protein spread hypothesis of 
neurodegeneration. Nat Rev Neurosci, 2016. 17(4): p. 251-60. 
56. Piccini, P. and Brooks, D.J., New developments of brain imaging for Parkinson's disease and related 
disorders. Mov Disord, 2006. 21(12): p. 2035-41. 
57. Chaudhuri, K.R. and Schapira, A.H., Non-motor symptoms of Parkinson's disease: dopaminergic 
pathophysiology and treatment. Lancet Neurol, 2009. 8(5): p. 464-74. 
58. Chaudhuri, K.R. and Naidu, Y., Early Parkinson's disease and non-motor issues. J Neurol, 2008. 255: 
p. 33-8. 
59. Collier, T.J., Kanaan, N.M., and Kordower, J.H., Ageing as a primary risk factor for Parkinson's 
disease: evidence from studies of non-human primates. Nat Rev Neurosci, 2011. 12(6): p. 359-66. 
60. Driver, J.A., et al., Incidence and remaining lifetime risk of Parkinson disease in advanced age. 
Neurology, 2009. 72(5): p. 432-8. 
61. Rodriguez, M., et al., Parkinson's disease as a result of aging. Aging Cell, 2015. 14(3): p. 293-308. 
62. Takubo, K., et al., Telomere lengths are characteristic in each human individual. Exp Gerontol, 2002. 
37(4): p. 523-31. 
63. Double, K.L., et al., Selective cell death in neurodegeneration: why are some neurons spared in 
vulnerable regions? Prog Neurobiol, 2010. 92(3): p. 316-29. 
64. Kusumi, M., et al., Epidemiology of Parkinson's disease in Yonago City, Japan: comparison with a 
study carried out 12 years ago. Neuroepidemiology, 1996. 15(4): p. 201-7. 
65. Shulman, L.M., Gender differences in Parkinson's disease. Gend Med, 2007. 4(1): p. 8-18. 
66. Ozelius, L.J., et al., LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. New 
England Journal of Medicine, 2006. 354(4): p. 424-425. 
67. Gordon, P.H., et al., Parkinson's disease among American Indians and Alaska natives: a nationwide 
prevalence study. Mov Disord, 2012. 27(11): p. 1456-9. 
68. Wermuth, L., Pakkenberg, H., and Jeune, B., High age-adjusted prevalence of Parkinson's disease 
among Inuits in Greenland. Neurology, 2002. 58(9): p. 1422-1425. 
69. Polymeropoulos, M.H., et al., Mutation in the alpha-synuclein gene identified in families with 
Parkinson's disease. Science, 1997. 276(5321): p. 2045-7. 
70. Mullin, S. and Schapira, A., The genetics of Parkinson's disease. Br Med Bull, 2015. 114(1): p. 39-
52. 
71. Keller, M.F., et al., Using genome-wide complex trait analysis to quantify 'missing heritability' in 
Parkinson's disease. Hum Mol Genet, 2012. 21(22): p. 4996-5009. 
130 Andrej Bieri 
72. Lill, C.M., et al., Comprehensive research synopsis and systematic meta-analyses in Parkinson's 
disease genetics: The PDGene database. PLoS Genet, 2012. 8(3): p. e1002548. 
73. Nalls, M.A., et al., Large-scale meta-analysis of genome-wide association data identifies six new risk 
loci for Parkinson's disease. Nat Genet, 2014. 46(9): p. 989-93. 
74. Marras, C., et al., Nomenclature of genetic movement disorders: Recommendations of the 
international Parkinson and movement disorder society task force. Movement Disorders, 2016. 31(4): 
p. 436-457. 
75. Marques, S.C., et al., Epigenetics in neurodegeneration: a new layer of complexity. Prog 
Neuropsychopharmacol Biol Psychiatry, 2011. 35(2): p. 348-55. 
76. Feng, Y., Jankovic, J., and Wu, Y.C., Epigenetic mechanisms in Parkinson's disease. Journal of the 
Neurological Sciences, 2015. 349(1-2): p. 3-9. 
77. Pan-Montojo, F. and Reichmann, H., Considerations on the role of environmental toxins in idiopathic 
Parkinson's disease pathophysiology. Transl Neurodegener, 2014. 3: p. 10. 
78. Brown, T.P., et al., Pesticides and Parkinson's disease--is there a link? Environ Health Perspect, 
2006. 114(2): p. 156-64. 
79. Ritz, B., et al., Traffic-Related Air Pollution and Parkinson's Disease in Denmark: A Case-Control 
Study. Environ Health Perspect, 2016. 124(3): p. 351-6. 
80. Willis, A.W., et al., Metal emissions and urban incident Parkinson disease: a community health study 
of Medicare beneficiaries by using geographic information systems. Am J Epidemiol, 2010. 172(12): 
p. 1357-63. 
81. Harris, M.A., et al., Association of Parkinson's disease with infections and occupational exposure to 
possible vectors. Mov Disord, 2012. 27(9): p. 1111-7. 
82. Niehaus, I. and Lange, J.H., Endotoxin: is it an environmental factor in the cause of Parkinson's 
disease? Occup Environ Med, 2003. 60(5): p. 378. 
83. Crane, P.K., et al., Association of Traumatic Brain Injury With Late-Life Neurodegenerative 
Conditions and Neuropathologic Findings. JAMA Neurol, 2016. 73(9): p. 1062-9. 
84. Chin-Chan, M., Navarro-Yepes, J., and Quintanilla-Vega, B., Environmental pollutants as risk 
factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci, 
2015. 9: p. 124. 
85. Ehringer, H. and Hornykiewicz, O., Distribution of noradrenaline and dopamine (3-
hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. 
Klin Wochenschr, 1960. 38: p. 1236-9. 
86. Hornykiewicz, O., Dopamine miracle: from brain homogenate to dopamine replacement. Mov 
Disord, 2002. 17(3): p. 501-8. 
87. Cotzias, G.C., Van Woert, M.H., and Schiffer, L.M., Aromatic amino acids and modification of 
parkinsonism. N Engl J Med, 1967. 276(7): p. 374-9. 
88. LeWitt, P.A. and Fahn, S., Levodopa therapy for Parkinson disease: A look backward and forward. 
Neurology, 2016. 86(14 Suppl 1): p. S3-12. 
89. Aquino, C.C. and Fox, S.H., Clinical spectrum of levodopa-induced complications. Mov Disord, 
2015. 30(1): p. 80-9. 
90. Poewe, W. and Antonini, A., Novel formulations and modes of delivery of levodopa. Mov Disord, 
2015. 30(1): p. 114-20. 
91. Schapira, A.H., Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of 
symptomatic and potential disease-modifying effects. CNS Drugs, 2011. 25(12): p. 1061-71. 
92. Youdim, M.B.H. and Bakhle, Y.S., Monoamine oxidase: isoforms and inhibitors in Parkinson's 
disease and depressive illness. British Journal of Pharmacology, 2006. 147: p. 287-96. 
93. Youdim, M.B., Edmondson, D., and Tipton, K.F., The therapeutic potential of monoamine oxidase 
inhibitors. Nat Rev Neurosci, 2006. 7(4): p. 295-309. 
94. Connolly, B.S. and Lang, A.E., Pharmacological treatment of Parkinson disease: a review. JAMA, 
2014. 311(16): p. 1670-83. 
95. Crosby, N., Deane, K.H., and Clarke, C.E., Amantadine in Parkinson's disease. Cochrane Database 
Syst Rev, 2003(1): p. CD003468. 
Bibliography  131 
 
96. Jankovic, J. and Poewe, W., Therapies in Parkinson's disease. Curr Opin Neurol, 2012. 25(4): p. 433-
47. 
97. Voges, J., et al., Thirty days complication rate following surgery performed for deep-brain-
stimulation. Mov Disord, 2007. 22(10): p. 1486-9. 
98. Deuschl, G. and Agid, Y., Subthalamic neurostimulation for Parkinson's disease with early 
fluctuations: balancing the risks and benefits. Lancet Neurol, 2013. 12(10): p. 1025-34. 
99. Bloem, B.R., de Vries, N.M., and Ebersbach, G., Nonpharmacological treatments for patients with 
Parkinson's disease. Mov Disord, 2015. 30(11): p. 1504-20. 
100. Ahlskog, J.E., Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology, 
2011. 77(3): p. 288-94. 
101. Lotia, M. and Jankovic, J., New and emerging medical therapies in Parkinson's disease. Expert Opin 
Pharmacother, 2016. 17(7): p. 895-909. 
102. Schenk, D.B., et al., First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal 
antibody, in healthy volunteers. Mov Disord, 2017. 32(2): p. 211-218. 
103. Bartus, R.T., Weinberg, M.S., and Samulski, R.J., Parkinson's disease gene therapy: success by 
design meets failure by efficacy. Mol Ther, 2014. 22(3): p. 487-497. 
104. Blits, B. and Petry, H., Perspective on the Road toward Gene Therapy for Parkinson's Disease. Front 
Neuroanat, 2016. 10: p. 128. 
105. Olanow, C.W., et al., A double-blind controlled trial of bilateral fetal nigral transplantation in 
Parkinson's disease. Ann Neurol, 2003. 54(3): p. 403-14. 
106. Barker, R.A., Drouin-Ouellet, J., and Parmar, M., Cell-based therapies for Parkinson disease-past 
insights and future potential. Nat Rev Neurol, 2015. 11(9): p. 492-503. 
107. Brundin, P., Barker, R.A., and Parmar, M., Neural grafting in Parkinson's disease Problems and 
possibilities. Prog Brain Res, 2010. 184: p. 265-94. 
108. Barker, R.A., et al., Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 
2016? J Parkinsons Dis, 2016. 6(1): p. 57-63. 
109. Grealish, S., et al., Human ESC-derived dopamine neurons show similar preclinical efficacy and 
potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell, 2014. 
15(5): p. 653-65. 
110. Kordower, J.H., et al., Lewy body-like pathology in long-term embryonic nigral transplants in 
Parkinson's disease. Nat Med, 2008. 14(5): p. 504-6. 
111. Li, J.Y., et al., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-
graft disease propagation. Nat Med, 2008. 14(5): p. 501-3. 
112. Brundin, P. and Kordower, J.H., Neuropathology in transplants in Parkinson's disease: implications 
for disease pathogenesis and the future of cell therapy. Prog Brain Res, 2012. 200: p. 221-41. 
113. Ueda, K., et al., Molecular cloning of cDNA encoding an unrecognized component of amyloid in 
Alzheimer disease. Proc Natl Acad Sci U S A, 1993. 90(23): p. 11282-6. 
114. Jakes, R., Spillantini, M.G., and Goedert, M., Identification of two distinct synucleins from human 
brain. FEBS Lett, 1994. 345(1): p. 27-32. 
115. Polymeropoulos, M.H., et al., Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. 
Science, 1996. 274(5290): p. 1197-9. 
116. Kruger, R., et al., Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. 
Nat Genet, 1998. 18(2): p. 106-8. 
117. Zarranz, J.J., et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body 
dementia. Ann Neurol, 2004. 55(2): p. 164-73. 
118. Appel-Cresswell, S., et al., Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's 
disease. Mov Disord, 2013. 28(6): p. 811-3. 
119. Kiely, A.P., et al., alpha-Synucleinopathy associated with G51D SNCA mutation: a link between 
Parkinson's disease and multiple system atrophy? Acta Neuropathol, 2013. 125(5): p. 753-69. 
120. Chartier-Harlin, M.C., et al., Alpha-synuclein locus duplication as a cause of familial Parkinson's 
disease. Lancet, 2004. 364(9440): p. 1167-9. 
132 Andrej Bieri 
121. Singleton, A.B., et al., alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003. 
302(5646): p. 841. 
122. Spillantini, M.G., et al., alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's 
disease and dementia with lewy bodies. Proc Natl Acad Sci U S A, 1998. 95(11): p. 6469-73. 
123. Nussbaum, R.L., The Identification of Alpha-Synuclein as the First Parkinson Disease Gene. J 
Parkinsons Dis, 2017. 7(s1): p. 45-51. 
124. Xia, Y., et al., Characterization of the human alpha-synuclein gene: Genomic structure, transcription 
start site, promoter region and polymorphisms. J Alzheimers Dis, 2001. 3(5): p. 485-494. 
125. Davidson, W.S., et al., Stabilization of alpha-synuclein secondary structure upon binding to synthetic 
membranes. J Biol Chem, 1998. 273(16): p. 9443-9. 
126. Rodriguez, J.A., et al., Structure of the toxic core of alpha-synuclein from invisible crystals. Nature, 
2015. 525(7570): p. 486-90. 
127. Vilar, M., et al., The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A, 2008. 105(25): p. 
8637-42. 
128. Emamzadeh, F.N., Alpha-synuclein structure, functions, and interactions. J Res Med Sci, 2016. 21: p. 
29. 
129. Ulmer, T.S., et al., Structure and dynamics of micelle-bound human alpha-synuclein. Journal of 
Biological Chemistry, 2005. 280(10): p. 9595-9603. 
130. Weinreb, P.H., et al., NACP, a protein implicated in Alzheimer's disease and learning, is natively 
unfolded. Biochemistry, 1996. 35(43): p. 13709-15. 
131. Lashuel, H.A., et al., The many faces of alpha-synuclein: from structure and toxicity to therapeutic 
target. Nat Rev Neurosci, 2013. 14(1): p. 38-48. 
132. Bartels, T., Choi, J.G., and Selkoe, D.J., alpha-Synuclein occurs physiologically as a helically folded 
tetramer that resists aggregation. Nature, 2011. 477(7362): p. 107-10. 
133. Wang, W., et al., A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci 
U S A, 2011. 108(43): p. 17797-802. 
134. Fauvet, B., et al., alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, 
and Escherichia coli exists predominantly as disordered monomer. J Biol Chem, 2012. 287(19): p. 
15345-64. 
135. Fauvet, B., et al., Characterization of semisynthetic and naturally Nalpha-acetylated alpha-synuclein 
in vitro and in intact cells: implications for aggregation and cellular properties of alpha-synuclein. J 
Biol Chem, 2012. 287(34): p. 28243-62. 
136. Chen, S.W., et al., Structural characterization of toxic oligomers that are kinetically trapped during 
alpha-synuclein fibril formation. Protein Science, 2015. 24: p. 136-136. 
137. Winner, B., et al., In vivo demonstration that alpha-synuclein oligomers are toxic. Proceedings of the 
National Academy of Sciences of the United States of America, 2011. 108(10): p. 4194-4199. 
138. Crowther, R.A., Daniel, S.E., and Goedert, M., Characterisation of isolated alpha-synuclein filaments 
from substantia nigra of Parkinson's disease brain. Neurosci Lett, 2000. 292(2): p. 128-30. 
139. Conway, K.A., et al., Accelerated oligomerization by Parkinson's disease linked alpha-synuclein 
mutants. Ann N Y Acad Sci, 2000. 920: p. 42-5. 
140. Bousset, L., et al., Structural and functional characterization of two alpha-synuclein strains. Nat 
Commun, 2013. 4: p. 2575. 
141. Giasson, B.I., et al., A hydrophobic stretch of 12 amino acid residues in the middle of alpha-
synuclein is essential for filament assembly. J Biol Chem, 2001. 276(4): p. 2380-6. 
142. Der-Sarkissian, A., et al., Structural organization of alpha-synuclein fibrils studied by site-directed 
spin labeling. J Biol Chem, 2003. 278(39): p. 37530-5. 
143. Guerrero-Ferreira, R., et al., Cryo-EM structure of alpha-synuclein fibrils. bioRxiv, 2018. 
144. McLean, P.J., et al., Membrane association and protein conformation of alpha-synuclein in intact 
neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem, 2000. 275(12): p. 8812-6. 
145. Jo, E., et al., alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem, 2000. 
275(44): p. 34328-34. 
Bibliography  133 
 
146. Beyer, K., Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell 
Biochem Biophys, 2007. 47(2): p. 285-99. 
147. Bartels, T., et al., The N-terminus of the intrinsically disordered protein alpha-synuclein triggers 
membrane binding and helix folding. Biophys J, 2010. 99(7): p. 2116-24. 
148. Pfefferkorn, C.M., Jiang, Z., and Lee, J.C., Biophysics of alpha-synuclein membrane interactions. 
Biochim Biophys Acta, 2012. 1818(2): p. 162-71. 
149. Middleton, E.R. and Rhoades, E., Effects of curvature and composition on alpha-synuclein binding to 
lipid vesicles. Biophys J, 2010. 99(7): p. 2279-88. 
150. Nuscher, B., et al., Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a 
thermodynamics study. J Biol Chem, 2004. 279(21): p. 21966-75. 
151. Alim, M.A., et al., Tubulin seeds alpha-synuclein fibril formation. J Biol Chem, 2002. 277(3): p. 
2112-7. 
152. Chen, L., et al., Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res 
Commun, 2007. 356(3): p. 548-53. 
153. Liu, G., Aliaga, L., and Cai, H., alpha-synuclein, LRRK2 and their interplay in Parkinson's disease. 
Future Neurol, 2012. 7(2): p. 145-153. 
154. Alvarez-Castelao, B. and Castano, J.G., Synphilin-1 inhibits alpha-synuclein degradation by the 
proteasome. Cell Mol Life Sci, 2011. 68(15): p. 2643-54. 
155. Neystat, M., et al., Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-
galactosidase liquid assay. Neurosci Lett, 2002. 325(2): p. 119-23. 
156. Lee, F.J., et al., Direct binding and functional coupling of alpha-synuclein to the dopamine 
transporters accelerate dopamine-induced apoptosis. FASEB J, 2001. 15(6): p. 916-26. 
157. Chen, R.H., et al., alpha-Synuclein membrane association is regulated by the Rab3a recycling 
machinery and presynaptic activity. J Biol Chem, 2013. 288(11): p. 7438-49. 
158. Wirdefeldt, K., et al., Expression of alpha-synuclein in the human brain: relation to Lewy body 
disease. Brain Res Mol Brain Res, 2001. 92(1-2): p. 58-65. 
159. Huang, Z., et al., Determining nuclear localization of alpha-synuclein in mouse brains. Neuroscience, 
2011. 199: p. 318-32. 
160. Goers, J., et al., Nuclear localization of alpha-synuclein and its interaction with histones. 
Biochemistry, 2003. 42(28): p. 8465-71. 
161. Masliah, E., et al., Dopaminergic loss and inclusion body formation in alpha-synuclein mice: 
implications for neurodegenerative disorders. Science, 2000. 287(5456): p. 1265-9. 
162. Kahle, P.J., et al., Subcellular localization of wild-type and Parkinson's disease-associated mutant 
alpha -synuclein in human and transgenic mouse brain. J Neurosci, 2000. 20(17): p. 6365-73. 
163. Irizarry, M.C., et al., Characterization of the precursor protein of the non-A beta component of senile 
plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol, 1996. 55(8): p. 
889-95. 
164. Murphy, D.D., et al., Synucleins are developmentally expressed, and alpha-synuclein regulates the 
size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci, 2000. 20(9): p. 
3214-20. 
165. Nemani, V.M., et al., Increased expression of alpha-synuclein reduces neurotransmitter release by 
inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 2010. 65(1): p. 66-79. 
166. Lundblad, M., et al., Impaired neurotransmission caused by overexpression of alpha-synuclein in 
nigral dopamine neurons. Proc Natl Acad Sci U S A, 2012. 109(9): p. 3213-9. 
167. Scott, D. and Roy, S., alpha-Synuclein inhibits intersynaptic vesicle mobility and maintains 
recycling-pool homeostasis. J Neurosci, 2012. 32(30): p. 10129-35. 
168. Burre, J., The Synaptic Function of alpha-Synuclein. J Parkinsons Dis, 2015. 5(4): p. 699-713. 
169. Chandra, S., et al., Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell, 
2005. 123(3): p. 383-96. 
170. Bonini, N.M. and Giasson, B.I., Snaring the function of alpha-synuclein. Cell, 2005. 123(3): p. 359-
61. 
134 Andrej Bieri 
171. Burre, J., et al., Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 
2010. 329(5999): p. 1663-7. 
172. Burre, J., Sharma, M., and Sudhof, T.C., alpha-Synuclein assembles into higher-order multimers 
upon membrane binding to promote SNARE complex formation. Proc Natl Acad Sci U S A, 2014. 
111(40): p. E4274-83. 
173. Wang, L., et al., alpha-synuclein multimers cluster synaptic vesicles and attenuate recycling. Curr 
Biol, 2014. 24(19): p. 2319-26. 
174. Ostrerova, N., et al., alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. 
J Neurosci, 1999. 19(14): p. 5782-91. 
175. Park, S.M., et al., Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing 
domain of alpha-synuclein, a molecular chaperone. J Biol Chem, 2002. 277(32): p. 28512-20. 
176. Lucke, C., et al., Interactions between fatty acids and alpha-synuclein. J Lipid Res, 2006. 47(8): p. 
1714-24. 
177. Jin, H., et al., alpha-Synuclein negatively regulates protein kinase Cdelta expression to suppress 
apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci, 
2011. 31(6): p. 2035-51. 
178. Zhu, M., et al., Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated 
lipid in vesicles. Biochemistry, 2006. 45(26): p. 8135-42. 
179. Latchoumycandane, C., et al., Protein kinase Cdelta is a key downstream mediator of manganese-
induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther, 2005. 313(1): p. 46-55. 
180. Kahle, P.J., et al., Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic 
animal models based on a Parkinson's disease-associated protein. Ann N Y Acad Sci, 2000. 920: p. 
33-41. 
181. Rockenstein, E., et al., Differential neuropathological alterations in transgenic mice expressing alpha-
synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res, 2002. 68(5): 
p. 568-78. 
182. Abeliovich, A., et al., Mice lacking alpha-synuclein display functional deficits in the nigrostriatal 
dopamine system. Neuron, 2000. 25(1): p. 239-52. 
183. Cabin, D.E., et al., Synaptic vesicle depletion correlates with attenuated synaptic responses to 
prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci, 2002. 22(20): p. 8797-
807. 
184. Ibanez, P., et al., Causal relation between alpha-synuclein gene duplication and familial Parkinson's 
disease. Lancet, 2004. 364(9440): p. 1169-71. 
185. Melki, R., Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other 
Neurodegenerative Diseases. J Parkinsons Dis, 2015. 5(2): p. 217-27. 
186. Luk, K.C., et al., Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly 
progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med, 2012. 209(5): p. 975-86. 
187. Luk, K.C., et al., Pathological alpha-synuclein transmission initiates Parkinson-like 
neurodegeneration in nontransgenic mice. Science, 2012. 338(6109): p. 949-53. 
188. Caughey, B. and Lansbury, P.T., Protofibrils, pores, fibrils, and neurodegeneration: separating the 
responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci, 2003. 26: p. 267-
98. 
189. Campioni, S., et al., The presence of an air-water interface affects formation and elongation of alpha-
Synuclein fibrils. J Am Chem Soc, 2014. 136(7): p. 2866-75. 
190. Conway, K.A., et al., Acceleration of oligomerization, not fibrillization, is a shared property of both 
alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis 
and therapy. Proc Natl Acad Sci U S A, 2000. 97(2): p. 571-6. 
191. Ingelsson, M., Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other 
Lewy Body Disorders. Front Neurosci, 2016. 10: p. 408. 
192. Rockenstein, E., et al., Accumulation of oligomer-prone alpha-synuclein exacerbates synaptic and 
neuronal degeneration in vivo. Brain, 2014. 137(Pt 5): p. 1496-513. 
193. Sharon, R., et al., The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty 
acids and enhanced in Parkinson's disease. Neuron, 2003. 37(4): p. 583-95. 
Bibliography  135 
 
194. Paleologou, K.E., et al., Detection of elevated levels of soluble alpha-synuclein oligomers in post-
mortem brain extracts from patients with dementia with Lewy bodies. Brain, 2009. 132(Pt 4): p. 
1093-101. 
195. Choi, B.K., et al., Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle 
docking. Proc Natl Acad Sci U S A, 2013. 110(10): p. 4087-92. 
196. Diogenes, M.J., et al., Extracellular alpha-synuclein oligomers modulate synaptic transmission and 
impair LTP via NMDA-receptor activation. J Neurosci, 2012. 32(34): p. 11750-62. 
197. Volles, M.J., et al., Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the 
pathogenesis and treatment of Parkinson's disease. Biochemistry, 2001. 40(26): p. 7812-9. 
198. Volles, M.J. and Lansbury, P.T., Jr., Vesicle permeabilization by protofibrillar alpha-synuclein is 
sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry, 
2002. 41(14): p. 4595-602. 
199. Danzer, K.M., et al., Different species of alpha-synuclein oligomers induce calcium influx and 
seeding. J Neurosci, 2007. 27(34): p. 9220-32. 
200. Mattson, M.P. and Chan, S.L., Dysregulation of cellular calcium homeostasis in Alzheimer's disease: 
bad genes and bad habits. J Mol Neurosci, 2001. 17(2): p. 205-24. 
201. Xilouri, M., Brekk, O.R., and Stefanis, L., alpha-Synuclein and protein degradation systems: a 
reciprocal relationship. Mol Neurobiol, 2013. 47(2): p. 537-51. 
202. Kaushik, S. and Cuervo, A.M., Proteostasis and aging. Nat Med, 2015. 21(12): p. 1406-15. 
203. Emmanouilidou, E., Stefanis, L., and Vekrellis, K., Cell-produced alpha-synuclein oligomers are 
targeted to, and impair, the 26S proteasome. Neurobiol Aging, 2010. 31(6): p. 953-68. 
204. Winslow, A.R., et al., alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. 
J Cell Biol, 2010. 190(6): p. 1023-37. 
205. Martinez-Vicente, M., et al., Dopamine-modified alpha-synuclein blocks chaperone-mediated 
autophagy. J Clin Invest, 2008. 118(2): p. 777-88. 
206. Mazzulli, J.R., et al., alpha-Synuclein-induced lysosomal dysfunction occurs through disruptions in 
protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A, 2016. 
113(7): p. 1931-6. 
207. Ryan, B.J., et al., Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic 
disease. Trends Biochem Sci, 2015. 40(4): p. 200-10. 
208. Devi, L., et al., Mitochondrial import and accumulation of alpha-synuclein impair complex I in 
human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem, 2008. 283(14): p. 
9089-100. 
209. Robotta, M., et al., Alpha-synuclein binds to the inner membrane of mitochondria in an alpha-helical 
conformation. Chembiochem, 2014. 15(17): p. 2499-502. 
210. Swerdlow, R.H., et al., Matrilineal inheritance of complex I dysfunction in a multigenerational 
Parkinson's disease family. Ann Neurol, 1998. 44(6): p. 873-81. 
211. Parihar, M.S., et al., Alpha-synuclein overexpression and aggregation exacerbates impairment of 
mitochondrial functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem 
Cell Biol, 2009. 41(10): p. 2015-24. 
212. Chinta, S.J., et al., Mitochondrial alpha-synuclein accumulation impairs complex I function in 
dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett, 2010. 486(3): p. 
235-9. 
213. Plotegher, N., Gratton, E., and Bubacco, L., Number and Brightness analysis of alpha-synuclein 
oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim 
Biophys Acta, 2014. 1840(6): p. 2014-24. 
214. Nakamura, K., et al., Direct membrane association drives mitochondrial fission by the Parkinson 
disease-associated protein alpha-synuclein. J Biol Chem, 2011. 286(23): p. 20710-26. 
215. Luth, E.S., et al., Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, 
Ca2+-induced mitochondrial dysfunction. J Biol Chem, 2014. 289(31): p. 21490-507. 
216. Faustini, G., et al., Mitochondria and alpha-Synuclein: Friends or Foes in the Pathogenesis of 
Parkinson's Disease? Genes (Basel), 2017. 8(12). 
136 Andrej Bieri 
217. Martinez, T.N. and Greenamyre, J.T., Toxin models of mitochondrial dysfunction in Parkinson's 
disease. Antioxid Redox Signal, 2012. 16(9): p. 920-34. 
218. Colla, E., et al., Accumulation of toxic alpha-synuclein oligomer within endoplasmic reticulum 
occurs in alpha-synucleinopathy in vivo. J Neurosci, 2012. 32(10): p. 3301-5. 
219. Colla, E., et al., Endoplasmic reticulum stress is important for the manifestations of alpha-
synucleinopathy in vivo. J Neurosci, 2012. 32(10): p. 3306-20. 
220. Castillo-Carranza, D.L., et al., Differential activation of the ER stress factor XBP1 by oligomeric 
assemblies. Neurochem Res, 2012. 37(8): p. 1707-17. 
221. Park, J.Y., et al., Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated 
alpha-synuclein: implications for Parkinson's disease. Glia, 2008. 56(11): p. 1215-23. 
222. Lee, H.J., et al., Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory 
responses in synucleinopathies. J Biol Chem, 2010. 285(12): p. 9262-72. 
223. Hoffmann, A., et al., Alpha-synuclein activates BV2 microglia dependent on its aggregation state. 
Biochem Biophys Res Commun, 2016. 479(4): p. 881-886. 
224. Zhang, W., et al., Aggregated alpha-synuclein activates microglia: a process leading to disease 
progression in Parkinson's disease. FASEB J, 2005. 19(6): p. 533-42. 
225. Wilms, H., et al., Suppression of MAP kinases inhibits microglial activation and attenuates neuronal 
cell death induced by alpha-synuclein protofibrils. Int J Immunopathol Pharmacol, 2009. 22(4): p. 
897-909. 
226. Kim, C., et al., Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for 
paracrine activation of microglia. Nat Commun, 2013. 4: p. 1562. 
227. Arawaka, S., et al., Lewy body in neurodegeneration with brain iron accumulation type 1 is 
immunoreactive for alpha-synuclein. Neurology, 1998. 51(3): p. 887-9. 
228. Galvin, J.E., et al., Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-
, beta-, and gamma-synuclein neuropathology. Am J Pathol, 2000. 157(2): p. 361-8. 
229. Takei, Y., et al., alpha-Synuclein coaggregation in familial amyotrophic lateral sclerosis with SOD1 
gene mutation. Hum Pathol, 2013. 44(6): p. 1171-6. 
230. Forman, M.S., et al., Tau and alpha-synuclein pathology in amygdala of Parkinsonism-dementia 
complex patients of Guam. Am J Pathol, 2002. 160(5): p. 1725-31. 
231. Yancopoulou, D., et al., Tau and alpha-synuclein inclusions in a case of familial frontotemporal 
dementia and progressive aphasia. J Neuropathol Exp Neurol, 2005. 64(3): p. 245-53. 
232. Mori, F., et al., Pick's disease: alpha- and beta-synuclein-immunoreactive Pick bodies in the dentate 
gyrus. Acta Neuropathol, 2002. 104(5): p. 455-61. 
233. Nishioka, K., et al., Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body 
disease. Arch Neurol, 2010. 67(8): p. 970-5. 
234. Arai, K., et al., Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci 
Lett, 2000. 296(2-3): p. 171-3. 
235. Mori, H., et al., Lewy bodies in progressive supranuclear palsy. Acta Neuropathol, 2002. 104(3): p. 
273-8. 
236. Smith, B.R., et al., Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe 
disease. J Pathol, 2014. 232(5): p. 509-21. 
237. Yamashita, S., et al., Concomitant accumulation of alpha-synuclein and TDP-43 in a patient with 
corticobasal degeneration. J Neurol, 2014. 261(11): p. 2209-17. 
238. Jellinger, K.A., Significance of brain lesions in Parkinson disease dementia and Lewy body 
dementia. Front Neurol Neurosci, 2009. 24: p. 114-25. 
239. Parkkinen, L., et al., Widespread and abundant alpha-synuclein pathology in a neurologically 
unimpaired subject. Neuropathology, 2005. 25(4): p. 304-14. 
240. Parkkinen, L., Pirttila, T., and Alafuzoff, I., Applicability of current staging/categorization of alpha-
synuclein pathology and their clinical relevance. Acta Neuropathol, 2008. 115(4): p. 399-407. 
241. Watanabe, I., Vachal, E., and Tomita, T., Dense core vesicles around the Lewy body in incidental 
Parkinson's disease: an electron microscopic study. Acta Neuropathol, 1977. 39(2): p. 173-5. 
Bibliography  137 
 
242. Shahmoradian, S.H., et al., Lewy pathology in Parkinson's disease consists of a crowded organellar 
membranous medley. bioRxiv, 2017. 
243. Sato, S., et al., Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor 
dysfunction in aged mice. Sci Rep, 2018. 8(1): p. 2813. 
244. Braak, H., et al., Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's 
plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett, 2006. 396(1): 
p. 67-72. 
245. Brundin, P., et al., Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev 
Neurosci, 2008. 9(10): p. 741-5. 
246. Bieri, G., Gitler, A.D., and Brahic, M., Internalization, axonal transport and release of fibrillar forms 
of alpha-synuclein. Neurobiol Dis, 2018. 109(Pt B): p. 219-225. 
247. Devine, M.J., et al., Parkinson's disease and alpha-synuclein expression. Mov Disord, 2011. 26(12): 
p. 2160-8. 
248. Soldner, F., et al., Parkinson-associated risk variant in distal enhancer of alpha-synuclein modulates 
target gene expression. Nature, 2016. 533(7601): p. 95-9. 
249. Danzer, K.M., et al., Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers 
and rescues trans-synaptic toxicity. FASEB J, 2011. 25(1): p. 326-36. 
250. Freundt, E.C., et al., Neuron-to-neuron transmission of alpha-synuclein fibrils through axonal 
transport. Ann Neurol, 2012. 72(4): p. 517-24. 
251. Brahic, M., et al., Axonal transport and secretion of fibrillar forms of alpha-synuclein, Abeta42 
peptide and HTTExon 1. Acta Neuropathol, 2016. 131(4): p. 539-48. 
252. Tran, H.T., et al., Alpha-synuclein immunotherapy blocks uptake and templated propagation of 
misfolded alpha-synuclein and neurodegeneration. Cell Rep, 2014. 7(6): p. 2054-65. 
253. Volpicelli-Daley, L.A., et al., Exogenous alpha-synuclein fibrils induce Lewy body pathology 
leading to synaptic dysfunction and neuron death. Neuron, 2011. 72(1): p. 57-71. 
254. Masuda-Suzukake, M., et al., Prion-like spreading of pathological alpha-synuclein in brain. Brain, 
2013. 136(Pt 4): p. 1128-38. 
255. Recasens, A., et al., Lewy body extracts from Parkinson disease brains trigger alpha-synuclein 
pathology and neurodegeneration in mice and monkeys. Ann Neurol, 2014. 75(3): p. 351-62. 
256. Gousset, K., et al., Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol, 2009. 
11(3): p. 328-36. 
257. Abounit, S., et al., Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of 
lysosomes. EMBO J, 2016. 35(19): p. 2120-2138. 
258. Dieriks, B.V., et al., alpha-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells 
and primary brain pericytes from Parkinson's disease patients. Sci Rep, 2017. 7: p. 42984. 
259. Lee, H.J., Patel, S., and Lee, S.J., Intravesicular localization and exocytosis of alpha-synuclein and its 
aggregates. J Neurosci, 2005. 25(25): p. 6016-24. 
260. Jang, A., et al., Non-classical exocytosis of alpha-synuclein is sensitive to folding states and 
promoted under stress conditions. J Neurochem, 2010. 113(5): p. 1263-74. 
261. Lee, J.G., et al., Unconventional secretion of misfolded proteins promotes adaptation to proteasome 
dysfunction in mammalian cells. Nat Cell Biol, 2016. 18(7): p. 765-76. 
262. Fontaine, S.N., et al., DnaJ/Hsc70 chaperone complexes control the extracellular release of 
neurodegenerative-associated proteins. EMBO J, 2016. 35(14): p. 1537-49. 
263. Emmanouilidou, E., et al., Cell-produced alpha-synuclein is secreted in a calcium-dependent manner 
by exosomes and impacts neuronal survival. J Neurosci, 2010. 30(20): p. 6838-51. 
264. Alvarez-Erviti, L., et al., Lysosomal dysfunction increases exosome-mediated alpha-synuclein 
release and transmission. Neurobiol Dis, 2011. 42(3): p. 360-7. 
265. Pinotsi, D., et al., Nanoscopic insights into seeding mechanisms and toxicity of alpha-synuclein 
species in neurons. Proc Natl Acad Sci U S A, 2016. 113(14): p. 3815-9. 
266. Rey, N.L., et al., Transfer of human alpha-synuclein from the olfactory bulb to interconnected brain 
regions in mice. Acta Neuropathol, 2013. 126(4): p. 555-73. 
138 Andrej Bieri 
267. Guo, J.L., et al., Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. 
Cell, 2013. 154(1): p. 103-17. 
268. Sacino, A.N., et al., Conformational templating of alpha-synuclein aggregates in neuronal-glial 
cultures. Mol Neurodegener, 2013. 8: p. 17. 
269. Lee, H.J., et al., Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int 
J Biochem Cell Biol, 2008. 40(9): p. 1835-49. 
270. Desplats, P., et al., Inclusion formation and neuronal cell death through neuron-to-neuron 
transmission of alpha-synuclein. Proc Natl Acad Sci U S A, 2009. 106(31): p. 13010-5. 
271. Konno, M., et al., Suppression of dynamin GTPase decreases alpha-synuclein uptake by neuronal and 
oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener, 2012. 7: p. 
38. 
272. Sung, J.Y., et al., Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-
synuclein. J Biol Chem, 2001. 276(29): p. 27441-8. 
273. Schonberger, O., et al., Novel heparan mimetics potently inhibit the scrapie prion protein and its 
endocytosis. Biochem Biophys Res Commun, 2003. 312(2): p. 473-9. 
274. Horonchik, L., et al., Heparan sulfate is a cellular receptor for purified infectious prions. J Biol 
Chem, 2005. 280(17): p. 17062-7. 
275. Holmes, B.B., et al., Heparan sulfate proteoglycans mediate internalization and propagation of 
specific proteopathic seeds. Proc Natl Acad Sci U S A, 2013. 110(33): p. E3138-47. 
276. Ihse, E., et al., Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate 
depends on aggregate conformation and cell type. Sci Rep, 2017. 7(1): p. 9008. 
277. Mao, X., et al., Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation 
gene 3. Science, 2016. 353(6307). 
278. Shrivastava, A.N., et al., alpha-synuclein assemblies sequester neuronal alpha3-Na+/K+-ATPase and 
impair Na+ gradient. EMBO J, 2015. 34(19): p. 2408-23. 
279. Surmeier, D.J., Obeso, J.A., and Halliday, G.M., Parkinson's Disease Is Not Simply a Prion Disorder. 
J Neurosci, 2017. 37(41): p. 9799-9807. 
280. Brundin, P. and Melki, R., Prying into the Prion Hypothesis for Parkinson's Disease. J Neurosci, 
2017. 37(41): p. 9808-9818. 
281. Lee, S.J. and Masliah, E., Neurodegeneration: Aggregates feel the strain. Nature, 2015. 522(7556): p. 
296-7. 
282. Peelaerts, W., et al., alpha-Synuclein strains cause distinct synucleinopathies after local and systemic 
administration. Nature, 2015. 522(7556): p. 340-4. 
283. Vingill, S., Connor-Robson, N., and Wade-Martins, R., Are rodent models of Parkinson's disease 
behaving as they should? Behav Brain Res, 2017. 352: p. 133-41. 
284. Lazaro, D.F., Pavlou, M.A.S., and Outeiro, T.F., Cellular models as tools for the study of the role of 
alpha-synuclein in Parkinson's disease. Exp Neurol, 2017. 298(Pt B): p. 162-171. 
285. Falkenburger, B.H. and Schulz, J.B., Limitations of cellular models in Parkinson's disease research. J 
Neural Transm Suppl, 2006(70): p. 261-8. 
286. Falkenburger, B.H., Saridaki, T., and Dinter, E., Cellular models for Parkinson's disease. J 
Neurochem, 2016. 139: p. 121-130. 
287. Astashkina, A., Mann, B., and Grainger, D.W., A critical evaluation of in vitro cell culture models 
for high-throughput drug screening and toxicity. Pharmacol Ther, 2012. 134(1): p. 82-106. 
288. Hansen, C., et al., alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons 
and seeds aggregation in cultured human cells. J Clin Invest, 2011. 121(2): p. 715-25. 
289. Lazaro, D.F., et al., Systematic comparison of the effects of alpha-synuclein mutations on its 
oligomerization and aggregation. PLoS Genet, 2014. 10(11): p. e1004741. 
290. Xie, H.R., Hu, L.S., and Li, G.Y., SH-SY5Y human neuroblastoma cell line: in vitro cell model of 
dopaminergic neurons in Parkinson's disease. Chin Med J (Engl), 2010. 123(8): p. 1086-92. 
291. Wang, H.Q., et al., Cell type-specific upregulation of Parkin in response to ER stress. Antioxid Redox 
Signal, 2007. 9(5): p. 533-42. 
Bibliography  139 
 
292. Kovalevich, J. and Langford, D., Considerations for the use of SH-SY5Y neuroblastoma cells in 
neurobiology. Methods Mol Biol, 2013. 1078: p. 9-21. 
293. Kriks, S., et al., Dopamine neurons derived from human ES cells efficiently engraft in animal models 
of Parkinson's disease. Nature, 2011. 480(7378): p. 547-51. 
294. Chung, C.Y., et al., Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived 
neurons. Science, 2013. 342(6161): p. 983-7. 
295. Xiao, B., et al., Induced pluripotent stem cells in Parkinson's disease: scientific and clinical 
challenges. J Neurol Neurosurg Psychiatry, 2016. 87(7): p. 697-702. 
296. Holmqvist, S., et al., Creation of a library of induced pluripotent stem cells from Parkinsonian 
patients. NPJ Parkinsons Dis, 2016. 2: p. 16009. 
297. Lotharius, J., et al., Effect of mutant alpha-synuclein on dopamine homeostasis in a new human 
mesencephalic cell line. J Biol Chem, 2002. 277(41): p. 38884-94. 
298. Lotharius, J., et al., Progressive degeneration of human mesencephalic neuron-derived cells triggered 
by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J 
Neurosci, 2005. 25(27): p. 6329-42. 
299. Paul, G., et al., Tyrosine hydroxylase expression is unstable in a human immortalized mesencephalic 
cell line--studies in vitro and after intracerebral grafting in vivo. Mol Cell Neurosci, 2007. 34(3): p. 
390-9. 
300. Schildknecht, S., et al., Requirement of a dopaminergic neuronal phenotype for toxicity of low 
concentrations of 1-methyl-4-phenylpyridinium to human cells. Toxicol Appl Pharmacol, 2009. 
241(1): p. 23-35. 
301. Scholz, D., et al., Rapid, complete and large-scale generation of post-mitotic neurons from the human 
LUHMES cell line. J Neurochem, 2011. 119(5): p. 957-71. 
302. Stiegler, N.V., et al., Assessment of chemical-induced impairment of human neurite outgrowth by 
multiparametric live cell imaging in high-density cultures. Toxicol Sci, 2011. 121(1): p. 73-87. 
303. Tong, Z.B., et al., Characterization of three human cell line models for high-throughput neuronal 
cytotoxicity screening. J Appl Toxicol, 2017. 37(2): p. 167-180. 
304. Zhang, X.M., Yin, M., and Zhang, M.H., Cell-based assays for Parkinson's disease using 
differentiated human LUHMES cells. Acta Pharmacol Sin, 2014. 35(7): p. 945-56. 
305. Schildknecht, S., et al., Generation of genetically-modified human differentiated cells for 
toxicological tests and the study of neurodegenerative diseases. ALTEX, 2013. 30(4): p. 427-44. 
306. Stepkowski, T.M., Meczynska-Wielgosz, S., and Kruszewski, M., mitoLUHMES: An Engineered 
Neuronal Cell Line for the Analysis of the Motility of Mitochondria. Cell Mol Neurobiol, 2017. 
37(6): p. 1055-1066. 
307. Efremova, L., et al., Prevention of the degeneration of human dopaminergic neurons in an astrocyte 
co-culture system allowing endogenous drug metabolism. Br J Pharmacol, 2015. 172(16): p. 4119-
32. 
308. Efremova, L., et al., Switching from astrocytic neuroprotection to neurodegeneration by cytokine 
stimulation. Arch Toxicol, 2017. 91(1): p. 231-246. 
309. Ilieva, M. and Dufva, M., SOX2 and OCT4 mRNA-expressing cells, detected by molecular beacons, 
localize to the center of neurospheres during differentiation. PLoS One, 2013. 8(8): p. e73669. 
310. Smirnova, L., et al., A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing 
long-term exposure and cellular resilience analysis. Arch Toxicol, 2016. 90(11): p. 2725-2743. 
311. Dinh, N.D., et al., Microfluidic construction of minimalistic neuronal co-cultures. Lab Chip, 2013. 
13(7): p. 1402-12. 
312. Scholz, D., Regulation of Alzheimer’s disease-relevant protein processing in human neurons of the 
LUHMES cell line. Dissertation, 2011. 
313. Mehling, M. and Tay, S., Microfluidic cell culture. Curr Opin Biotechnol, 2014. 25: p. 95-102. 
314. Link, D.R., et al., Electric control of droplets in microfluidic devices. Angew Chem Int Ed Engl, 
2006. 45(16): p. 2556-60. 
315. Vyawahare, S., Griffiths, A.D., and Merten, C.A., Miniaturization and parallelization of biological 
and chemical assays in microfluidic devices. Chem Biol, 2010. 17(10): p. 1052-65. 
140 Andrej Bieri 
316. Halldorsson, S., et al., Advantages and challenges of microfluidic cell culture in 
polydimethylsiloxane devices. Biosens Bioelectron, 2015. 63: p. 218-31. 
317. Toepke, M.W. and Beebe, D.J., PDMS absorption of small molecules and consequences in 
microfluidic applications. Lab Chip, 2006. 6(12): p. 1484-6. 
318. Zheng, W., et al., Fluid flow stress induced contraction and re-spread of mesenchymal stem cells: a 
microfluidic study. Integr Biol (Camb), 2012. 4(9): p. 1102-11. 
319. Luk, K.C., et al., Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like 
intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A, 2009. 106(47): p. 20051-6. 
320. Brettschneider, J., et al., Spreading of pathology in neurodegenerative diseases: a focus on human 
studies. Nat Rev Neurosci, 2015. 16(2): p. 109-20. 
321. Guo, J.L. and Lee, V.M., Cell-to-cell transmission of pathogenic proteins in neurodegenerative 
diseases. Nat Med, 2014. 20(2): p. 130-8. 
322. Poehler, A.M., et al., Autophagy modulates SNCA/alpha-synuclein release, thereby generating a 
hostile microenvironment. Autophagy, 2014. 10(12): p. 2171-92. 
323. Taylor, A.M., et al., A microfluidic culture platform for CNS axonal injury, regeneration and 
transport. Nat Methods, 2005. 2(8): p. 599-605. 
324. Kunze, A., et al., Co-pathological connected primary neurons in a microfluidic device for Alzheimer 
studies. Biotechnol Bioeng, 2011. 108(9): p. 2241-5. 
325. Wu, J.W., et al., Small misfolded Tau species are internalized via bulk endocytosis and anterogradely 
and retrogradely transported in neurons. J Biol Chem, 2013. 288(3): p. 1856-70. 
326. Ilieva, M., et al., Tracking neuronal marker expression inside living differentiating cells using 
molecular beacons. Front Cell Neurosci, 2013. 7: p. 266. 
327. Nishimura, M., et al., Synaptophysin and chromogranin A immunoreactivities of Lewy bodies in 
Parkinson's disease brains. Brain Res, 1994. 634(2): p. 339-44. 
328. Maier, T., Guell, M., and Serrano, L., Correlation of mRNA and protein in complex biological 
samples. FEBS Lett, 2009. 583(24): p. 3966-73. 
329. Peng, C., Gathagan, R.J., and Lee, V.M., Distinct alpha-Synuclein strains and implications for 
heterogeneity among alpha-Synucleinopathies. Neurobiol Dis, 2018. 109(Pt B): p. 209-218. 
330. Richardson, S.C.W., Tracking Intracellular Polymer Localization Via Fluorescence Microscopy, in 
Organelle-Specific Pharmaceutical Nanotechnology, G.G.M.D.S. Volkmar Weissig, Editor. 2010, 
Wiley Online Library. p. 177-192. 
331. Yagi, H., et al., Ultrasonication-dependent formation and degradation of alpha-synuclein amyloid 
fibrils. Biochim Biophys Acta, 2015. 1854(3): p. 209-17. 
332. Fusco, G., et al., Structural basis of membrane disruption and cellular toxicity by alpha-synuclein 
oligomers. Science, 2017. 358(6369): p. 1440-1443. 
333. Arnold, S.A., et al., Blotting-free and lossless cryo-electron microscopy grid preparation from 
nanoliter-sized protein samples and single-cell extracts. J Struct Biol, 2017. 197(3): p. 220-226. 
334. Kemmerling, S., et al., Single-cell lysis for visual analysis by electron microscopy. J Struct Biol, 
2013. 183(3): p. 467-473. 
335. Arnold, S.A., et al., Total Sample Conditioning and Preparation of Nanoliter Volumes for Electron 
Microscopy. ACS Nano, 2016. 10(5): p. 4981-8. 
336. Dubochet, J., et al., Cryo-electron microscopy of vitrified specimens. Q Rev Biophys, 1988. 21(2): p. 
129-228. 
337. Callaway, E., The revolution will not be crystallized: a new method sweeps through structural 
biology. Nature, 2015. 525: p. 172-174. 
338. Kuhlbrandt, W., Biochemistry. The resolution revolution. Science, 2014. 343(6178): p. 1443-4. 
339. Nogales, E., The development of cryo-EM into a mainstream structural biology technique. Nature 
Methods, 2015. 13: p. 24-27. 
340. Milazzo, A.-C., et al., Initial evaluation of a direct detection device detector for single particle cryo-
electron microscopy. Journal of Structural Biology, 2011. 176(3): p. 404-408. 
341. Ruskin, R.S., Yu, Z., and Grigorieff, N., Quantitative characterization of electron detectors for 
transmission electron microscopy. Journal of Structural Biology, 2013. 184(3): p. 385-393. 
Bibliography  141 
 
342. Veesler, D., et al., Maximizing the potential of electron cryomicroscopy data collected using direct 
detectors. Journal of Structural Biology, 2013. 184(2): p. 193-202. 
343. Grigorieff, N., FREALIGN: high-resolution refinement of single particle structures. J Struct Biol, 
2007. 157(1): p. 117-25. 
344. Lyumkis, D., et al., Likelihood-based classification of cryo-EM images using FREALIGN. J Struct 
Biol, 2013. 183(3): p. 377-88. 
345. Scheres, S.H.W., RELION: implementation of a Bayesian approach to cryo-EM structure 
determination. Journal of Structural Biology, 2012. 180(3): p. 519-530. 
346. Baker, L.A. and Rubinstein, J.L., Chapter fifteen – radiation damage in electron cryomicroscopy. 
Methods in enzymology, 2010. 
347. Kemmerling, S., et al., Connecting µ-fluidics to electron microscopy. J Struct Biol, 2012. 177(1): p. 
128-34. 
348. Glaeser, R.M., How good can cryo-EM become ? Nat Methods, 2016. 13: p. 28-32. 
349. Jain, T., et al., Spotiton: a prototype for an integrated inkjet dispense and vitrification system for 
cryo-TEM. Journal of structural biology, 2012. 179: p. 68-75. 
350. Razinkov, I., et al., A new method for vitrifying samples for cryoEM. Journal of Structural Biology, 
2016. 195(2): p. 190-198. 
351. Magdesian, M.H., et al., Rapid Mechanically Controlled Rewiring of Neuronal Circuits. J Neurosci, 
2016. 36(3): p. 979-87. 
352. Konradi, R., Acikgoz, C., and Textor, M., Polyoxazolines for nonfouling surface coatings--a direct 
comparison to the gold standard PEG. Macromol Rapid Commun, 2012. 33(19): p. 1663-76. 
353. Ogaki, R., et al., Temperature-induced ultradense PEG polyelectrolyte surface grafting provides 
effective long-term bioresistance against mammalian cells, serum, and whole blood. 
Biomacromolecules, 2012. 13(11): p. 3668-77. 
354. Kovach, K.M., et al., The effects of PEG-based surface modification of PDMS microchannels on 
long-term hemocompatibility. J Biomed Mater Res A, 2014. 102(12): p. 4195-205. 
355. Wachter, A., et al., Analysis of Reverse Phase Protein Array Data: From Experimental Design 
towards Targeted Biomarker Discovery. Microarrays (Basel), 2015. 4(4): p. 520-39. 
356. Tabakman, S.M., et al., Plasmonic substrates for multiplexed protein microarrays with femtomolar 
sensitivity and broad dynamic range. Nat Commun, 2011. 2: p. 466. 
357. Chang, H., et al., PSA Detection with Femtomolar Sensitivity and a Broad Dynamic Range Using 
SERS Nanoprobes and an Area-Scanning Method. ACS Sensors, 2016. 1(6): p. 645-649. 
358. Brase, J.C., et al., Increasing the sensitivity of reverse phase protein arrays by antibody-mediated 
signal amplification. Proteome Sci, 2010. 8: p. 36. 
359. Arnold, S.A., Nanoliter sample preparation for electron microscopy and single-cell analysis. 
(Doctoral dissertation), 2017. 
360. Frey, T.G., Perkins, G.A., and Ellisman, M.H., Electron tomography of membrane-bound cellular 
organelles. Annu Rev Biophys Biomol Struct, 2006. 35: p. 199-224. 
361. Shahmoradian, S.H., et al., Preparation of primary neurons for visualizing neurites in a frozen-
hydrated state using cryo-electron tomography. J Vis Exp, 2014(84): p. e50783. 
362. Garvalov, B.K., et al., Luminal particles within cellular microtubules. J Cell Biol, 2006. 174(6): p. 
759-65. 
363. Lucic, V., et al., Multiscale imaging of neurons grown in culture: from light microscopy to cryo-
electron tomography. J Struct Biol, 2007. 160(2): p. 146-56. 
364. Fernandez-Busnadiego, R., et al., Insights into the molecular organization of the neuron by cryo-
electron tomography. J Electron Microsc (Tokyo), 2011. 60 Suppl 1: p. S137-48. 
365. Ibiricu, I., et al., Cryo electron tomography of herpes simplex virus during axonal transport and 
secondary envelopment in primary neurons. PLoS Pathog, 2011. 7(12): p. e1002406. 
366. Tao, C.L., et al., Differentiation and Characterization of Excitatory and Inhibitory Synapses by Cryo-
electron Tomography and Correlative Microscopy. J Neurosci, 2018. 38(6): p. 1493-1510. 
367. Gao, F., et al., Mitophagy in Parkinson's Disease: Pathogenic and Therapeutic Implications. Front 
Neurol, 2017. 8: p. 527. 
142 Andrej Bieri 
368. Ludtmann, M.H., et al., Monomeric Alpha-Synuclein Exerts a Physiological Role on Brain ATP 
Synthase. J Neurosci, 2016. 36(41): p. 10510-10521. 
369. Subramaniam, S.R., et al., Region specific mitochondrial impairment in mice with widespread 
overexpression of alpha-synuclein. Neurobiol Dis, 2014. 70: p. 204-13. 
370. Tapias, V., et al., Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective 
dopamine neurodegeneration in part via iNOS-mediated nitric oxide production. Cell Mol Life Sci, 
2017. 74(15): p. 2851-2874. 
371. Pozo Devoto, V.M. and Falzone, T.L., Mitochondrial dynamics in Parkinson's disease: a role for 
alpha-synuclein? Dis Model Mech, 2017. 10(9): p. 1075-1087. 
372. Mastronarde, D.N., Automated electron microscope tomography using robust prediction of specimen 
movements. J Struct Biol, 2005. 152(1): p. 36-51. 
373. Jacob, W.A., et al., Mitochondrial matrix granules: their behavior during changing metabolic 
situations and their relationship to contact sites between inner and outer mitochondrial membranes. 
Microsc Res Tech, 1994. 27(4): p. 307-18. 
374. Peachey, L.D., Electron Microscopic Observations on the Accumulation of Divalent Cations in 
Intramitochondrial Granules. J Cell Biol, 1964. 20: p. 95-111. 
375. Raza, M., et al., Aging is associated with elevated intracellular calcium levels and altered calcium 
homeostatic mechanisms in hippocampal neurons. Neurosci Lett, 2007. 418(1): p. 77-81. 
376. Beirowski, B., et al., The progressive nature of Wallerian degeneration in wild-type and slow 
Wallerian degeneration (WldS) nerves. BMC Neurosci, 2005. 6: p. 6. 
377. Kerschensteiner, M., et al., In vivo imaging of axonal degeneration and regeneration in the injured 
spinal cord. Nat Med, 2005. 11(5): p. 572-7. 
378. Krug, A.K., et al., Transcriptional and metabolic adaptation of human neurons to the mitochondrial 
toxicant MPP(+). Cell Death Dis, 2014. 5: p. e1222. 
379. Nonaka, T., et al., Seeded aggregation and toxicity of alpha-synuclein and tau: cellular models of 
neurodegenerative diseases. J Biol Chem, 2010. 285(45): p. 34885-98. 
380. Huang, C., et al., A new method for purification of recombinant human alpha-synuclein in 
Escherichia coli. Protein Expr Purif, 2005. 42(1): p. 173-7. 
381. Biyani, N., et al., Focus: The interface between data collection and data processing in cryo-EM. J 
Struct Biol, 2017. 198(2): p. 124-133. 
382. Hu, Y., Qu, L., and Schikorski, T., Mean synaptic vesicle size varies among individual excitatory 
hippocampal synapses. Synapse, 2008. 62(12): p. 953-7. 
 
 
  
Acknowledgements  143 
 
ACKNOWLEDGEMENTS 
First of all, I would like to thank Thomas Braun and Henning Stahlberg for the opportunity 
to do my PhD under their supervision and for providing a great environment for research. I 
am also honored that Prof. Dr. Roland Riek accepted to be the external co-referee for my 
thesis.  
I wish to greatly acknowledge Rosmarie Sütterlin for bringing some light in an electron 
microscopy lab. She did most of the immunolabeling work, sat hours at the confocal, and 
often took the turn for the weekend cell culture maintenance.  
Many thanks to Gabriel Schweighauser, Elliot Smith, and Adrian Najer for proof-reading 
my thesis.  
I thank Mohamed, Kenny, Lubomir, Carola and Ariane for discussions about sample 
preparation, help with microscopy work, and maintenance of the microscopes.  
I would like to thank Alexander Stettler for letting me into his cleanroom and Albert 
Martel for helping me to keep everything clean in there.  
Stefan Arnold and Claudio Schmidli is thanked for collaboration on their setup.  
Thanks to the administrative professionals Karen Bergmann and Heidi Brönnimann who 
kept most bureaucracy far from me.  
I thank Pratibha Kumari and Cedric Eichmann for the help with a-syn, and Simon Gutbier 
for the introduction into LUHMES cell culturing. 
With a special mention to my former colleagues, Benjamin Bircher, Stefan Arnold, Gabriel 
Schweighauser, Christopher Bleck, Simon Kemmerling, Sebastian Scherrer, Misha 
Kudryashev and Jarek Sedzick. It was fantastic to work with you guys during some parts 
of my PhD.  
Furthermore, I would like to greatly acknowledge the nice and group atmospheres I have 
met in this lab. To all Braunis and Cina wutzl team: have a good time and keep training.  
I would like to thank all my friends and my former flatmates. We had a great time in basel.  
144 Andrej Bieri 
I am grateful to my siblings and parents, who have provided me support during my studies 
for the last decade.  
Finally, and the most, I would like to thank Mona, for her patience and support.  
 
Big thanks for all your help and support! 
 
